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Summary
With little to no progress in the treatment of pancreatic cancer over the past decades, novel
approaches to cover the high unmet medical need are long overdue. However, the long lasting
notion of PDAC being a ‘non-immunogenic’ neoplasm lacking uniform infiltration of effector lym-
phocytes and holding an immunosuppressive microenvironment has so far precluded the use
of adoptive T cell therapy in this malignancy. Furthermore, the overall low mutational burden
of pancreatic cancer led to the assumption of decreased frequencies in immunogenic neoepi-
topes targeted by T cells. Nevertheless, the recent identification of frequently occurring effector
T cells recognizing their autologous tumor in pancreatic cancer indicates a potential use of
PDAC derived TILs against the malignancy. In addition, exome analyses of larger patient co-
horts indicated that formation of immunogenic, mutation derived epitopes in PDAC might be
more frequent than previously expected. Nevertheless, to date functional analyses identifying
and characterizing the epitopes recognized by pancreatic cancer TIL are yet to be carried out.
Thus, we set out to develop screening approaches to reliably identify mutation derived epitopes
within pancreatic cancer patients. This development was approached with two complementary
strategies, first by looking into the antigens recognized by PDAC TILs and second by directly
identifying the epitopes presented on the surface of the PDAC derived tumor cells.
We addressed the antigen recognition by developing a novel expression based screening sys-
tem. Since PDAC is frequently infiltrated by CD4+ and CD8+ T cells (both of which populations
potentially mount anti tumor immune responses), combined with a low number of tumor muta-
tions, we needed an approach able to screen for both, MHC-I and MHC-II restricted antigens.
Therefore, we designed a system based on shuttling antigens into both, the major histocom-
patibility complex (MHC)-I and -II antigen presentation pathways, in order to define the reac-
tivity of PDAC TILs in a completely unbiased fashion (i.e. not depending on MHC restriction
and/or epitope prediction algorithms). Furthermore, we validated the use of a targeted mass
spectrometry based approach to directly identify epitopes presented on the surface of PDAC
derived cells lines. In addition, the application of both approaches in a small patient cohort was
used to draw initial conclusions on the feasibility of both approaches for an extension to larger
patient cohorts.
Taken together, the presented study describes the development and validation of screening
methodologies capable of identifying antigens in the context of low mutational burden malig-
nancies such as pancreatic cancer. These methodologies lay the foundation for the functional
proof of concept studies of antigen reactive T cells infiltrating pancreatic cancer, opening new
ways for the application of adoptive T cell transfer in this fatal disease.
Zusammenfassung
Angesichts der geringen Fortschritte bei der Behandlung von Bauchspeicheldrüsenkreb in den
letzten Jahrzehnten sind neue Ansätze zur Deckung des hohen Behandlungsbedarfs längst
überfällig. Aufgrund der Annahme, dass ductale Adenokarzinome des Pankreas (PDAC) „nicht
immunogene“ Neoplasien seien, welche nicht von Effektorlymphozyten infiltriert sind und über
ein immunsuppressives Mikromilieu verfügen, wurde eine adoptive T-Zell Therapie für diese
Erkrankung bisher ausgeschlossen. Darüber hinaus führte die geringeMutationslast von Bauch-
speicheldrüsenkrebs zu der Annahme, dass die von T Zellen erkannten, immunogenenNeoepi-
tope seltener vorhanden sind. Dennoch deutet die kürzlich gezeigte Häufung von Effektor-T-
Zellen (TILs), die ihren autologen Tumor erkennen, auf eine mögliche Verwendung von PDAC
TILs gegen den Tumor hin. Darüber hinaus zeigten Exomanalysen größerer Patientenko-
horten, dass die Bildung immunogener, von Mutationen abgeleiteter Epitope in PDAC häufiger
auftreten als bislang erwartet. Jedoch fehlen bislang funktionelle Analysen zur Identifizierung
und Charakterisierung der von PDAC TIL erkannten Epitope.
In der vorliegenden Arbeit haben wir verschiedene Screening Abläufe entwickelt, um muta-
tionsbedingte Epitope bei Pankreaskrebspatienten zuverlässig zu identifizieren. Die Entwick-
lung dieser Ansätze wurde mit zwei komplementären Strategien verfolgt. Zum Einen durch
die Untersuchung der von PDAC TILs erkannten Antigene und zum Anderen durch direkte
Identifizierung der auf der Oberfläche der von PDAC abgeleiteten Tumorzellen präsentierten
Epitope.
Im Zusammenhang der Antigenerkennung durch PDAC TIL haben wir ein neues expressions-
basiertes Screening System entwickelt. Da PDAC häufig von CD4+- und CD8+-T-Zellen infil-
triert wird (von denen beide Populationen potenzielle anti tumor Immunantworten aufweisen),
benötigten wir einen Ansatz, der gleichzeitig MHC-I und MHC-II restringierte Antigene iden-
tifiziert. Aus diesem Grund haben wir ein System entwickelt, das darauf basiert Antigene in
den Haupthistokompatibilitätskomplex (MHC)-I- und -II Präsentationspfad zu leiten, um die
Reaktivität von PDAC TILs völlig unvoreingenommen zu bestimmen (d.h. unabhängig von
der MHC-Restriktion und von Epitopvorhersagealgorithmen). Darüber hinaus validierten wir
die Verwendung eines zielgerichteten massenspektrometrischen Ansatzes zur direkten Iden-
tifizierung von Epitopen, die auf der Oberfläche von PDAC-abgeleiteten Zelllinien präsentiert
werden. Zudem wurden aus der Anwendung beider Ansätze in einer kleinen Patientenkohorte
erste Rückschlüsse auf die Durchführbarkeit beider Ansätze für eine Ausweitung auf größere
Patientenkohorten gezogen.
Zusammengefasst beschreibt die vorgestellte Studie die Entwicklung und Validierung von Screen-
ing Methoden, mit denen Antigene im Zusammenhang vonmalignen Erkrankungenmit geringer
Mutationsbelastung (z.B. Bauchspeicheldrüsenkreb) identifiziert werden können. Die vorgestell-
ten Methoden bilden die Grundlage für funktionelle Studien von antigenreaktiven T-Zellen,
die PDAC infiltrieren, und eröffnen neue Möglichkeiten für die Anwendung des adoptiven T-
Zelltransfers bei dieser tödlichen Krankheit.
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11 Introduction
1.1 The Pancreas
The organ was first described around 300 B.C. by Herophilus of Chalcedon and later (around
100 A.D.) named by Ruphos of Ephesus as pancreas (greek: παν/pan=all and κρέας/kreas=meat)
[1, 2]. The pancreas is approximately 14 - 18 cm large and is located in the anterior pararenal
space, posterior to the parietal peritoneum [3]. Macroscopically, the glandular organ is divided
into four parts - head, neck, body and tail - and microscopically holds endocrine, as well as
exocrine functions [3, 4].
Its endocrine function is rendered by islets of Langerhans, scattered throughout the whole
organ in close proximity to blood vessels [5]. First described by Paul Langerhans in 1869
[6], these islets secrete various hormones from specialized cells into the circulation. Islets
of Langerhans consist to about 60% of β-cells (producing insulin), 30% α-cells (producing
glucagon), <10% δ-cells (producing somatostatin), <5% γ-cells (producing pancreatic polypep-
tide) and ε-cells (producing ghrelin) [7, 8].
The exocrine portion of a healthy pancreas consists of two major cellular subpopulations: Aci-
nar cells form lobuli in the pancreatic parenchyma and synthesize as well as secrete diges-
tive enzymes (trypsinogen, chymotrypsinogen, amylase, and lipase) into the main pancreatic
duct [9]. Epithelial cells line the pancreatic ducts and collect digestive enzymes from the acini
[10, 11]. The main pancreatic duct (duct of Wirsung) spans the whole organ and combines with
the common bile duct, forming the ampulla of Vater, at the pancreatic head [4]. Penetrating the
duodenal wall, both ducts empty into the duodenal lumen via the major duodenal papilla [4].
Figure 1 – The healthy adult pancreas. (Left) Location and connectivity of the pancreas in the an-
terior pararenal space. (Right) Schematic visualization of the cellular composition of the endocrine
and exocrine pancreas. Taken from [12]
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1.2 Pancreatic Cancer
Over the course of a lifetime, this central digestive and endocrine organ can undergo atypi-
cal transformation, giving rise to one of the most life threatening diseases, pancreatic cancer.
The majority of cases are diagnosed at a median age of 71 years in both men and women
[13]. A diagnosis at an age younger than 40 years is rare [13, 14]. The combination of an
initially symptomless progression and early-stage metastasis contribute largely to the overall
poor prognosis of pancreatic cancer [15–18]. In most cases patients experience unspecific
abdominal discomfort, back pain, weight loss or indigestion prior to diagnosis [19–21].
1.2.1 Subtypes of pancreatic cancer
In accordance with their respective anatomical localization, pancreatic malignancies are subdi-
vided into two categories (i.e. malignancies of the endocrine and the exocrine pancreas):
Malignancies of the endocrine pancreas
Pancreatic Neuroendocrine Tumors (PNET) Due to its anatomical location within the organ
this subtype of pancreatic malignancy was previously termed “islet cell tumor” or “pancreatic
carcinoid tumor”. In order to arrive at a better consensus, the term neuroendocrine neoplasm
was suggested for pancreatic malignancies showing an endocrine phenotype [22–24].
Pancreatic neuroendocrine tumors (PNETs) form a rare subtype of pancreatic malignancies
with an overall incidence of 1 - 3% [14, 18, 23–25]. In addition, they grow comparatively slow
and are, in most cases, diagnosed at a non-malignant stage, resulting in a better prognosis
after surgical treatment compared to tumors of the exocrine portion of the organ [14, 23, 25].
Further sub-classifications of these neuroendocrine neoplasms involve the distinction between
tumors with an elevated hormone production (functional; 60 - 70% incidence) and regular lev-
els of hormone production (non-functional; 30 - 40% incidence) [23]. Clinically, non-functional
PNETs are often detected at later stages, due to the absence of hormone-related symptoms.
In the case of functional PNETs, an earlier diagnosis is mainly possible due to clinical signs of
hormone over-expression.
Depending on the respective over-expressed hormone, functional PNETs are further sub-
categorized into insulinomas (20 - 30%), gastrinomas (15 - 20%), VIPomas (2 - 4%), glucagono-
mas (1 - 3%) and somatostatinoma (≈1%) [23, 26].
Malignancies of the exocrine pancreas
Approximately 95% of all pancreatic malignancies arise in the exocrine portion of the organ
[18, 25]. Based on the cellular subtype and differentiation, these malignancies are further sub-
divided into the following categories:
Ductal adenocarcinoma With an incidence of approximately 85 - 90% of all cases diagnosed
with a pancreatic neoplasm, pancreatic ductal adenocarcinoma represents the most frequent
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malignancy of the exocrine pancreas [14, 18]. A detailed description of this subtype is given in
section 1.3.
MucinousCystadenocarcinoma (MCN) The mucinous cystadenocarcinoma (MCN) is found
in approximately 2 - 5% of patients with neoplasms in the exocrine pancreas [18]. MCN should
not be mistaken with the mucinous noncystic carcinoma (MNC), a histological variant of the
ductal adenocarcinoma [18].
The uni- or multilocular lesions of mucinous cystadenocarcinoma are formed by two distinct
cellular subtypes, a luminal epithelial layer and an outer stromal layer which form a frequently
calcified capsular structure. These lesions are mostly found in the body and tail of the pancreas
[18]. Due to its encapsulated appearance, non-invasive MCN can be resected with an overall
good prognosis. In the case of invasive disease, a high degree of invasion is strongly correlated
with a poor prognosis [18].
Acinar cell carcinoma The acinar cell carcinoma is comprised of acinar cells, forming small
glandular units with an absence of large desmoplastic areas [18]. Diagnosis of this subtype
is mostly based on immunohistochemical staining of trypsin and chymotrypsin, as these are
highly expressed in about 95% of cases [18]. In total this malignancy represents about 1 - 2%
of all pancreatic exocrine neoplasms [14, 18]. The overall prognosis of acinar cell carcinoma is
comparable to that of ductal adenocarcinoma with an overall 5-year survival rate of less than
10% [18].
Pancreatoblastoma This special pancreatic neoplasia represents the only form almost ex-
clusively diagnosed in children with a median age of diagnosis of 4 years [18]. With an overall
incidence rate of 0.5% of pancreatic malignancies in the whole population, it is one of the least
frequent cancers of the pancreas. However, it accounts for 30 - 50% of pancreatic neoplasia di-
agnosed in children [18]. Macroscopically these lesions present with a defined lobular structure
separated by fibrous tissue. Patients with local disease are generally treated by a combination
of surgery followed by chemotherapy, leading to an overall very good prognosis. In the case
of metastatic disease and in rare occurrences during adulthood treatment remains a challenge
[18].
1.3 Pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) arises from the exocrine portion of the pancreas
and can occur throughout the whole organ. Nevertheless, approximately 60 - 70% of presented
cases arise within the pancreatic head [18]. Histologically, the microenvironment of PDAC is
characterized by a dense desmoplastic network, making up about 80% of the tumor mass,
mainly produced by activated pancreatic stellate cells [14, 27, 28]. The main components of
this dense stromal architecture are formed by collagen I/ III and fibronectin, creating an overall
hypoxic and nutrient deprived microenvironment [14, 29, 30]. Besides this, the origin of the
malignant cells (i.e. acinar cell, duct epithelium or ductal progenitor cells), sparsely distributed
throughout the tumor stroma, are currently a matter of debate [31–33].
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Altogether, PDAC is by far the most prevalent subtype of pancreatic neoplasms with an inci-
dence rate of 85 - 90% of all cases [13, 14, 18]. Yearly, approximately 340.000 new cases
(2.5% of all malignancies) of PDAC emerge worldwide, making it the twelfth most frequent can-
cer in both males and females [18, 34]. However, with overall 5-year survival rates of 25 %
for localized, 9.9 % for regionally metastasized and 2.3 % for distantly metastasized disease, it
currently forms the fourth leading cause of cancer related deaths (figure 2) [14, 18, 35].
Figure 2 – Annual cancer related death statistics. Indicated are the ten most common causes
of cancer related deaths in both male and female patients. The number of annual fatal cases in
combination with the respective percentile of all cancer related deaths worldwide are indicated.
Adapted from [35]
Given the initially symptomless progression of pancreatic neoplasms, approximately 50 - 60%
of patients present at an already unresectable stage of disease with advanced vascular involve-
ment and formation of distant metastases. For these patients there are currently no efficient
therapies available (figure 3) [25, 28, 36]. The remainder of patients, presenting with either
locally restricted/ primary resectable (15 - 20%) or locally advanced/ borderline resectable (30 -
40% - after neoadjuvant chemotherapy) disease, can currently only undergo extensive surgery
followed by chemotherapy [14, 36, 37]. Furthermore, within less than 24 months, approximately
80 - 90% of the patients who undergo surgery and chemotherapy demonstrate fast progress-
ing disease recurrence with an ultimately fatal outcome [38, 39]. Within 5-years post-surgery,
almost 95% of patients currently succumb to their disease [18, 38, 39]. Here, the main sites
of (metastatic) disease recurrence are either local (pancreatic tissue) or distal (liver, lung and
peritoeum; see figure 4) [18, 38, 40].
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Figure 3 – Surgical resectability of pancreatic cancer. Showing a schematic overview of the anatom-
ical structures leading to PDAC unresectability when involved in tumor progression. Taken from [13]
Figure 4 – Patterns of PDAC recurrence following surgery. Indicating the most common site of
disease recurrence within 5 years after surgical resection. Taken from [40]
1.3.1 From precursor lesion to invasive malignancy - pathophysiological assessment
Since the transformation process from healthy pancreas to malignant disease can take sev-
eral decades, multiple stages of premalignant lesions preceding invasive PDAC have been
described [13, 18, 41, 42]. Over the course of a lifetime, the number and degree of atypia of
premalignant lesions can gradually increase. Nevertheless, it should be noted, that the sole
formation of lower grade premalignant lesions does not necessarily lead to full-blown invasive
PDAC [43–45]. The following paragraphs show the current consensus of premalignant lesions,
associated with PDAC development in more detail:
Pancreatic intraepithelial neoplasia (PanIN) Representing the most common precursor
lesion, pancreatic intraepithelial neoplasia (PanIN) is associated with approximately 90% of
PDAC cases diagnosed [41]. Depending on the degree of cytologic atypia, PanINs are sub-
divided into three grades, from minimal (PanIN-1) to high degree atypic deformation (PanIN-3)
(see figure 5A) [46]. Upon atypic progression, genetic alterations begin to accumulate within
the premalignant cells. Here, activating mutations of KRAS already appear in over 95% of early
grade PanIN lesions, making it by far the most frequent initiating driver mutation of malignant
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cell transformation (see figure 5B) [47, 48]. Additionally, mutational inactivation of CDKN2A/
p16, TP53/ p53 and SMAD4 increases in frequency with progression to higher grades of pre-
malignant lesions [14, 47].
Intraductal papillary mucinous neoplasm (IPMN) The second most frequent premalignant
lesion is represented by intraductal papillary mucinous neoplasms (IPMNs). Here, it needs
to be distinguished between the more prevalent non-invasive (60 - 70%) and the infrequent
invasive (30 - 40%) lesions [13, 49]. Upon resection, the prognosis for the first is far better,
with an overall 5-year survival rate of 70 - 100%. In contrast, the overall 5-year survival for
invasive lesions is significantly lower (approximately 30%) [18, 41, 50, 51]. In addition, only
approximately 4 - 9% of all PDAC cases are linked to prior formation or presence of IPMN
[49, 52, 53].
Histopathologically, these premalignant lesions consist of mucin producing, epithelial papillae
associated with the main pancreatic duct or its branches [41] (see figure 5A). With increasing
tissue atypia, a growing number of activating mutations in KRAS (40 - 60%) and allelic losses
(40 - 60%) of CDKN2A/ p16 and TP53/p53 is detected within these neoplasias [18, 54].
Mucinous noncystic (colloid) carcinoma (MNC or CC) These epithelial neoplasms rep-
resent the third most common (2 - 3%) pre-malignant lesion of invasive pancreatic cancer
[15, 18, 41, 42]. Overall, these neoplasms mostly manifest as cystic, mucin producing (> 50%
of the tumor) nodules in the pancreatic head [55, 56] (see figure 5A). The main recurring mu-
tational alterations found in MNC involve activating mutations in KRAS (> 90%), inactivation
of TP53/ p53 (>40%), as well as SMAD4 (> 80%), and aberrant methylation of CDKN2A/ p16
(>10%) [54, 55, 57–59].
Figure 5 – Development of PDAC from healthy tissue. Schematic overview of the histological
progression from healthy pancreas to pancreatic ductal adenocarcinoma through different precursor
lesions (top). Increase of molecular and physiological changes taking place with the progression
from healthy tissue to PDAC (bottom). Adapted from [48, 60].
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1.3.2 Molecular subtypes and mutational landscape of pancreatic ductal adenocarci-
noma
The possibility to describe and classify malignancies on a molecular level allowed researchers
to further decipher the mutational landscape of pancreatic cancer. Here, two major findings
should be highlighted: On the one hand, recurrent mutations together with the involved signal-
ing pathways found in PDAC [61–65] and on the other hand the definition of molecular subtypes
of PDAC [64–67]. Both findings might improve patient care in the future. The following para-
graphs will briefly summarize the current state of discussions on these topics.
Recurrent Mutations and the involved signaling pathways in PDAC Despite the overall
low mutational burden of pancreatic cancer (see figure 6), in-depth whole exome analyses re-
vealed sets of recurring genetic alterations in pancreatic cancer patients [61, 63–65]. With a
prevalence of >90%, activating mutations of the proto-oncogene KRAS constitute by far the
most common recurring mutations found in pancreatic malignancies [64, 65, 68]. Particularly
mutations of KRAS codon 12 (>40% G12D; >20% G12V; >10% G12R) were found early on
during pancreatic cancer development [65]. Due to the central role of KRAS in cell signaling,
these mutations lead the constitutive activation of the MAPK/ ERK signaling pathway and re-
sult in increased cell proliferation rates, as well as apoptosis suppression [61, 69]. Patients
displaying KRAS wild type variants were recently shown to hold alternative driver mutations
in central signaling pathways of cell proliferation, i.e. BRAF (MAPK/ ERK pathway), GNAS
(cAMP-dependent pathway) and CTNNB1 (Wnt signaling) [65]. Additional hotspots of genetic
alteration found in PDAC include inactivating mutations of CDKN2A (30 - 40%; G1-S tran-
sition regulation), TP53 (>70%; DNA damage control) and SMAD4 (>30%; TGFβ signaling)
[64, 65, 68]. Furthermore, a small subset of patients (5 - 10%) presents with inherited muta-
tions in DNA damage repair genes (BRCA1, BRCA2, ATM and PALB2) [64, 65, 70, 71]. Taken
together, these recurring mutations found in PDAC are limited to few signaling pathways in-
volved in cell survival and proliferation (see table 2) [61, 65]. The complexity of communication
between these pathways, however, should not be underestimated, as further unraveling of their
interplay might help to explain the slow progress in PDAC treatment efficacy and give rise to
more effective combination therapies in the future. Besides this, the majority of mutations found
in PDAC remain passenger mutations that are typically patient specific (see figure 7).
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Figure 6 – Tumor associated mutational burden. Shown is the estimated frequency of somatic
mutations in combination with frequency of neoantigen forming mutations for malignancies of dif-
ferent anatomical structures. The coloured boxes indicate the range and likelihood of neoantigen
formation. Taken from [72].
Table 2 – Core signaling pathways involved in PDAC progression. Indicated are the commonly
affected recurring pathways in combination with the fraction of patients affected and the mostly
affected genes. Adapted from [61, 64, 65, 73, 74].
Function Fraction of patients [%] Commonly affected genes
RAS-MAPK signaling 90 - 95 KRAS, MAP2K4, RASGRP3, BRAF
Cell cycle control 70 - 80 CDKN2A, TP53, TP53BP2
TGFβ signaling 40 - 50 SMAD4, SMAD3, TGFBR1, ACVR1B
Histone modification 20 - 25 KDM6A, SETD2, MLL2, MLL3
RNA processing 16 SF3B1, U2AF1, RBM10
SWI/ SNF complex 10 - 15 ARID1A, PBRM1, SMARCA4
DNA repair 5 - 12 BRCA1, BRCA2, ATM, PALB2, ATF2
ROBO/ SLIT pathway 5 - 15 ROBO1, ROBO2, SLIT2, MYCBP2
Wnt/ Notch signaling < 10 RNF43, MARK2, MIB1, GATA6, TLE4
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Figure 7 – Mutational landscape of pancreatic ductal adenocarcinoma. Depicted are the most
common recurring genomic alterations of 149 PDAC patients. Taken from [65].
Molecular Subtypes of PDAC Over the past years, multiple groups have worked on defining
specific molecular subtypes of PDAC, based on gene expression profiling [64–67]. Here, espe-
cially the recent work of the “Cancer Genome Atlas Research Network” needs to be mentioned,
as they elegantly combined different previous findings on subtype characterization and could
confirm parts of these [65]. Splitting their analysis set into high and low purity samples, based
on the number on neoplastic cells, they confirmed certain subtype overlaps between previous
studies and ruled out other formerly defined subtypes as artifacts of low tumor cell content.
Based on this, the currently confirmed molecular subtypes described for pancreatic cancer are
divided into the classical/ progenitor [64–67] and the basal-like/ squamous subtype [64, 65, 67].
In the case of the classical/ progenitor subtype a correlation with the expression of genes in-
volving pancreatic cell/ lineage development, fatty acid oxidation, drug metabolism and steroid
hormone biosynthesis was found [64]. The basal-like/ squamous subtype on the other hand is
characterized by the expression of genes involved in inflammation, hypoxia response, metabolic
reprogramming, autophagy and endodermal cell fate abrogation [64]. Although deeper insight
into the molecular characteristics of PDAC subtypes is still needed, the recent results show
promising future treatment opportunities tailored to recurrent gene expression networks.
1.3.3 Risk factors associated with PDAC
Over the past decades of intensive statistical analyses, certain factors have been associated
with an increased risk of developing pancreatic cancer. As expected, factors directly involving
the pancreas (chronic inflammation, familial PDAC, diabetes mellitus and obesity) rank among
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the most highly increased risks for the development of pancreatic cancer [75–81]. In addi-
tion, genetic predispositions with an overall increased risk of unspecific cancer development -
Peutz-Jeghers syndrome, familial atypical multiple mole and melanoma (FAMMM) and lynch
syndrome - are associated with PDAC [82–86]. A brief summary of the associated risk factors
and genetic predispositions is given in table 3.
Table 3 – Risk factors and lifetime risk of inherited syndroms associated with PDAC. FAMMM =
Familial atypical multiple mole and melanoma syndrome. Adapted from [13, 14, 18].
Variable Associated risk
Risk factor Relative risk [%]
Chronic pancreatitis[76, 81] 2 - 6
Smoking[87] 2 - 3
Diabetes mellitus[88] 2
Obesity[80] 2
Genetic predisposition (associated genes) Lifetime risk [%]
Hereditary pancreatitis (PRSS1, SPINK1)[75, 79] 50 - 65
Peutz-Jeghers syndrome (STK11)[83] 30 - 40
FAMMM (CDKN2A/ p16)[82, 84, 85] 10 - 35
Familial pancreatic cancer (>2 first degree relatives)[65, 77, 78] 5 - 10
Lynch syndrome (MLH1, MSH2, MSH6)[86] 4 - 9
Cystic fibrosis (CFTR) [89] 5
Hereditary breast and ovarian cancer (BRCA1, BRCA2, PALB2)[90, 91] 1 - 4
1.3.4 Current standard treatments of pancreatic ductal adenocarcinoma
Seeing the high complexity, diversity and fatality of PDAC, a lot of effort was put into finding
a consensus for patient treatment and care. These efforts range from initial diagnosis and
staging of the disease up to defining the ideal treatment options for each stage of pancreatic
malignancy. The following paragraphs briefly summarize these efforts based on current treat-
ment consensus.
Diagnosis and Staging Due to the short time window available for treatment of PDAC an
accurate initial assessment of the disease stage prior to therapy is crucial. Over the past years
it was generally agreed to stage PDAC based on the tumor node metastasis (TNM) system
[92, 93]. A primary diagnosis of the disease usually appears by chance during routine screen-
ings or medical examinations due to unspecific abdominal discomfort [19–21]. Upon suspicion
of PDAC, patients are immediately screened with current state-of-the-art imaging techniques
to rule out any kind of misdiagnosis. These techniques involve magnetic resonance imag-
ing (MRI), positron emission tomography (PET), multi-detector computer tomography (MDCT)
or endoscopic ultrasonography [13, 14, 94]. Due to arterial and venous phasing techniques
[13, 95], MDCT currently forms the most robust and widely available imaging technique for
initial staging of the disease [14, 18, 92]. For histological characterization of the tumor stage
and potential origin, pathological assessment by endoscopic ultrasonography guided fine nee-
dle aspiration is usually applied [14, 96, 97]. Assessing combinations of general serum tumor
markers, such as carbohydrate antigen 19-9 (CA19-9), carcinoemryonic antigen (CEA), DU-
PAN-2 or Span-1, in the context of PDAC is mainly applied as an indicator of metastatic disease
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and to monitor disease recurrence [13, 14, 18, 98–102]. Baseline levels of these markers in
patients with low stage disease rule out their use as diagnostic markers [14]. Following diag-
nosis and staging of the disease, surgical resection currently forms the only potentially curative
treatment for PDAC [13, 14].
Surgery For patients diagnosed with primary or borderline resectable disease (following neoad-
juvant chemotherapy), surgery currently represents the only potentially curative option. Suc-
cessfully performed for the first time in 1909 by W. Kausch [103], and later optimized amongst
others by A. Whipple [104], the pancreaticoduodenectomy (Kausch-Whipple procedure) is the
most common surgical intervention for pancreatic malignancies to date [14, 105]. Depending on
the disease localization, partial (head), distal (tail) or total (whole organ) pancreaticoduodenec-
tomy is carried out [106, 107] (see figure 8). Due to an increased risk of post surgical com-
plications, total pancreaticoduodenectomy is avoided whenever possible [105]. During early
applications of the procedure, post-surgical complications and mortality occurred in approxi-
mately 10 - 45% of the patients, depending on the experience of the surgeon. Over the past
decades, these complications were counteracted by further improving and refining the proce-
dure, resulting in a post-operation mortality of approximately 2% in highly specialized disease
centers today [108–110]. As favorable as improvements of these surgical techniques seemed
over the last years, the overall 5-year survival of both, primary and borderline resectable pa-
tients, converges to approximately 20 - 25% [36, 111, 112]. This is mainly associated with a
fast disease recurrence in almost 90% of the patients receiving surgical resection and follow-up
treatments [13, 14].
A
B
C
D
Figure 8 – Schematic representation of different PDAC surgeries. Indicated are the outcomes of
the most commonly applied surgical procedures (B - C). In addition, the healthy organ environment
surrounding the pancreas is shown in (A). Depending on the organs affected by surgery, the applied
procedures include distal pancreatectomy (B), Kausch-Whipple (C) or total pancreatectomy (D).
Neoadjuvant and adjuvant Chemotherapy In the context of pancreatic cancer, chemother-
apeutic regimen are applied in either a neoadjuvant or adjuvant setting. In the case of neoad-
juvant treatment, the main goal is an overall reduction of tumor mass in patients with borderline
resectable disease, allowing for later surgical resection of the remaining tumor tissue. Patients
who received surgical resection are later followed up by adjuvant chemotherapy with the aim of
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improving disease outcome [13, 14, 18]. Over the past decades, regimen applicable for adju-
vant chemotherapy could rarely improve the overall outcome. The major milestones in adjuvant
PDAC chemotherapy are summarized below.
Discovered in the context of liver cancer in 1957, 5-fluorouracil (5-FU) later found its way into
the early treatment regimen of pancreatic cancer, resulting in an increase in median survival
of 9 months compared to surgery alone (20 vs 11 months) [113–116]. Until the late 1990-ies,
5-FU monotherapy was the central therapeutic for advanced pancreatic cancer with no combi-
nation therapy giving rise to improved survival [117–120]. In 1997 a randomized trial (CONKO-
001) revealed gemcitabine to be the first regimen to modestly improve patients median survival
compared to 5-FU in an adjuvant setting (5.7 vs 4.4 months). The improved clinical response
(23.8% vs 4.8%) and increased 12-month survival (18% vs 2%) in patients treated with gemc-
itabine (versus 5-FU) made it the first-line chemotherapeutic regimen for more than the follow-
ing decade [38, 121]. During this time, the use of targeted therapies against the main signaling
pathways involved in PDAC rarely led to a significant improvement of patients overall survival
[122, 123]. Here, a combination therapy of Erlotinib, an inhibitor of the epidermal growth factor
receptor (EGFR), and gemcitabine formed the first targeted treatment receiving FDA approval
in 2005 [124]. Later, Everolismus (mTOR inhibitor) and Sunitinib (receptor tyrosine kinase in-
hibitor) followed for the treatment of progressive neuroendocrine tumors [125, 126]. In 2011 a
phase III clinical trial (PRODIGE 4/ACCORD 11) was the first to show an unequivocal benefit
of FOLFIRINOX (folinic acid (leucovorin), 5-fluorouracil, irinotecan and oxaliplatin) compared
to gemcitabine monotherapy (11.1 vs 6.8 months median survival) [39]. A less favorable haz-
ard profile later limited the use of FOLFIRINOX to younger and physically fit PDAC patients
[39, 127]. Since then, only a few additional studies could show supplementary clinical benefit
of gemcitabine combination therapy compared to gemcitabine monotherapy. Especially com-
binations with nano albumin bound (nab-) paclitaxel (8.5 vs 6.7 months) or capecitabine (10.1
vs 7.4 months) revealed significant survival benefits compared to gemcitabine monotherapy
[128, 129]. These results later led to the adaptation of adjuvant therapy of PDAC to a combi-
nation regimen of gemcitabine and nab-paclitaxel for patients unable to receive FOLFIRINOX
treatment [130].
1.3.5 Disease outcome with current standard of care
However promising recent attempts may seem, even with current standard of care treatments
approximately 90 - 95% of patients will ultimately die from their disease within only a few
months. All together, the overall 5-year survival currently converges to 25 % for localized, 9.9 %
for regionally metastasized and 2.3 % for distantly metastasized disease [14, 18, 35]. Reasons
for this poor prognosis include the late diagnosis in most patients, deeming them unresectable,
as well as the high rate of disease recurrence in resectable patients after initially successful
surgery and chemotherapy [13, 14]. Taken together it becomes obvious, that there is currently
no curative option for PDAC available. Treatments applied rather serve palliative care than cure
patients, elongating their lives by merely a few months at best.
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Figure 9 – Current standard of care workflow for the treatment of PDAC. Indicated are the different
sections of pancreatic cancer care from disease staging followed by stage dependent treatments to
the fatal outcome of the majority of patients.
1.4 Tumor Immunology
Based on Paul Ehrlich’s initial assumptions on tumor control by the immune system, back in
1909, a plethora of potential new therapies against one of mankind’s most frightening diseases
arose [131]. The complex interplay between tumors and the immune system was aptly sum-
marized by H.F. Dvorak as a “wound that does not heal” [132]. The following paragraphs will
give a brief overview of the research surrounding tumor immunology, with an emphasis on T
cell mediated tumor immunity.
1.4.1 The role of T cells in the anti tumor response
A first indication connecting an immune response to an anti tumor reaction was found when the
immunization of mice with irradiated, carcinogen-induced tumor cells led to a subsequent rejec-
tion of the non-irradiated cells from the same tumor upon re-challenge [133, 134]. These early
results not only indicated that mutation-induced alterations of tumor cells raised an immune
response, but also that the immune system was able to create a certain memory against these
tumors (after immunization). Nevertheless, these results did not reveal which cell populations
were involved in tumor recognition and rejection.
Only later, using immunodeficient, syngeneic mouse strains (e.g. RAG2-/-, a strain lacking ma-
ture B and T cells [135]and / or Foxn1nu, an athymic strain lacking T cells [136]), the influence of
certain immune cell populations on specific tumor cells could be studied in detail. During early
pre-clinical experiments with these mice, researchers observed an increased susceptibility to
carcinogen-induced tumors in immunodeficient mice compared to their wild type counterparts,
highlighting the importance of T cells in the protection against carcinogen-induced or sponta-
neous tumors [137].
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The realization of the unequivocal significance of T cells in the anti tumor immune response
resulted in the implementation of a first clinical trial which applied tumor infiltrating lymphocytes
(TILs) for the treatment of melanoma [138, 139]. The promising results in melanoma therapy
were later followed by the use of TILs for the treatment of a variety of malignancies. Results
varied from barely measurable responses to durable regressions [140–145]. Further analyses
of the target epitopes of these T cells revealed that they consisted of tumor specific mutations
or over-expressed self antigens [142, 144, 146], indicating that using T cells was a promising
approach for the treatment of malignancies.
1.4.2 Dynamic tumor evolution and neoepitope identification
The most important characteristic of tumor progression is the evolutionary accumulation of ge-
netic alterations during a persons lifetime, leading to selective advantages (e.g. proliferation,
survival), as well as disadvantages (e.g. death, senescence), or no influence on the cells over-
all fate [147–150]. This is especially relevant since each new alteration slowly distinguishes
transformed cells from the untransformed surrounding, resulting in their traceability by or pro-
tection from the immune system.
The introduction of high throughput sequencing, focussing on the expressed tumor exome,
constituted an important milestone in understanding the mutational landscape of tumors on
a bigger scale [151–154]. Over the past decades it thus became apparent, that the process
of tumor evolution differs greatly between each patient (intertumoural heterogeneity), giving
each tumor an individual set of mutational configurations [72, 155]. In addition to these pa-
tient variabilities, single lesions were found to already consist of multiple subclonal populations
(intratumoural heterogeneity), each with a defined subset of mutations (see figure 10) [156–
158]. Thus, genomic instability results in a complex, dynamic set of genetic changes in each
malignant cell. In addition, these dynamics could explain the development of therapeutical re-
sistance after initial objective response to a certain treatment [159–162]. Consequently, the
use of T cells based therapies against small numbers of mutations might be largely influenced
by intratumor heterogeneity and tissue sampling.
The likelihood of exposing malignant cell progression to the immune system by antigen presen-
tation on major histocompatibility complexes (MHC) increases with each additional genetic al-
teration [163, 164]. These antigens may include over-expressed self-antigens with incomplete
T cell tolerance (e.g. by tissue restricted expression), as well as mutation-derived epitopes
(neoepitopes) [72]. Over the years, targeting of neoepitopes gained special interest, as the
respective T cell pool is not affected by central tolerance and expression is truly tumor-specific
[72, 165]. However, their identification was limited by technological hurdles for a long time.
Hence, the scope of antitumor T cell immunity remained unclear [155, 166]. Following techno-
logical progression and sophisticated experimental execution, it was later shown, that initially
nonimmunogenic murine leukemia cells were capable of inducing cytolytic T cell reactivity after
chemical mutagenesis [167]. These results reignited the idea of (neo-)antigens involved in the
anti tumor T cell response, ultimately resulting in the identification of the first immunogenic,
nonmutated self-antigens (MAGE-A1, tyrosinase, Mart-1 and gp100), as well as the realization
that mutation derived epitopes are involved in malignancy progression [168–174]. The clinical
relevance of neoepitopes was recently further underlined in multiple studies examining T cell
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reactivity against certain mutation-derived epitopes [142–144, 146, 175, 176]. Here, the forma-
tion, presentation and recognition of neoepitopes resulted in complete disease remission or led
to reduced recurrence frequencies [142, 144, 176]. For pancreatic cancer the frequent forma-
tion of potentially immunogenic neoepitopes was recently shown bioinformatically (i.e. without
functional validation) by patient-based epitope prediction [177, 178].
In addition to the identification of neoepitopes by induction of T cell responses, researchers
recently began to explore the tumor HLA ligandome by high-sensitivity mass spectrometry, al-
lowing for direct identification of naturally processed and presented antigens [179–181]. With
an expected increase in sensitivity and accessibility in the near future, this approach might
become particularly interesting for the identification of true HLA binding epitopes, especially,
when taking into account that the current algorithm based epitope prediction methods are far
from optimal. To date, predictions for HLA-A02:01 binding epitopes are the most reliable, while
other MHC-I alleles and all MHC-II alleles lag behind in prediction accuracy due to smaller
training sets for the algorithm’s artificial neural networks [182, 183].
Figure 10 – Models of tumor evolution. Depicted are the two most common pathways of clonal
tumor evolution: The linear model of tumor evolution, with surviving dominant clones inheriting
the ancestral alterations, leading to a homogenous mutational landscape (Top) and the branched
evolution model, leading to the formation of distinct subclonal populations diverging from common
ancestral cells (Bottom). Taken from [158].
1.4.3 From immunesurveillance to immunoediting
Technological hurdles hindered the prosecution of Ehrlich’s initial ideas, taking another half
a century for the field of tumor immunology to slowly start moving ahead. This time by the
more precise - yet controversial at the time - assumption of immunosurveillance by Burnet and
Thomas, who proposed a sentinel function of the immune system in recognition and elimination
of nascent malignancies [184, 185]. Almost another 50 years passed before technologies were
advanced enough to collect data supporting their hypothesis and the concept of tumor immune
editing was accepted. The current model of immune editing describes a triptych of darwinian
selection, from the early onset of atypic transformation over a balanced disease control by the
immune system to the fatal outgrowth of the malignancy [186, 187]. During the past decade,
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this hypothesis was strengthened by findings in mouse experiments and human clinical trials
[144, 153, 188, 189]. The following paragraphs briefly summarize the three stages of this
interplay between tumor and immune system.
Elimination This process describes the initial stage of immunoediting, based on the assump-
tions of immunosurveillance by Burnet and Thomas [186]. During this stage, spontaneous
accumulation of transformed cells leads to the initiation of a response cascade mediated by
cells of the innate, as well as the adaptive immune system. By upregulation of stress induced
markers (e.g. NKG2D, surface calreticulin), transformed cells are initially mainly recognized by
natural killer cells (NK cells). NK cell activation in turn leads to the induction of apoptotic tumor
cell death (e.g. TRAIL or perforin/ granzyme mediated) and to secretion of pro-inflammatory
cytokines (e.g. IFNγ, IL-12). Additionally, macrophages and granulocytes secrete TNFα, IL-1β,
IL-12 and reactive oxygen species (ROS), amplifying the inflammatory anti-tumor response.
Furthermore, remnants of dying tumor cells are ingested by dendritic cells (DCs), which mi-
grate to the tumor draining lymph nodes, priming CD4+ and CD8+ T cells by processing and
presenting tumor derived antigens [190]. In the final stage of malignant cell elimination, tumor
specific T cells home to the site of inflammation, inducing antigen specific tumor cell death
mediated by Fas and TRAIL receptor pathways.
Equilibrium Due to a constant immune selective pressure and their inherent genetic instabil-
ity, the remaining malignant cells undergo genetic and epigenetic alterations, ultimately leading
to the rise of less immunogenic tumor cell clones. The equilibrium phase of immunoediting is
often referred to as a stage of immune mediated tumor dormancy, where anti-tumor (e.g. IFNγ,
IL-12) and tumor promoting (e.g. IL-10, IL-23) factors are evened out [187, 191]. It was shown,
that specifically T cells, but not innate immune cells, mediate this stage of tumor progression,
mainly by antigen specific activation [187, 192–194].
Escape The persistent immune selective pressure against genetically unstable cells ultimately
results in the development of clones resistant to immune recognition. The main mechanisms
of evasion involve the loss of immune recognition (e.g. loss of MHC-I or tumor antigen ex-
pression), increased tumor cell survival by upregulation of antiapoptotic mechanisms (e.g. in-
creased expression the transcription factors STAT3 and Bcl-2), or creation of an immunosup-
pressive environment (e.g. inhibition of T cell responses by expression of PD-L1 on the tumor
cell surface) [144, 195–197]. In addition, an increasing number of immunosuppressive cells
- regulatory T cells (Treg), myeloid derived suppressor cells (MDSC) and M2 macrophages -
begins to infiltrate the expanding malignant environment [198]. By secretion of regulatory (e.g.
iNOS, arginase) and immunesupressive (e.g. TGFβ, IL-10) molecules these cells enhance the
inhibition of tumor reactive, effector T cells [191]. All together, the increasingly immunosup-
pressive environment facilitates disease progression. These mechanisms are summarized in
figure 11.
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Figure 11 – Schematic representation of the cancer immunoediting concept. Depicted is the trans-
formation from healthy tissue (top right) to tumor suppression (bottom left) or invasive malignant
disease under the surveillance of the immune system (middle left to right). Taken from [187]
1.4.4 Cell mediated tumor eradication
It becomes more and more apparent, that the interplay between the tumor and the immune
system involves a complex network of cellular interactions. Particularly genome instability, i.e.
emerging mutations, is of special interest, as the generated neoepitopes are potentially rec-
ognized by immune cells. The following paragraphs will focus on the two major immune cell
populations involved in tumor derived antigen presentation and recognition (see figure ?? for a
summary of the described processes).
Dendritic cells As professional antigen presenting cells, dendritic cells (DCs) control the initi-
ation and guidance of immune responses. They are phagocytic cells derived from bone marrow
haematopoietic progenitor cells (CD34+) and initially differentiate into immature precursors with
enhanced antigen uptake and low T cell priming capacity [199–201]. These immature DCs ex-
press low levels of MHC and co-stimulatory molecules (e.g. CD80, CD86, CD40) [202]. They
reside in the tissue where they screen their surroundings for foreign antigens and molecules,
using pattern recognition receptors (PRRs) such as toll-like receptors (TLRs) or NOD-like re-
ceptors (NLRs) specialized in the recognition of non-self molecules (e.g. viral nucleic acids or
bacterial components) [203, 204]. Once foreign molecules or cellular debris (e.g. from dying tu-
mor cells) are recognized, DCs undergo a maturation process, upregulating the surface expres-
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sion of MHC and co-stimulatory molecules, thus increasing their capacity to prime naïve T cells.
In addition, this activation leads to an increased uptake of the recognized molecules or cells,
combined with enhanced antigen processing and presentation on MHC molecules [205, 206].
Initially, phagocytosed antigens are broken down in the phagosomes and presented on MHC
class II molecules. Following an export to the cytosol, combined with proteasomal degradation,
antigens may also be cross-presented on MHC class I [203, 204, 207]. Once fully matured,
DCs can home to a local lymph node to induce priming of naïve CD4+ and CD8+ T cells. In
the context of tumor immunology, the process of dendritic cell maturation upon antigen uptake
and presentation can lead to the presentation of mutation derived epitopes, leading to effector
T cell responses against the respective neoepitopes.
T cells Originating from haematopoietic stem cells of the bone marrow, this cellular subset
matures in the thymus [208]. T cells are carefully selected here in order to avoid self-reactivity.
In an initial step, the cells are selected for the capability of their T cell receptor (TCR) to bind
either MHC-I or MHC-II on cortical thymic epithelial cells (cTECs) [209–211]. Depending on
MHC-TCR interaction, the ensuing maturation of the initially CD4/CD8 double-positive T cells
is determined. Increased MHC-I binding leads to CD8+ T cell maturation, whereas MHC-II
interaction promotes CD4+ maturation. For the second step of selection, T cells home to the
thymic medulla, where they are monitored for self-antigen reactivity [209–211]. Here, T cells
binding self-antigens presented by medullary thymic epithelial cells (mTECs) with high affinity
receive a death signal and undergo apoptosis. The resulting, naïve T cell pool leaves the thy-
mus and migrates to secondary lymphoid organs awaiting the encounter of target antigens. For
proper priming, naïve T cells require presentation of their specific antigen on DCs in order to fur-
ther differentiate into effector cells. The required signal cascade for this differentiation involves
three distinct signals: recognition of the peptide:MHC complex, interaction with costimulatory
molecules (such as CD28/B7) expressed by the antigen-presenting cell and the T cell, respec-
tively, and the presence of cytokines secreted by DCs (e.g. IL-12, IL-4, TGFβ) [212, 213]. In
the context of CD4+ T cell polarization, the cytokines present during the priming phase deter-
mine the later function of the emerging effector cells (see table 4) [213]. Afterwards, resulting
effector T cells migrate to the site of inflammation, screening the local tissue for their specific
antigen and either initiate destruction of affected cells (CD8+ cytotoxic T cells) or yield support
during this reaction (CD4+ helper T cells). Upon recognition of a specific antigen, effector T
cells can undergo further differentiation into long-lived memory subsets. They might develop
into central memory T cell (Tcm), residing in secondary lymphoid organs, or into effector mem-
ory cells (Tem), mainly circulating in peripheral tissues [214, 215]. These antigen experienced
T cells can in turn, unlike naïve T cells, be activated by antigen presenting macrophages and B
cells [216, 217]. Prolonged antigen exposure, however, may result in the exhaustion of specific
T cell clones. Exhausted T cells are characterized by an upregulated expression of inhibitory
receptors (e.g. PD1, LAG-3, TIM-3) and loss of effector cytokine secretion [215, 218, 219].
In the context of tumor control and eradication, primed T cells home from the draining lymph
node to the malignant site, searching for their cognate antigen. Arriving in the tumor, CD4+
and CD8+ effector T cells can take over the role of direct tumor killing [220–223]. The main
mechanisms involved in this include the expression of Fas ligand (FasL) and, in the case of
CD8+ effector cells, TNF-related apoptosis inducing ligand (TRAIL) or secretion of Perforin/
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GranzymeB [223, 224]. In addition, CD4+ effector cells can augment an indirect response in
MHC-IIneg tumors, via MHC-II restricted antigen recognition on macrophages [222].
Table 4 – Brief overview of T cell subset differentiation. Shown are the different T cell subsets in
combination with the cytokines inducing their differentiation from naïve T cells, the surface markers
and the effector cytokines characterizing each subset. Adapted from [215].
Subset Polarization Induction Factors Surface marker Effector Cytokines
CD8+ Cytotoxic T cell IL-2, IL-12 CD3, CD8 IFNγ, Perforin, Granzyme
CD4+
TH1 IL-2, IL-12, IFNγ CXCR3, CCR5 IFNγ
TH2 IL-2, IL-4 CCR4, CCR8 IL-4, IL-5, IL-13
TH9 IL-2, IL-4, TGFβ CCR3, CXCR3, CCR6 IL-9
TFH IL-6, IL-21 CXCR5, CD40L IL-21
TH17 IL-6, IL-21, IL-23, TGFβ CCR6 IL-17, IL22
TReg IL-2, TGFβ PD1, CTLA4 IL-10, TGFβ
CD4
(Th1)
CD8
IFNg
TNFa
IL-2 IL-12
-
-
+
+
+
+
pAPC
Antigen Uptake
sRFasL
Figure 12 – Schematic overview of T Cell mediated tumor erradication. Shown is the tumor antigen
uptake by dendritic cells, subsequent naïve T cell priming and the resulting direct mechanisms
involved in the T cell anti tumor response.
1.5 Tumor Immunotherapy
In view of the effective responses our immune system mounts against foreign invaders and its
active role in malignancy control, using it to directly target malignancies appears feasible. The
following paragraph will give a brief overview of immune therapeutic approaches which have
successfully improved our fight against cancer. In light of the aims of the presented thesis, the
major focus will be put on adoptive T cell transfer therapies.
1.5.1 Antibody mediated therapy
Monoclonal antibody production and their use in the treatment of haematological malignan-
cies already dates back to the late 1970s. With the approval of Rituximab (anti-CD20) the
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first antibody mediated cancer therapy became available in 1997 [225–229]. With the identifi-
cation and characterization of factors dampening the anti-tumor T cell response (e.g. PD-L1,
PD-1, CTLA4) in a broader range of malignancies, especially solid malignancies, a new era in
antibody mediated immunotherapy emerged [230–235]. In healthy individuals, these immune-
inhibitory molecules are needed to avoid autoimmunity and exacerbated immune reactions
[234]. In the course of tumor progression, upregulation of these factors strongly reduces tu-
mor specific T cell immunity, thereby promoting rapid disease progression [234]. As a direct
inhibitor of effector T cell function, CTLA4 (a negative regulator of TCR activation) was tar-
geted by the first immune checkpoint inhibitor (Ipilimumab) approved by the FDA in 2011 for
patients with advanced melanoma due to its significant impact on tumor regression and pa-
tient survival [236–238]. In recent years, more and more immune checkpoint antibodies and
their combinations showed clinical efficacy in solid malignancies and received FDA approval
(see table 5). Besides the massive success in immune checkpoint inhibition, new therapeutic
approaches involve immune stimulatory antibodies (e.g. anti-CD40, anti-CD137, anti-OX40)
as well as bi-specific T cell engagers (BiTE antibodies) and are currently being investigated
[239–242].
Table 5 – Selected list of currently approved antibody mediated cancer therapies. Based on [243,
244]
Antibody Target Type First FDA Approval Current indications
Rituximab CD20 Chimeric IgG1 1997 non-Hodgkin lymphoma
Trastuzumab HER-2 Humanized IgG1 1998 Breast cancer
Ipilimumab CTLA4 Human IgG1 2011 Metastatic melanoma
Pembrolizumab PD-1 Human IgG4 2014 Metastatic melanoma, stomach, lung and bladder cancer
Nivolumab PD-1 Human IgG4 2014 Metastatic melanoma, lung, liver, kidney and colorectal cancer
Avelumab PD-L1 Human IgG1 2015 Merkel cell carcinoma
Nivolumab + Ipilimumab PD-1 + CTLA4 Human IgG4/ IgG1 2015 Metastatic melanoma and renal cell carcinoma
Atezolizumab PD-L1 Human IgG1 2016 Non-small cell lung and bladder cancer
Durvalumab PD-L1 Human IgG1/κ 2018 Urothelial carcinoma
1.5.2 Therapeutic vaccination
The efficacy of preventive vaccinations against virus (e.g. by HPV, HBV) and bacteria (e.g.
H. pylori) induced malignancies has been known for a long time and will, therefore, not be
discussed in detail here [245, 246]. Therapeutic vaccines inducing immunity against already
established tumors on the other hand gained more attention only recently. Two major ap-
proaches are distinguished with regard to their target: Over-expressed self-antigens com-
monly found in certain types of malignancies, and patient specific, mutation derived epitopes
[72, 176, 245, 247, 248]. In the case of vaccination against over-expressed self-antigens (e.g.
NY-ESO-1, TP53, MUC-1), central tolerance and autoimmunity are the main hurdles in the in-
duction of tumor restricted, high avidity effector T cells and have dampened the enthusiasm in
the past years [246, 249, 250]. With Sipuleucel-T (Provenge), a vaccine consisting of autolo-
gous dendritic cells expressing GM-CSF and prostatic acid phosphatase (PAP), a cell based
vaccine against prostate cancer received FDA approval in 2010 [251]. A promising approach,
focussing on patient specific neoepitopes, became more apparent with an increased access
to genome sequencing [154, 176, 248, 252, 253]. Now it was possible to individually tailor
multiepitope vaccination approaches to each patient. Even though these formulations do not
prevent malignant transformation, they impressively prolonged the patients’ progression free
survival after surgical resection [176, 248]. These findings indicate that tumor derived candi-
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date neoepitopes can induce strong anti tumor T cell immunity.
1.5.3 Adoptive T cell therapy
Considering the influence of T cells on malignancy progression it appears likely that certain
T cell subpopulations may counteract disease progression. A major obstacle during the early
days was the impossibility of ex vivo culture and expansion of T cells [254]. Only with the de-
scription and purification of interleukin-2 (IL-2), researchers were able to finally culture and ex-
pand T cells in vitro [255, 256]. This finding was immediately followed by preclinical studies us-
ing ex vivo expanded tumor infiltrating lymphocytes (TILs) to treat metastasized murine tumors,
revealing the capability of IL-2 and T cells to eradicate establishedmalignancies [139, 257, 258].
Subsequent in vitro tests with human melanoma TILs demonstrated their capacity to recognize
and specifically lyse their autologous tumor [259]. These results led to the first-in-human trans-
fer of autologous TILs to patients with metastatic melanoma by S. Rosenberg and coworkers
[138, 260, 261]. The overall high objective response rates (>30%) in the context of this study
were generally promising for future applications across various malignancies [138, 260, 261].
Further optimization of the treatment schedule, including nonmyeolablative lymphodepletion
prior to TIL administration, allowed an increase in objective responses of 49% and more in pa-
tients with metastatic melanoma [140, 262, 263]. Longterm follow up of these studies showed
total remission in approximately 22% of previously relapsed patients, highlighting the cura-
tive potential of adoptive TIL transfer [262]. In the following years, adoptive TIL transfer was
applied for the treatment of multiple solid malignancies, including colorectal and breast can-
cer, as well as cholangiocarcinoma achieving disease regression if not complete remission
[142, 144, 145, 264]. In addition to these advances, it was shown, that TILs of various entities
frequently recognize neoepitopes from the autologous tumor [142–146, 175]. In this regard,
two recent trials by E. Tran and coworkers revealed the first clinical evidence of neoepitope
derived TIL reactivity in connection with tumor regression and, in one case, immune editing
[142, 144]. Their first case showed a direct therapeutic efficacy of a CD4+ TIL infusion product
targeting a mutated ERBB2IP epitope in a patient with metastatic cholangiocarcinoma lead-
ing to a disease stabilization lasting for 35 months [142]. A second trial showed regression
of metastatic colon cancer, followed by immune evasion of a single lesion, upon administra-
tion of a HLA-C08:02 restricted, CD8+ TIL product with a single KRAS_G12D specificity [144].
Taken together, the recent results of studies employing adoptive TIL transfer seem promising
across multiple solid malignancies. However, it appears to be necessary to administer a com-
bination of CD4+ and CD8+ T cells covering multiple epitope reactivities in order to overcome
immune editing and augment cytotoxic reactivity [188, 220, 221, 265]. Focusing on tumor im-
mune infiltrates, researchers could later correlate an increased T cell tumor infiltration to an
overall improved patient survival, highlighting the importance of T cell mediated tumor control
and eradication [266–269].
An alternative approach to using unmodified TILs is the use of genetically engineered periph-
eral T cells with known antigen reactivity. Applied for the first time by transferring a TCR with
known reactivity (Mart1_27-35) into autologous peripheral T cells of melanoma patients, this
approach seemed promising for cases with limited access to autologous TILs [141]. Further
improvements in the use of genetically engineered T cells later also allowed the development of
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chimeric antigen receptor (CAR) transduced T cells expressing a group of receptors composed
of a single-chain variable fragment (scFv) with specific antigen binding (e.g. CD19) and an
intracellular signaling domain (e.g. CD3ζ) [270, 271]. With the latest advances in CAR-T cell
therapy, the FDA recently approved the first two applications of this approach in patients with
B cell acute lymphoblastic leukemia (Kymriah® - αCD19; Novartis) and non-hodgkin lymphoma
(Yescarta® - αCD19; Kite Pharma) [272, 273].
1.6 Immunology of PDAC
1.6.1 Immune cell infiltration in PDAC
Pancreatic cancer used to be portrayed as a poorly immunogenic malignancy, with low numbers
of TILs being able to engage malignant cells due to the high desmoplastic reaction [274–278].
Recent in-depth analyses of larger patient cohorts revealed frequent antigen experienced ef-
fector T cell infiltrates in PDAC, consisting to a slightly larger extent of CD4+ than CD8+ cells
[279–281]. The majority of tumor infiltrating CD4+ T cells display a conventional helper T cell
phenotype, while only approximately 5 - 15% are Treg cells [279, 282]. Furthermore, increased
effector T cell infiltration, both CD4+ and CD8+, was shown to be correlated with an improved
patient survival [269, 283, 284]. Moreover, unlike previously assumed, improved imaging tech-
niques suggest that the desmoplastic reaction of PDAC does not hinder the TILs from engaging
the tumor cell [269]. The TILs display an effector memory phenotype (CD45RA-, CCR7-, PD-
1+), reflected also in the overall antigen experience [279]. Parts of the T cell infiltrates found
in PDAC could additionally be shown to derive from local clonal expansion in tumor resident
tertiary lymphoid structures (TLS) [279]. These are formations of immune cells (DCs, B cells, T
cells) capable of proper priming of naïve T cells. This process is comparable to lymph node re-
stricted priming and the presence of TLS within PDAC is linked to an improved patient survival
[279, 285–287]. Recognition of autologous xenograft tumors and xenograft derived cell lines
by in vitro expanded TILs additionally highlights the possibility of T cell mediated tumor control
in PDAC [279]. Additional co-infiltration of myeloid derived suppressor cells (MDSCs) and M2
macrophages, however, might antagonize the anti tumor efficacy of PDAC infiltrating effector T
cells [269, 282, 288, 289].
1.6.2 Cancer immunotherapy in PDAC
Following the major success of cancer immunotherapy in various solid malignancies, researchers
aimed at translating these findings into the context of pancreatic cancer [251, 290–292]. The
upcoming paragraphs will give a brief overview of the most recent clinical attempts of applying
immunotherapy in PDAC.
Antibody mediated therapy The first major arm of immunotherapies applied in pancreatic
cancer is formed by the use of immunomodulatory antibodies. Here, especially antibodies
targeting the inhibitory molecules CTLA-4 and PD-L1 were tested in patients with advanced
stage PDAC, with no effect on patients overall survival or increase in therapy response rates
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[293–295]. A main factor for these weak responses is most likely the overall immunosuppres-
sive environment present in PDAC. An approach counteracting this suppressive environment
uses an agonist α-CD40 antibody to promote tumor reactive T cells and induce macrophage
mediated depletion of tumor stroma [296–298]. The first application of this antibody in PDAC
patients led to objective responses in a small subset of 21 patients [239]. Here, the efficacy
of the agonist CD40 antibody was highlighted by partial responses in four patients (19%) and
disease stabilization in an additional eleven patients (52%) [239].
Vaccination Even though vaccination against already establishedmalignancies appears chal-
lenging, a number of studies in PDAC could show promising initial results [299–302]. The most
promising of which, the GVAX approach, includes allogeneic GM-CSF secreting tumor cells,
fostering immune cell activation and inducing anti tumor immunity [299]. Further enhancements
of this approach, using low dose cyclophosphamide for Treg depletion in combination with CRS-
207 (mesothelin-expressing Listeria monocytogenes), later improved patients overall survival
and mounted mesothelin restricted CD8+ T cell immunity [303, 304]. These approaches are still
actively investigated and concluding results are yet to be evaluated. Nevertheless, the initial re-
sults indicate the possibility of mounting relevant anti-tumor T cell responses within pancreatic
cancer upon stimulation.
Adoptive T cell therapy Up to now adoptive T cell transfer in the context of PDAC has rarely
been investigated. A first study, using PBMCs, primed in vitro with a MUC-1 expressing al-
logeneic tumor cell line (YPK-1), showed tumor mass reduction upon intravenous injection in
patients [305, 306]. A second approach applied mesothelin specific CAR-T cells in an early
case report, resulting in 6 months lasting disease stabilization upon CAR-T cell infusion [307].
Even though further investigation of these approaches is necessary, the initial results reveal
additional evidence for the possibility of mounting effective anti-tumor T cell responses in pan-
creatic cancer.
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2 Materials
2.1 Consumables
Table 6 – List of consumable materials
Product Company Catalog Number
500ml ”rapid”-Filtermax 0.2 µm PES TPP Techno Plastic Products AG, Trasadingen, Switzerland 99500
96 well V-bottom VWR International GmbH, Darmstadt CLS3897-100EA
AbC™ capture beads Life Technologies GmbH, Darmstadt A10344
ArC™ reactive beads Life Technologies GmbH, Darmstadt A10346
BD Discard™ II Sysringe (5 mL) Becton Dickinson, Franklin Lakes, USA 309050
C-Chip Biochrom GmbH, Berlin P DHC-N01
Cell culture dish 100x20 mm Optilux Corning Inc. New York, USA 353003
Cell culture flasks (T25, T75, T150) TPP Techno Plastic Products AG, Trasadingen, Switzerland 90026, 90076, 90151
Cell culture plates (6-, 24-, 96-well) VWR International GmbH, Darmstadt 734-2323, 734-2325, 734-2328
Cell culture plates (non-tissue culture treated) Corning Inc. New York, USA CLS3736-100EA
Cell strainer Easystrainer (40, 70, 100 µm) Greiner Bio-One GmbH, Frickenhausen 542040, 542070, 542000
Centrifuge Tubes (15, 50 mL) Greiner Bio-One GmbH, Frickenhausen T1943, T2068
Centrifuge Tubes 225 mL Becton Dickinson, Franklin Lakes, USA 12556
Cryo vials 2 mL Simport Ltd., Quebec, Canada T311-2
Cryo-babies and cryotags Diversified Biotech, Dedham, MA, USA RNBW-2200
Disposable Scalpel Feather Safety Razor Co Ltd., Japan 02.001.30.020
Extra thick blot paoer (7 x 8.4 cm) Bio-Rad Laboratories GmbH, Munich 170-3966
FACS Tubes Corning Inc. New York, USA 352008
Falcon™ Disposable Polystyrene Serological Pipets (5, 10, 25, 50 mL) Corning Inc. New York, USA 7521, 7543, 7551, 7525, 7550
Gene Pulser/MicroPulser Cuvettes, 0.4 cm Bio-Rad Laboratories GmbH, Munich 165-2088
gentleMACS C tubes Miltenyi Biotech GmbH, Bergisch Gladbach 130-093-237
Incidin™ Foam Ecolab Deutschland GmbH, Monheim am Rhein 30 460 10
Incidin™ Pro Ecolab Deutschland GmbH, Monheim am Rhein 30 765 60
Incuwater-Clean™ AppliChem GmbH, Darmstadt A5219.0100
InLab® Buffer Solutions (pH meter) Mettler Toledo GmbH, Schwerzenbach, Switzerland 51302068
LS columns Miltenyi Biotech GmbH, Bergisch Gladbach 130-042-401
Medoject Needles (18G) Chirana T Injecta, Stara Tura, Slovakia CH18112SB
Microliter Filter Tips (10, 200, 1000 µL) STARLAB International GmbH, Hamburg S1120-3810, S1120-1810, S1120-8810, S1126-7810
Microliter Syringe ™ (50 µL) Hamilton Bonaduz AG, Bonaduz, Switzerland 80565/00
Microliter Tip Stack (200 µL) STARLAB International GmbH, Hamburg S1111-1206
Millex® Sterile Filter Unit (33 mm; 0.45 µm) Merck Millipore Ltd., Tullagreen, Ireland SLHV033RS
MiniPROTEAN precast gel (4-20%) Bio-Rad Laboratories GmbH, Munich 456-1093
MultiScreen® 96-well plate Merck Millipore Ltd., Tullagreen, Ireland MAHAS4510
Parafilm "M" Laboratory Film Bemis Flexible Packaging, Neenah, WI, USA PM-996
PCR SingleCap 8-SoftStrips 0.2 ml Biozym Scientific GmbH, Hessisch Oldendorf 710970
Petri dish (10 cm) Greiner Bio-One GmbH, Frickenhausen 616201
Polystyrene Round Bottom Tube (14 mL) Corning Inc. New York, USA 352059
Primaria cell culture flasks (T75, T150) Corning Inc. New York, USA 353810, 353112
Propan/ Butan CAMPINGAZ GmbH, Hattersheim C206GLS
PVDF-Membran Immobilon-P Merck KGaA, Darmstadt IPVH00010
Reaction Tubes DNA LoBind (1.5 mL) Eppendorf AG, Hamburg 0030108-051
Reaction Tubes Safe Lock (0.5, 1.5, 2.0 mL) Eppendorf AG, Hamburg 0030121-023, 0030120-086, 003120-094
Reagent reservoir 50ml Corning Inc. New York, USA 4870
Sekusept™ PLUS Ecolab Deutschland GmbH, Monheim am Rhein 30 309 10
SIGMA™ Cell Scraper Sigma-Aldrich Chemie GmbH, Munich SIAL0010-100EA
Ultracentrifuge tube Ultra Clear™ (14 mL) Beckman Coulter Ireland Inc., Galway, Ireland 344060
ViCell Sample Cup 4ml Beckman Coulter Ireland Inc., Galway, Ireland 383721
X-tracta Disposable Gel Extraction Tool STARLAB International GmbH, Hamburg N2000-0025
2.2 Kits
Table 7 – List of Kits
Kit Company Catalog Number
BD Cytofix/ Cytoperm™ Plus Becton Dickinson, Franklin Lakes, USA 555028
CD4+ T-cell isolation kit mouse Miltenyi Biotech Inc., Auburn, CA, USA 130-104-454
CD8a+ T-cell isolation kit mouse Miltenyi Biotech Inc., Auburn, CA, USA 130-104-075
Dneasy® Blood & Tissue Kit QIAGEN GmbH, Hilden 69506
EndoFree® Plasmid Maxi Kit QIAGEN GmbH, Hilden 12362
Human IFNγ ELISA MAX™ Deluxe Set BioLegend, San Diego, CA, USA 430104
human IFNγ ELISpotBASIC MABTECH, Nacka Strand, Sweden 3420-2A
human TNFα ELISpotBASIC MABTECH, Nacka Strand, Sweden 3510-2A
MinElute® PCR Purification Kit QIAGEN GmbH, Hilden 28004
Mouse Cell Depletion Kit Miltenyi Biotech Inc., Auburn, CA, USA 130-104-694
NucleoSpin® Gel and PCR Celan-up Macherey-Nagel GmbH & Co KG, Düren 740609.50
QIAprep® Spin Miniprep Kit QIAGEN GmbH, Hilden 27106
RNA 6000 Nano Agilent Technologies Inc., Santa Clara, CA, USA 5067-1511
Rneasy Mini RNA QIAGEN GmbH, Hilden 74104
Tumor dissociation Kit, Human Miltenyi Biotech Inc., Auburn, CA, USA 130-095-929
Tumor dissociation Kit, Mouse Miltenyi Biotech Inc., Auburn, CA, USA 130-096-730
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Table 8 – Hardware and machines
Product Company
2100 Bioanalyzer Agilent Technologies Inc., Santa Clara, CA, USA
37°C incubator Heraeus Instruments
Analytical scale Quintix124-1S Sartorius Lab Instruments GmbH & Co KG
BD HTS Becton Dickinson, Franklin Lakes, USA
BioRad GenePulser Xcell Bio-Rad Laboratories GmbH, Munich
Biorad PowerPac Basic Bio-Rad Laboratories GmbH, Munich
Bioreader 5000 F-beta BIO-SYS GmbH, Karben
BVC professional (S2 environment) Vacuubrand GmbH & Co KG, Wertheim
Cell cultre flows (Safe2020, MaxiSafe2020) Thermo Fisher Scientific, Waltham, MA, USA
Centrifuge 5810, 5810R, 5424, 5424R Eppendorf AG, Hamburg
CO2 incubator Heracell 150i & 240i Thermo Fisher Scientific, Waltham, MA, USA
CoolCell® Corning Inc. New York, USA
CTL ImmunoSpot® Cellular Technology Ltd., Cleveland, OH, USA
DNA gel printer INTAS Science Imaging GmbH, Göttingen
EnVision 2104 Multilabel Reader Perkin Elmer, Waltham, MA, USA
Eppendorf thermomixer comfort Eppendorf AG, Hamburg
Flow cytometer BD LSRFortessa Becton Dickinson, Franklin Lakes, USA
Freezer -20 °C Liebherr-International Deutschland GmbH, Biberach a.d. Riß
Freezer -80 °C Eppendorf AG, Hamburg
Fridge Liebherr-International Deutschland GmbH, Biberach a.d. Riß
Fujifilm Las-3000 Fujifilm, Tokio, Japan
Gel electrophoresis chambers Biometra GmbH, Göttingen
GenePulser Xcel (+CE module) Bio-Rad Laboratories GmbH, Munich
Heidolph Polymax 1040 Heidolph Instruments GmbH, Schwabach
INTAS UV-System INTAS Science Imaging GmbH, Göttingen
Integra Vacusafe Integra Biosciences AG, Zizers, Switzerland
Intensilight C-HGFI Nikon Corporation, Tokio, Japan
Laboratory glass bottles Schott AG, Mainz
MACS Mix Miltenyi Biotech GmbH, Bergisch Gladbach
Magnet Stand Miltenyi Biotech GmbH, Bergisch Gladbach
Mercury Lamp (HB-10101AF) Nikon Corporation, Tokio, Japan
Microliter Pipettes Eppendorf AG, Hamburg
MidiMACS Magnets Miltenyi Biotech GmbH, Bergisch Gladbach
Minitron 37°C shaker Infors AG, Bottmingen, Switzerland
Nanodrop8000 Thermo Fisher Scientific, Waltham, MA, USA
neoVortex® Mixer neoLab Migge GmbH, Heidelberg
Nikon DIAPHOT300 Nikon Corporation, Tokio, Japan
Nikon Eclipse TS100 Nikon Corporation, Tokio, Japan
Nikon Power Unit (12V; 100W) Nikon Corporation, Tokio, Japan
Optima™ L-90K Ultracentrifuge Beckman Coulter GmbH, Krefeld
Optima™ XPN-80 Ultracentrifuge Beckman Coulter GmbH, Krefeld
PerfectBlueTM “semi-dry” electro blotter VWR International GmbH, Darmstadt
pH Electrode SE 100 N Knick Elektronische Messgeräte GmbH & Co KG; Berlin
pH meter 766 Calimatic Knick Elektronische Messgeräte GmbH & Co KG; Berlin
Pipetboy-Sterilfilter 0.45 Integra Biosciences AG, Zizers, Switzerland
Plate washer EL406 BioTek Instruments GmbH, Bad Friedrichshall
PrimoVert Light Microscope Carl Zeiss AG, Oberkochen
Professional Trio Thermocycler Biometra GmbH, Göttingen
PyroMark Q24 QIAGEN GmbH, Hilden
Scale Kern 572 Kern & Sohn GmbH, Balingen
SDS PAGE chambers Bio-Rad Laboratories GmbH, Munich
SW40Ti ultracentrifuge rotor Beckman Coulter GmbH, Krefeld
Tissue dissociator gentleMACS Octo Dissociator Miltenyi Biotech GmbH, Bergisch Gladbach
Vi-CELL® XR cell counter and viability analyzer Beckman Coulter GmbH, Krefeld
Waterbath GFL Gesellschaft für Labortechnik mbH, Burgwedel
Wessamat Perfect Ice Micro Cubes Friedrich Wolf GmbH, Heidelberg
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2.4 Chemicals and reagents
Table 9 – List of reagents
Reagent Ingredient Amount
4x Laemmli buffer Bio-Rad Medical Diagnostics GmbH, Dreieich 1610747
Ammonium Persulfate MP Biomedical LLC, Solon, OH, USA 802811
Ampicillin (sodium salt) Sigma-Aldrich Chemie GmbH, Munich A0166-25G
BD FACSClean Becton Dickinson, Franklin Lakes, USA 340345
BD FACSFlow Becton Dickinson, Franklin Lakes, USA 342003
BD FACSRinse Becton Dickinson, Franklin Lakes, USA 340346
BSA - Type H1 GERBU Biotechnik GmbH, Heidelberg 10630100
Calcium chloride Sigma-Aldrich Chemie GmbH, Munich C7902-500G
CHAPS AppliChem GmbH, Darmstadt A1099.0005
Clarity Western ECL substrate kit Bio-Rad Laboratories GmbH, Munich 170-5060
cOmplete protease inhibitor Roche Diagnostics GmbH, Mannheim 11836153001
Corning® Matrigel® neoLab Migge GmbH, Heidelberg 356231
COULTER® CLENZ Cleaning Agent Beckman Coulter Ireland Inc., Galway, Ireland 8448222
COULTER® ISOTON® II Diluent Beckman Coulter Ireland Inc., Galway, Ireland 8448011
CountBright™ absolute counting beads Life Technologies GmbH, Darmstadt C36950
D-Glucose Carl Roth GmbH & Co KG, Karlsruhe X997.2
di-Sodium Hydrogen Phosphate Carl Roth GmbH & Co KG, Karlsruhe T877.1
Ethanol (absolute) Thermo Fisher Scientific, Waltham, MA, USA E/0650DF/C17
Ethidium bromide AppliChem GmbH, Darmstadt A1152.0010
GeneRuler™ DNA Ladder Mix Thermo Fisher Scientific, Waltham, MA, USA SM0331
HEPES EMD Millipore Corp., Billerica, MA, USA 391338-100GM
Hydrochloric acid (37%) VWR International GmbH, Darmstadt 20252290
Isopropanol Thermo Fisher Scientific, Waltham, MA, USA P/7500/PC17
Kanamycine Sulfate Carl Roth GmbH & Co KG, Karlsruhe T832.2
LB broth (Lysogeny Broth) Sigma-Aldrich Chemie GmbH, Munich L3022
LB-Agar Sigma-Aldrich Chemie GmbH, Munich L2897
Methanol Thermo Fisher Scientific, Waltham, MA, USA M/4000/PC17
n-Octyl-β-D-Glucopyranoside AppliChem GmbH, Darmstadt A1010.0001
PageRuler™ prestained protein ladder 10 to 180 kDa Thermo Fisher Scientific, Waltham, MA, USA 26616
Phenylmethylsulfonylfluorid Carl Roth GmbH & Co KG, Karlsruhe 6367.4
Potassium chloride Carl Roth GmbH & Co KG, Karlsruhe 6781.1
Retronectin® TaKaRa Bio Inc., Kusatsu, Japan T100B
rm-IL21 AIMM Therapeutics, Amsterdam, Netherlands —
RNase-ZAP™ Sigma-Aldrich Chemie GmbH, Munich R2020
Rotiphorese® Gel 30 Carl Roth GmbH & Co KG, Karlsruhe 3029.1
SIGMAFAST™ BCIP®/NBT Sigma-Aldrich Chemie GmbH, Munich B5655-25TAB
Sodium chloride Sigma-Aldrich Chemie GmbH, Munich 31434
Sodium Deoxycholate Sigma-Aldrich Chemie GmbH, Munich D6750-10G
Sodium hydroxide (solution) Thermo Fisher Scientific, Waltham, MA, USA 35256-1L
Sulfuric acid (96 %) Carl Roth GmbH + Co. KG, Karlsruhe 4623.3
TEMED Carl Roth GmbH & Co KG, Karlsruhe 2367.3
Tris buffered saline (10x TBS) Bio-Rad Laboratories GmbH, Munich 170-6435
Tris/Glycine Buffer (10x TG) Bio-Rad Laboratories GmbH, Munich 161-0771
Tris/Glycine/SDS Buffer (10x TGS) Bio-Rad Laboratories GmbH, Munich 161-0772
Trypan Blue solution Sigma-Aldrich Chemie GmbH, Munich T8154-100ML
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2.5 Molecular biology and western blot reagents
All enzymes were already supplied with the respective reaction buffers and supplements. En-
zymatic reactions were set up and performed according to the manufacturers guidelines.
Table 10 – List of molecular biology reagents
Reagent Company Catalogue Number
ApaI Thermo Fisher Scientific, Waltham, MA, USA ER1411
BglII Thermo Fisher Scientific, Waltham, MA, USA ER0081
BsmBI/ Esp3I Thermo Fisher Scientific, Waltham, MA, USA ER0451
BveI/ BspMI Thermo Fisher Scientific, Waltham, MA, USA ER1741
dNTP mix (10 mM) Thermo Fisher Scientific, Waltham, MA, USA R0191
EcoRI Thermo Fisher Scientific, Waltham, MA, USA ER0271
EndoH New England Biolabs GmbH, Ipswich, MA, USA P0702S
FastAP Thermo Fisher Scientific, Waltham, MA, USA EF0654
FastDigest BveI/ BspMI Thermo Fisher Scientific, Waltham, MA, USA FD1744
FastDigest Eco31I/ BsaI Thermo Fisher Scientific, Waltham, MA, USA FD0293
FastDigest NotI Thermo Fisher Scientific, Waltham, MA, USA FD0593
HindIII Thermo Fisher Scientific, Waltham, MA, USA ER0501
Library Efficiency DH5α Competent Cells Life Technologies GmbH, Darmstadt 18263012
MyTaq™ HS Mix Bioline Reagents Ltd. BIO-25045
NheI Thermo Fisher Scientific, Waltham, MA, USA ER0975
NotI Thermo Fisher Scientific, Waltham, MA, USA ER0595
Nuclease free water Thermo Fisher Scientific, Waltham, MA, USA R0581
Pfu DNA Polymerase Thermo Fisher Scientific, Waltham, MA, USA EP0501
PNGaseF New England Biolabs GmbH, Ipswich, MA, USA P0704S
SOC medium Thermo Fisher Scientific, Waltham, MA, USA 15544034
T4 DNA Ligase Thermo Fisher Scientific, Waltham, MA, USA EL0014
T4 Polynucleotide Kinase (T4 PNK) Thermo Fisher Scientific, Waltham, MA, USA EK0031
2.6 Cell lines
Table 11 – List of cell lines used during this work.
Cell line Organism Tissue Medium Provider Reference Comment
ø-NX Ampho human kidney ø-NX ATCC® CRL-3213™ [308–310] CD8+; MMULV (gag-pol+& env+)
771 B cells mouse B cell B cell AG Ossendorp (LUMC Leiden) [311, 312] MCF1233 MuLV-transformed
BOK mouse fibroblast BOK Schoenberger/ Offringa [313, 314] B7-1+, SigOVA(257-264)+, H2-Kb+
CD40L L cells mouse fibroblast B cell AIMM Therapeutics — Expresses CD40L
HEK293T human kidney ø-NX ATCC® CRL-3216™ [315] Expresses SV40 large T antigen
KBV623 human B cell B cell AG Heemskerk (LUMC Leiden) [316] EBV immortalized
T2 human B and T cell hybrid T2 ATCC® CRL-1992™ [317] TAP1-; TAP2-; LMP2-; LMP7-
TIPC102 human pancreas/ PDX derived PaCo AG Sprick (DKFZ) — Grows only in Primaria Flask
TIPC102_A2 human pancreas/ PDX derived PaCo + G418 AG Will (GPCF - DKFZ) — HLA-A02:01 transduced; neoR
TIPC113 human pancreas/ PDX derived PaCo AG Sprick (DKFZ) — Grows only in Primaria Flask
TIPC222 human pancreas/ PDX derived CSC — — —
TIPC222_CIITA human pancreas/ PDX derived CSC + G418 AG Will (GPCF - DKFZ) — CIITA transduced; neoR
TIPC253_Bcell human B cell B cell AIMM Therapeutics [318] Bcl-6/XL immortalized; GFP+
TIPC275_Bcell human B cell B cell AIMM Therapeutics [318] Bcl-6/XL immortalized; GFP+
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2.7 Cell culture solutions and reagents
Table 12 – List of cell culture products
Product Company Catalog Number
100x sodium pyruvate (100 mM) Life Technologies GmbH, Darmstadt 11360039
100x Streptomycin-Penicillin (10000 units/ml) (Pen/Strep) Thermo Fisher Scientific, Waltham, MA, USA 15140-122
12-O-Tetradecanoylphorbol-13-acetate (PMA) Sigma-Aldrich Chemie GmbH, Munich P-1585
2-Mercaptoethanol, 50 mM (1000X) Life Technologies GmbH, Darmstadt 31350-010
ACK (Ammonium-Chloride-Potassium) lysing buffer Lonza Group Ltd, Basel, Switzerland 10-548E
Advanced DMEM/ F12 Life Technologies GmbH, Darmstadt 12634
AIM V Life Technologies GmbH, Darmstadt 12055091
Albumin from bovine serum (BSA) Sigma-Aldrich Chemie GmbH, Munich A9418-100G
BSA 20% (Albumax I solution) Life Technologies GmbH, Darmstadt 11020-039
Collagenase Type IV Life Technologies GmbH, Darmstadt 17104-019
DMEM, high glucose (Dulbecco’s Modified Eagle Media) Life Technologies GmbH, Darmstadt 41965-039
DMSO Hybri-max sterile filtered Sigma-Aldrich Chemie GmbH, Munich D2650-100ML
DNase I AppliChem GmbH, Darmstadt A3778
Dulbeccos Phosphate buffered saline (+ Calciumchloride) Sigma-Aldrich Chemie GmbH, Munich D8662-24x500ml
DynaBeads® Human T-Activator CD3/CD28 Life Technologies GmbH, Darmstadt 11131D
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich Chemie GmbH, Munich 1233508
Fetal bovine serum (FBS superior) Biochrom GmbH, Berlin S 0615
Ficoll Paque Plus GE Healthcare Bio-Science AB, Uppsala, Sweden AM/17144003/000001
Fungizone/ Amphotericin B Life Technologies GmbH, Darmstadt 15290018
G418 disulfate salt solution Sigma-Aldrich Chemie GmbH, Munich G8168-10ML
Gentamicin Life Technologies GmbH, Darmstadt 15750060
Glucose 45% Sigma-Aldrich Chemie GmbH, Munich G8769
Glucose solution (200 g/L) Life Technologies GmbH, Darmstadt A24940-01
Glutamine Life Technologies GmbH, Darmstadt 25030024
GolgiPlug™ Becton Dickinson, Franklin Lakes, USA 555029
GSH (L-Glutathione reduced) Sigma-Aldrich Chemie GmbH, Munich G6013-5G
Heparine 2 mg/mL Sigma-Aldrich Chemie GmbH, Munich H3149
HEPES buffer solution (1 M) Life Technologies GmbH, Darmstadt H0887-100ml
Human Serum Albumin (20%) CSL Behring GmbH, Marburg L0744411A
Human Serum Type AB (male) Sigma-Aldrich Chemie GmbH, Munich H4522-100ML
HyClone H2O GE Healthcare Bio-Science AB, Uppsala, Sweden SH3052902
Hygromycin B Life Technologies GmbH, Darmstadt 10687010
IGFR3 (LONG(R) R3 IGF-1, HUMAN) Sigma-Aldrich Chemie GmbH, Munich I1271-1MG
IMDM (Iscove’s Modified Dulbecco’s Media) Life Technologies GmbH, Darmstadt 12440053
Ionomycin Sigma-Aldrich Chemie GmbH, Munich I-3909
L-Glutamine Life Technologies GmbH, Darmstadt 25030-024
Lipid Mix Life Technologies GmbH, Darmstadt 11905-031
Medium199 Thermo Fisher Scientific, Waltham, MA, USA 31150022
MEM NEAA (100X) Life Technologies GmbH, Darmstadt 11140-035
N2 Supplement Life Technologies GmbH, Darmstadt 18045-070
Opti-MEM® Rreduced serum medium (1X) Life Technologies GmbH, Darmstadt 31985047
Phytohaemagglutinin (PHA) Sigma-Aldrich Chemie GmbH, Munich L-8754
Proleukin® S Novartis Pharma AG, Basel, Switzerland 2238131
Recombinant human basic FGF PeproTech Germany, Hamburg 100-18B
Recombinant human EGF PeproTech Germany, Hamburg AF-100-15
Recombinant Human FGF-10 PeproTech Germany, Hamburg AF-100-26
Recombinant Human IFNγ Becton Dickinson, Franklin Lakes, USA 554617
Recombinant Human Nodal R&D Systems, Minneapolis, MN, USA 3218-ND-025/CF
Recombinant Human β2 Microglobulin Becton Dickinson, Franklin Lakes, USA 551089
RPMI 1640 Medium Life Technologies GmbH, Darmstadt 52400025
β-MercaptoEthanol Life Technologies GmbH, Darmstadt 31350-010
StemPro Accutase Life Technologies GmbH, Darmstadt A11105-01
Trace Elements A VWR International GmbH, Darmstadt MDTH25-021-CI
Trace Elements B VWR International GmbH, Darmstadt MDTH25-022-CI
Trace Elements C VWR International GmbH, Darmstadt MDTH25-023-CI
Trypan Blue Solution (Cell Culture) Sigma-Aldrich Chemie GmbH, Munich T8154-100mL
Tween-20 AppliChem GmbH, Darmstadt A1389.0500
UltraPure™ 0.5 M EDTA pH8 Thermo Fisher Scientific, Waltham, MA, USA 15575020
Water (f.i. or cell culture grade) Life Technologies GmbH, Darmstadt A12873-01
X-Vivo 15 Lonza Group Ltd, Basel, Switzerland BE02-060Q
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2.8.1 Fluorescence antibodies and markers
Table 13 – Flow cytometry antibodies and reagents for human cells
Marker Fluorophore Clone Supplier Catalogue Number Amount per sample [µL]
HLA-DR, DP, DQ FITC Tu39 Becton Dickinson, Franklin Lakes, USA 563591 2.5
CD3 BV711 OKT3 BioLegend, San Diego, CA, USA 317328 2.5
CD4 APC-Cy7 SK3 BioLegend, San Diego, CA, USA 344616 1.0
CD8 Alf-700 HIT8a BioLegend, San Diego, CA, USA 300920 2.5
CD271 (NGFR) APC ME20.4 BioLegend, San Diego, CA, USA 345108 3.0
FLAG APC L5 BioLegend, San Diego, CA, USA 637308 4.0
HLA-A, B, C FITC W6/32 BioLegend, San Diego, CA, USA 311410 2.5
CD326 (EpCAM) APC-Vio770 HEA-125 Miltenyi Biotech Inc., Auburn, CA, USA 130-101-161 2.5
HLA-A2 FITC BB7.2 BioLegend, San Diego, CA, USA 343304 2.0
TNF-α APC MAb11 BioLegend, San Diego, CA, USA 502912 4.0
IFN-γ PE B27 Becton Dickinson, Franklin Lakes, USA 559327 5.0
mTCR-β BV421 H57-597 BioLegend, San Diego, CA, USA 109229 3.0
CD4 BV510 OKT4 BioLegend, San Diego, CA, USA 317443 2.0
FLAG APC L5 BioLegend, San Diego, CA, USA 637308 3.0
Dextramer (HLA-A2_Mart1) PE — Immudex, Copenhagen, Denmark WB2162_PE 10.0
Dextramer (HLA-A2_neg) PE — Immudex, Copenhagen, Denmark WB2666_PE 10.0
Table 14 – Flow cytometry antibodies and reagents for mouse cells
Marker Fluorophore Clone Supplier Catalogue Number Amount per sample [µL]
CD45.1 BV711 A20 BioLegend, San Diego, CA, USA 110739 0.5
CD45.2 PE/ Dazzle594 104 BioLegend, San Diego, CA, USA 109846 0.5
H2-Kb APC AF6-88.5 BioLegend, San Diego, CA, USA 116518 0.5
H2-Kb- SIINFEKL PE 25-D1.16 BioLegend, San Diego, CA, USA 141603 0.5
CD3 APC 17A2 BioLegend, San Diego, CA, USA 100236 0.1
CD8a APC-Cy7 53-6.7 BioLegend, San Diego, CA, USA 100714 0.1
CD4 Pacific Blue RM4-5 BioLegend, San Diego, CA, USA 100531 0.1
Table 15 – Additional flow cytometry reagents
Product Company Catalogue Number
Fixable LIVE/ DEAD cell marker Aqua Thermo Fisher Scientific, Waltham, MA, USA L34957
Fixable LIVE/ DEAD cell marker 488 Thermo Fisher Scientific, Waltham, MA, USA L23101
Zombie Violet™ Fixable Viability Kit BioLegend, San Diego, CA, USA 423113
5(6)-Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) Sigma-Aldrich Chemie GmbH, Munich 21888
2.8.2 Western blot
Table 16 – Western blot antibodies
Marker Host Company Catalogue Number Dilution
α-GAPDH rabbit GeneTex Inc., Irvine, CA, USA GTX100118 1:1000
α-FLAG (M2) mouse Sigma-Aldrich Chemie GmbH, Munich F1804 1:1000
α-rabbit-HRP goat SantaCruz Biotechnology Inc., Dallas, TX, USA sc-2004 1:20.000
α-mouse-HRP goat SantaCruz Biotechnology Inc., Dallas, TX, USA sc-2005 1:20.000
2.8.3 Additional
Table 17 – Additional antibody formats
Marker Isotype Company Catalogue Number
HLA-DP,DQ,DR CR3/43 Dako Denmark A/S, Glostrup, Denmark M0775
Ultra-LEAF™ HLA-A,B,C W6/32 BioLegend, San Diego, CA, USA 311428
CD3 OKT3 Life Technologies GmbH, Darmstadt 16-0037-85
CD28 CD28.2 Thermo Fisher Scientific, Waltham, MA, USA 16-0289-85
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2.9 Buffers and media
Table 18 – List of media used for cell culturing. (part1) (# = as described in [319]).
Medium Ingredient (Stock concentration) Amount Comments
T2 RPMI 500 mL
FCS 50 mL
ø-NX culture medium DMEM 500 mL
NEAA 5 mL
Pen/Strep 5 mL
Cryomedium FCS 45 mL
DMSO 5 mL
B cell medium IMDM 500 mL
L-Glutamine (200 mM) 5 mL
FCS 50 mL
Pen/Strep 5 mL
CSC Medium Advanced DMEM/ F12 500 mL
B27 Supplement 10 mL
L-Glutamine (200 mM) 5 mL
Glucose (200 g/L) 15 mL
Heparine (12 mg/mL) 500 µL
HEPES (1 M) 2.5 mL
Pen/Strep 5 mL
PaCo medium# Advanced DMEM/ F12 500 mL
N2 Supplement 5 mL
L-Glutamine (200 mM) 5 mL
GSH (2mg/mL) 250 µL Stock in H20
human basic FGF (250 µg/ mL) 250 µL Stock in PBS + 1% BSA
human EGF (100 µg/ mL) 200 µL Stock in PBS + 1% BSA
IGFR3 (1 mg/ mL) 5 µL Stock in 10 mM HCl
β-mercapto ethanol 1 mL
water 25 mL
10x PaCo Master Mix 8.45 mL
10x PaCo Master Mix# Glucose (45 %) 17 mL
Trace Elements A 2.5 mL
Trace Elements B 5 mL
Trace Elements C 5 mL
BSA - Albumax I solution (20 % w/V) 15 mL Stock in PBS
Heparine (2 mg/ mL) 5 mL
Lipid Mix 10 mL
HEPES (1 M) 25 mL
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Table 19 – List of media used for cell culturing (part 2)
Medium Ingredient (Stock concentration) Amount Comments
Transport medium X-Vivo 15* 140 mL
HSA 20 mL
Fungizone (250 µg/ mL) 20 mL
Gentamicin (50 mg/ mL) 80 µL
Pen/Strep 20 mL
TIL culture medium I X-Vivo15* 1000 mL Supplemented with either:
Fungizone (250 µg/ mL) 10 mL 2% Human AB serum or 2% HSA
Gentamicin (50 mg/ mL) 400 µL and
Pen/Strep 10 mL 600 IU/ mL human IL-2
OT culture medium DMEM 500 mL
FCS 50 mL
β-mercapto ethanol 500 µL
HEPES (1 M) 5 mL
Sodium pyruvate 5 mL
Pen/ Strep 5 mL
BOK culture medium DMEM 500 mL
FCS 50 mL
Pen/Strep 5 mL
G418 300 µg/ mL
Hygromycin B 300 µg/ mL
TIL-medium X-vivo 15* 1000 mL Supplemented with:
HSA 100 mL 300 IU/ mL human IL-2
Pen/Strep 10 mL
* Due to issues with the production and delivery X-vivo15 was later replaced with a mix of
RPMI1640 and AIM-V (50% each).
Table 20 – List of bacterial growth media. *SOC medium was delivered with the Library Efficiency
DH5α bacteria.
Buffer Ingredient Amount
LB Medium ddH2O 800 mL
LB broth 16 g
LB agar ddH2O 400 mL
LB agar 14 g
SOC medium* Tryptone 2%
Yeast extract 0.5%
Sodium chloride 10 mM
Potassium chloride 2.5 mM
Magnesium chloride 10 mM
Magnesium sulfate 10 mM
Glucose 20 mM
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Table 21 – List of additional buffers used
Buffer Ingredient (Stock concentration) Amount/ Concentration Comment
FACS buffer PBS 500 mL
BSA 2.5 g
EDTA 2 mM
2x HBS ddH2O —
NaCl 274 mM
KCl 10 mM
Na2HPO4 1.4 mM
D-Glucose 15 mM
HEPES 42 mM
Lysis Buffer PBS 5.25 mL CHAPS later changed for:
CHAPS 0.6% [w/V] n-Octyl-β-D-Glucopyranoside (1% [w/V])
PMSF (100 mM) 52 µL Sodium Deoxycholate (0.25% [w/V])
cOmplete protease inhibitor 1 Tablet to avoid clogging of the spectrometer
ELISpot-wash buffer PBS 500 mL
Tween-20 0.05% [V/V]
ELISpot-blocking buffer X-Vivo15 10 mL
HSA (20%) 500 µL
Transfer buffer 10x TG 100 mL
Methanol 200 mL
H2O 700 mL
TBS buffer 10x TBS 100 mL
H2O 900 mL
SDS running buffer 10x TGS 100 mL
H2O 900 mL
TBE buffer (10x) Tris-Base 540 g
Boric Acid 275 g
EDTA (0.5 M) 200 mL
H2O 5000 mL
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2.10 Primers
Primers were ordered from Sigma Aldrich as 100 µM, HPLC purified stock solutions in H2O.
Table 22 – List of regular sequencing primers. *Primer kindly provided by Dr. M. Volkmar and used
by J. Rebmann during PyroSequencing.
Primer name Sequence Tm [°C]
pMP71_forward CGTCTTGTCTGCTGCAGCAT 67.1
pMP71_reverse AGAGGTTGATTAACAGGAACAGAGCGT 68.8
Lampum_Fsh TATAGCGGCCGCGCTAGCATGGCTGCCCCTGGCAG 74.2
Lampum_R TATGAATTCTCAGATGGTCTGGTAGCCGGCGTG 64.9
Lamp1_αBveI_F CATGACCTTCGATCTGCCCAGCGACGCC 67.7
Lamp1_αBveI_R CGTCGCTGGGCAGATCGAAGGTCATGT 65.7
DBY_F1 GCTGTACACCACCGCCGAGGAGCTGG 68.4
DBY_F2 CCGGCATCGGCATCCTGAC 61.4
DBY_F3 CGTGATCCTGGGCGTGTGCC 63.7
DBY_F4 CCCCCCACATCGAGAACTTCAGCGACAT 65.3
DBY_F5 CGACATGGGCGAGATCATCATGGGCAACAGC 66.9
DBY_R1 CGTCGCTGTTGCCCATGATGATCTCGCCCA 68.2
DBY_R2 TGTCGATGTCGCTGAAGTTCTCGATGTG 61.8
DBY_R3 GGGGGGGCACACGCC 63.9
DBY_R4 CAGGATCACGGTCAGGATGC 57.9
DBY_R5 CGATGCCGGCCAGCTCCTC 63.8
DBY_R6 GGCGGTGGTGTA 56.0
LAMP-Hind-F GAAGCTTCCGTCTCGGACGAG 59.6
LAMP-Apa-R AAGGGCCCTCAGATGGTCTG 59.2
LAMP-G390R-F CCGTGGGCAGAGCCCTGGCTGGAC 70.0
LAMP-G390R-R CAGGGCTCTGCCCACGGC 64.7
LAMP-L395K-F GGCTGGAAAGGTGCTGATCGTGC 62.8
LAMP-L395K-R TCAGCACCTTTCCAGCCAGGGC 64.4
LAMP-GLtoRK-F CCGTGGGCAGAGCCCTGGCTGGAAAGGTGCTGATCGTGC 73.8
LAMP-GLtoRK-R TCAGCACCTTTCCAGCCAGGGCTCTGCCCACGGC 73.7
Ova-F1 GCTGCTGGAACAGCTGGAAAGCATTATTAACTTTGAAAAAC 63.3
Ova-F2 TGACCGAATGGACCAGCCTGAAAATTAGCCAG 64.5
Ova-F3 GCGGTGCATGCGGCGCATGCGGAAATTAAC 68.7
Ova-F4 GAAGCGGGCCGCGAAGTGGTGGGCAGC 72.6
Ova-R1 CGTCGCTGCCCACCACTTCGCGGCCCGCTTC 74.4
Ova-R2 GTTAATTTCCGCATGCGCCGCATGCACCGCCTGG 71.0
Ova-R3 CTAATTTTCAGGCTGGTCCATTCGGTCAGTTTTTC 62.0
Ova-R4 AAAGTTAATAATGCTTTCCAGCTGTTCCAG 57.8
CIITA_F1 GCCTCCCAACATCTCCAGAC 68.0
CIITA_F2 CGGCTTCTCCATGGAGCAG 69.0
CIITA_R1 ACACAGCTGAGTCCCACGAG 70.0
CIITA_R2 TGCTCCATGGAGAAGCCG 68.0
pcDNA1090_R TCCAGGGTCAAGGAAG 60.0
pcDNA1061_R CAAACAACAGATGGCTG 58.0
pcDNA802_F TCTATATAAGCAGAGCTCTC 57.0
pcDNA830_F TAGAGAACCCACTGCTTAC 61.0
TanCon_F CCATGCACCTGCGAGAGC 70.0
TanCon_R CTCATCACACCTGCTCTCC 65.0
HLA-A2_Seq CGGAGCTCGTGGAGACCAG 71.0
A2_attB1_F_Seq TGTACAAAAAAGCAGGCTTAACCATG 66.0
A2_attB1_F GGGGACAAGTTTGTACAAAAAAGCAGGCTTAACCATGGCGCCCCGAACC 83.0
A2_attb2_R GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACACTTTACAAGCTGTGAGAGACAC 80.0
Spec_PyroRBio* [Btn]TACCTACCCACCAAAATCAACAAGG 67.0
Spec_PyroF* TGGATCTTATATGTAGAGCCCATCAGG 67.0
Spec_PyroS1* ATATGTAGAGCCCATCAGG 60.0
GBAS_S1* AGGAACCATGATTGAATG 56.0
DTNBP_S1* TTCTCTACCTCCTCAAAACT 59.0
ATAD2_S1* AAAAATCTCTCCATAATCAC 54.0
RASSF6_S1* GCTTTCTTACCTCCTGTT 58.0
FILIP1L_S1* CCTTTTTTGGAGTGACA 56.0
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Table 23 – List primer pairs for mutation validation. *Primer pair kindly provided by Dr. M. Volkmar
for PCR amplification of the respective mutated gene later sequenced by pyrosequencing using the
S1 primers found in table 22.
Patient Gene Mutation Forward Tm [°C] Reverse Tm [°C] Product Length [bp]
TIPC102 FOXJ2 D4G ACTTGCCCCCAGTATTTTCGT 59.9 GGGGGAGCCAGTCTATGGAG 61.1 106
MAP2K4 G294R ATAGACCCAAGCGCATCACG 60.5 AACGAACGGGGAAGTCTGAT 59.0 160
CDC16 L447V AGCAGTTACCCTGGCCTTGT 61.4 GATGCTGATTTTATCTGAGCAGCC 60.3 340
LRP12 R330H TCCCCTTGCAGCATTCACTT 59.8 TGGGAACATTGACTGCCTTGA 59.8 373
FILIP1L* F109V CCTCTAACACCTTTTTTGGAGTGA 55.3 [Btn]CGAGATGAGGTCATAGGCATTTTA 55.0 100
ATAD2* R913C GGCTTAGCAGCTTGTTTTAGAATT 54.8 [Btn]AACCATTGTAAGTTGGGGATCAT 54.6 190
GBAS* G203D CACAGAAGAACTAACAAACCAAATC 53.5 [Btn]CCCTAGAATTAACACTATGGCCTAA 54.3 140
DTNBP1* A123V CCCACATAAGTCTTCCAGATGC 55.6 [Btn]TGATTGAGGATTCTGACTTTTGAGG 55.4 125
RASSF6* A238V GGCAGCAAACTGTAGCACTCT 57.8 [Btn]AGTCCCCAGGATTTTGCTCT 55.6 100
KRAS* G12D CATTATTTTTATTATAAGGCCTGC 49.2 [Btn]CAAAATGATTCTGAATTAGCTGT 50.3 120
TIPC113 TLE4 S48G TTCGCCTGTGATGTGGGCTA 61.5 ATACCTTTGTGACGCCCCCA 61.4 256
PGM3 L156F TGCCTTTCCATATCGGCCAC 60.4 TGACACAAAAGGATTTGTCACCC 59.6 184
KIFC1 P435L TTTGCCTATGGCCAGACAGG 60.0 GGTCCCGGACAGTCTCATTG 60.1 196
SARM1 F591L TGTCTTCATCAGCTACCGCC 59.8 GGTCTTGCATGCACTTGTCC 59.7 282
CDH1 R90W GATTGCACCGGTCGACAAAG 59.8 GCGCACTAAAACAACAGCGA 60.0 258
UGT1A6 H54N TAGCACTTTGGGGCATGGTT 59.8 TCTTGGTCATACGGCACTGG 59.7 202
CDKN2A P114R GCTCTCAGGGTACAAATTCTCAGAT 60.4 TCTGGCAGGTCATGATGATGGG 62.1 353
FAM193B I530V GAGGGGAGCCCAAAGTCAAA 59.8 AAAGACTCCATCCGTGCCAG 60.0 181
DCAF6 A242V CAGAGGAAGAACCTCTACTGGAAA 59.4 CGTGCTGTATCATCTTTCGGG 59.1 325
KRAS* G12V CATTATTTTTATTATAAGGCCTGC 49.2 [Btn]CAAAATGATTCTGAATTAGCTGT 50.3 120
TIPC222 AGPAT6 T344I TATCTGGGGTAAAGGGCCAAC 59.4 AGTGTGTACCATCGGAGGTC 58.8 166
ANKRD32 L1010R CAGCAACTTGAATTTGGCTCCT 59.7 ATCAAGGCCTCAGTGTGTACC 59.7 284
AUTS2 R1154C CCTGCTAAGGAACGACCCG 60.1 GATAGTGCATGCTGGGGAGT 59.5 302
BARD1 R150Q AGGCTGGGTTTGCACTGAAG 60.8 GAGCTCCATGTGGGAGCAATA 59.8 198
CEP44 A153T ATACACCTGTGACTGGGAACTC 59.4 GCCACTGATATCAACGCCAAC 59.9 319
CSNK1A1 E60D CTACCCACTTCCCCATTCCG 59.8 TCTTTCCCCTGCAGGAAGTG 59.6 182
DDX5 R263S CTTCTTTTGGCCAAGTCGCA 59.3 TGCAACACCTGGAAGACTGAT 59.5 280
KDM6B P272S TCTCCTAGACTGGCCTTCCC 60.0 CCATGCAGGGTACTCCACAG 60.1 157
KLHL13 R336M TGGGGGCTAACGATTTCCAC 60.0 TGCAGCCAGTTATGCAGTCA 59.9 153
KPNA7 P371S TCTTCAGAATGGAACGCCCC 60.0 CTCCTGCAACACAACAAGCC 59.9 313
KRAS* G12D CATTATTTTTATTATAAGGCCTGC 49.2 [Btn]CAAAATGATTCTGAATTAGCTGT 50.3 120
N4BP2 D1482N CTTGGTTGGACATACTGGGC 58.5 AAACCAGAATCAGAGACAGTAGCTT 59.9 236
PIK3CA I788F GCCACTGTGGTTGAATTGGG 59.6 TGGCTTTCAGTAGTTTTCATGGT 58.5 179
PPM1D N242S TCTCTGAACAGGAATTTTGGCT 57.9 AGTGAGTCGAGGTCGTTTCC 59.4 218
TROAP M465L CGCATCGGTATCCTGCAACA 60.8 CACTCCTCTGGAAGACAGGG 59.1 227
TIPC236 CCDC88C F27L CCATGCAACCTTCCACTCCA 60.2 GGGAGAGCTTTGGACCGTTT 60.2 254
CDKN2A G55V CATCTATGCGGGCATGGTTAC 59.1 TCTACACAAGCTTCCTTTCCGT 59.6 358
COPS7A T224M TGGCTGTAGCAGACAACCAG 59.9 GCCCTTTGAGGCTTTCTTGC 60.0 230
KRAS* G12D CATTATTTTTATTATAAGGCCTGC 49.2 [Btn]CAAAATGATTCTGAATTAGCTGT 50.3 120
N4BP1 M173T CCTGTGGCAGCATTCTGTGTA 60.6 ATTGGCCTTCTTGGCATCAGA 59.9 323
PRKACB W185S ACTTTGGGTTTGCCAAAAGAGT 59.1 AAAGTCCATAGGGATGCATGT 57.0 151
RBL2 V539A GACACACTTTGCACTCACTC 56.9 GAAAAAGTGACGACCTCAAGGC 60.0 191
SLC43A1 V86M GAAGCAGGCACTGTGGAGAC 60.9 AGCAGGACGAGATGCTCAAC 60.1 239
TGFBRAP1 T121M CGCCTGTGCTGTAATTGTGG 59.8 TTCAAGAAGCCCGTGAACGA 59.8 367
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2.11 Peptides
Peptides were ordered from, and synthesized by, M. Koch from the AG Eichmüller, DKFZ Hei-
delberg. Finished products were received as 2 - 4 mg aliquots of lyophilized peptide. Quality of
the HPLC purified peptides was routinely assessed by M. Koch using electronspray ionization
mass spectrometry.
Table 24 – List of non-patient derived peptides
Peptide Sequence MW (monoisotopic) [Da] Reference
NEF 136-145 PLTFGWCYKL 1226.62 [320]
GAG 77-85 SLYNTVATL 980.52 [320]
NEF 73-82 QVPLRPMTYK 1231.67 [320]
GAG 20-28 RLRPGGKKK 1038.68 [320]
NEF 120-128 YFPDWQNYT 1232.51 [320]
GAG 240-249 TSTLQEQIGW 1161.57 [320]
EBV GLCTLVAML 919.49 [321]
Mart1 ELAGIGILTV 984.59 [171]
Mart1_long KGHGHSYTTAEELAGIGILTVILGVLLLIG 3044.73
HY HIENFSDIDMGE 1405.58 [316, 322]
HY_long EATGSNCPPHIENFSDIDMGEIIMGNIELT 3246.45
SIINFEKL SIINFEKL 962.54 [323]
OVA_MHC-II ISQAVHAAHAEINEAGR 1772.89 [324]
CSNK1A1 GLFGDIYLAI 1080.59 [325]
GAS7 SLADEAEVYL 1108.53 [325]
HAUS3 ILNAMIAKI 985.60 [325]
Table 25 – Predicted patient peptides for TIPC102. Highlighted amino acids indicate the respective
position of the mutation within the predicted epitope.
Peptide Sequence MW (monoisotopic) [Da]
FILIP1L_1 ALLEAQYGV 962.51
FILIP1L_2 LALLEAQYGV 1075.59
FILIP1L_6 ALLEAQYGVV 1061.58
ATAD2_1 FICDYGEIFNV 1318.58
FILIP1L_3 LLEAQYGV 891.46
FILIP1L_4 DLALLEAQYGV 1190.61
FILIP1L_5 LALLEAQYGVV 1174.65
DTNBP1_1 MTANLTHLEV 1127.55
FOXJ2 GLESSLTSI 905.46
RASSF6_1 FALHIIFVT 1059.60
RASSF6_2 FALHIIFV 958.55
MAP2K4_1 SLRITLYEL 1106.62
KRAS_G12D KLVVVGADGV 955.559
CDC16 VTVDKWEPV 1071.54
DTNBP1_2 SMTANLTHLEV 1214.58
LRP12_1 KLLHVLTAF 1040.62
LRP12_2 KLLHVLTA 893.55
ATAD2_2 ELFICDYGEI 1200.52
MAP2K4_2 SLRITLYELA 1177.66
36 2 MATERIALS
Table 26 – Predicted patient peptides for TIPC113. Highlighted amino acids indicate the respective
position of the mutation within the predicted epitope.
Peptide Sequence MW (monoisotopic) [Da]
KIFC1_1 ILRALRHLFSV 1323.81
SARM1_1 VLIDVEKLEA 1127.64
SARM1_2 QLHGFSVLI 1012.57
SARM1_3 LQLHGFSVLI 1125.65
KRAS_G12V KLVVVGAVGV 939.61
UGT1A6_1 VLSDRGNEI 1001.51
CDKN2A RLRVDLAEEL 1212.68
SARM1_4 QLHGFSVLIDV 1226.67
UGT1A6_2 VLSDRGNEIV 1100.58
KIFC1_2 LRALRHLFSV 1210.73
SARM1_5 LQLHGFSVL 1012.57
FAM193B VNLDLSPLTL 1083.62
DCAF6 MVVRFIPSHL 1197.67
Table 27 – Predicted patient peptides for TIPC222. Highlighted amino acids indicate the respective
position of the mutation within the predicted epitope.
Peptide Sequence MW (monoisotopic) [Da]
AGPAT6_3 FEIGAIVYPV 1106.60
KLHL13_1 AIMSDTTHLV 1086.54
KLHL13_2 AIMSDTTHL 987.47
PIK3CA_1 WLNWENPDFM 1350.57
KLHL13_3 IMSDTTHLVT 1116.55
AGPAT6_1 SFEIGAIVYPV 1193.63
KDM6B GLATSSPFQL 1019.53
KLHL13_4 IMSDTTHLVTL 1229.63
BARD1 KMWFSPQSKKV 1364.73
CEP44 KISTEAVGV 902.51
AGPAT6_4 EIGAIVYPV 959.53
KLHL13_5 TAIMSDTTHLV 1187.59
KRAS_G12D KLVVVGADGV 955.57
PIK3CA_2 FMSELLFQN 1127.53
AGPAT6_2 FEIGAIVYPVA 1177.64
DDX5 MLDMGFEPQIS 1266.56
PPM1D VMNKSGVSRV 1075.58
AUTS2 HLDERECLHML 1394.64
ANKRD32 LLDRYAGNI 1033.56
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Table 28 – Software and bioinformatic tools
Software Company
GraphPad Prism 6.0 GraphPad Software Inc., La Jolla, CA, USA
Wallac EnVision Manager version 1.12 Perkin Elmer, Waltham, MA, USA
FlowJo v10.4.1 FlowJo LLC, Ashland, OR, USA
BD FACSDivaTM software version 6.2 Becton Dickinson (BD) GmbH, Heidelberg
Serial Cloner (Version 2.6.1) Serial Basics Software
SnapGene®Viewer (Version 4.1) GSL Biotech, Chicago, USA
Integrative Genomics Viewer Broad Institute, USA
ImageJ National Institute of Health, Bethesda, USA
Inkscape Free Software Foundation, Boston, USA
LyX - The Document Processor http://www.lyx.org/
HUSAR/GCG (Release 4.0) Genomics and Proteomics Core Facility (DKFZ), Heidelberg
MacOS (Version 10.12.6; Sierra) Apple Inc., Cupertino, USA
Microsoft Office Microsoft Corporation, Redmond, USA
CTL Immunospot Software (V 5.0) Cellular Technology Ltd., Cleveland, OH, USA
Vi-CELL XR Cell Viability Analyzer 2.03 Beckman Coulter Ireland Inc., Galway, Ireland
Motic Image Plus 2.0ML Motic China Group Co. Ltd., Xiamen, China
Image Reader LAS-3000 (V 2.21) Fujifilm, Tokio, Japan
Multigauge Fujifilm, Tokio, Japan
Intas GDS Intas Science Imaging Instruments GmbH, Göttingen
NanoDrop 8000 Operating Software (V 2.3.2) Thermo Fisher Scientific, Waltham, MA, USA
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3 Methods
3.1 Patient material
3.1.1 Sample collection
Resected tumor tissue and blood samples of pancreatic cancer patients were obtained from
the European Pancreas Center Heidelberg. Informed written consent was obtained from all
patients prior to sample collection. The study was approved by the local ethics committee and
conducted in accordance with the declaration of Helsinki [326].
3.1.2 Patient selection
Patients were primarily selected based on the availability of exome and transcriptome data of
the primary tumor and/ or xenograft. Depending on the screening approach, additional require-
ments had to be met to include a patient. In case of the expression based screening system,
expanded TILs, recognizing the autologous tumor had to be available in sufficient amounts. For
the development of the long peptide screening system, blood or spleen samples were needed
for the generation of immortalized B cells. To set up the targeted proteomics screening system,
patients had to be HLA-A02:01+ and the respective PDX derived cell line was needed.
3.2 Cell Culture
When working with virus producing cells, viral suspensions or EBV immortalized cell lines, all
experiments and cell cultures were performed in the central S2 facility of the German Cancer
Research Center (DKFZ). Cells immortalized with EBV were washed twice with PBS and either
fixed (4% formaldehyde) or irradiated prior to transfer to an S1 facility.
3.2.1 Processing of primary pancreatic tumor tissue
Freshly resected tumor was kept in transport medium during transfer from the operating theatre
to the laboratory. Afterwards, tumor tissue was immediately minced and several pieces (27
mm3each) snap frozen to -196 °C for RNA and DNA extraction. A slice from the middle of the
tumor piece (16 mm2) was embedded in Tissue-Tek®for histological analyses.
Residual pieces were used for in vitro expansion of TILs and xenograft generation.
3.2.2 In vitro expansion of tumor infiltrating lymphocytes
TIL cultures were set up from fresh tumor tissue as previously described[279, 327]. Briefly, the
expansion was split into two parts and performed as follows:
1. Day 0 - 14:
For an initial expansion, tumor pieces (1 mm3) were transferred to a 24-well plate. Per
well 1 mL TIL culture medium I (+ 2% HSA), containing 6000 U/mL
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one piece of tumor were incubated. After 24h half of the medium was exchanged. TIL
growth was monitored frequently and expanding wells were pooled on day 14. One part
of the TIL pool was cryopreserved, the other part was used for further rapid expansion to
either day 28 or day 42.
2. Day 14 onwards:
In order to generate larger amounts, the pre-expanded TILs were put on a rapid expansion
protocol [279]. PBMCs of three different allogenic donors were thawed, irradiated with 40
Gy, pooled at equal amounts and adjusted to 3x108 cells/mL in TIL culture medium I (+
2% human AB serum). Afterwards, 100 µL pooled PBMCs, 1x107 cells/donor, were trans-
ferred to each standing T25 flask together with 1x105 TILs, 30 ng/mL α-CD3 (OKT3) and
20 mL TIL culture medium I (+ 2% human AB serum).
The next day another 5 mL TIL culture medium I (+ 2% human AB serum), containing
1500 U/mL recombinant IL-2, were added to the culture, resulting in a final concentration
of 300 U/mL recombinant IL-2 per flask.
On day five of rapid expansion half of the medium was carefully removed, without disturb-
ing the cell layer, and replaced by the same amount of fresh TIL culture medium I (+ 2%
human AB serum), containing 600 U/ml recombinant IL-2.
The following days, growth was frequently monitored and cells split 1:1 into new culture
flasks if necessary.
After 14 days of rapid expansion TILs were harvested, analyzed by flow cytometry and
cryopreserved. Whenever necessary, this part could be repeated to expand TILs to a
maximum of 42 days.
3.2.3 Cell centrifugation
During regular cell culture, tissue digest, washing and after fixation cells were pelleted for 6 min
at 350 xg. For regular flow cytometry stainings, cells were pelleted for 2 min at 700xg unless
stated otherwise.
3.2.4 Cell count and viability assessment
Cell number and viability was monitored using a Vi-CELL™ XR cell counter (Beckman Coulter).
For each sample 450 µL PBS were mixed with 50 µL cell suspension and acquired using the
machines default settings. In the S2 facility and to counter check Vi-CELL results, cell con-
centration and viability were assessed using a hemocytometer. Here, the cell suspension was
mixed in a 1:10 ratio with trypan blue, applied to the hemocytometer and two sets of corner
squares counted. The cell concentration was calculated as follows:
[Cells]initial = 10000 ∗
∑
counted cells
2
∗Dilution factor (cells/mL) (1)
3.2.5 Cell irradiation
Cells were irradiated using a GammaCell1000 (Atomic Energy of Canada Limited). Here, cells
were placed in 15 mL reaction tubes in 5 - 10 mL fresh culture medium, placed inside the
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irradiation chamber and exposed to the desired amount of radiation. Due to radioactive de-
cay, the time of exposure had to be slightly adjusted every six month according to the data
sheet provided by the administrative department “Strahlenschutz und Dosimetrie (W060)” of
the DKFZ.
3.2.6 Cryopreservation and revival
For cryopreservation and storage, cells were pelleted, resuspended in 5 mL PBS and cell num-
ber, as well as viability were assessed. Cells were again pelleted and adjusted to the desired
concentration in cryomedium. Afterwards, 500 µL cell suspension were transferred to each cryo
vial and cells cooled down by -1 °C/min using CoolCell® freezing containers (BioCision) for 24
h at -80 °C. Afterwards, cells were transferred to -196 °C for long term storage.
Upon use, cells were put into a 37°C water bath for 3 min, carefully resuspended by adding
1 mL pre-warmed culture medium and transferred directly into 10 mL pre-warmed culture
medium. The suspension was pelleted, washed once with 10 mL pre-warmed culture medium,
counted and the cell number adjusted to the desired concentration for later use.
3.2.7 Culture and passaging of eukaryotic cells
Cells were generally kept and incubated at 37°C, 5% CO2 and 95% relative humidity unless
stated otherwise. Adherent cells were split at 85 - 90% confluency by washing once with 5 -
10 mL PBS and detached using StemPro Accutase (Thermo Fisher Scientific) according to the
manufacturers protocol. Cells were taken up in fresh culture medium, viability was assessed
and the desired amount of cells seeded in fresh culture flasks. Accutase was chosen for pas-
saging, since most PDX derived cell lines appeared sensitive to trypsin-EDTA dissociation and
were lost upon reseeding.
Stably transduced PDX derived cell lines were constantly cultured in the presence of the re-
spective selection antibiotic. Bcl-6/XL immortalized B cell lines were cultured as previously
described [? ]. Briefly, the cells were cultured in B cell medium supplemented with 50 ng/mL
rm-IL-21 and irradiated (50 Gy) murine L cell fibroblasts, stably expressing CD40L.
Suspension cells were pelleted, taken up in 5 mL fresh culture medium, viability was assessed
and cells were distributed to new culture flasks at the desired concentrations.
3.2.8 Generation of PDX derived cell lines
Cell lines for patients TIPC102 and TIPC113 were kindly provided by the group of M. Sprick
and grown in PaCo medium.
For other cell lines the resected xenograft was minced, transferred to 20 mL PBS (+ 1%
Pen/Strep) and centrifuged for 5 min at 110 xg. The pellet was washed twice with 25 mL
PBS (+1% Pen/Strep) at the same speed. Afterwards, it was resuspended in 20 mL Medium
199 followed by the addition of 120 µL CaCl2 (sterile stock at 25 mM in H2O), as well as 1 mL
Gibco® Collagenase Type IV (sterile stock at 40 mg/mL), and incubated for 2.5 h at 37°C. The
digested suspension was passed through a 100 µm strainer, washed with 10 mL PBS and the
3.3 Mouse Work 41
cells taken up in 12 mL CSC medium. Subsequently, the suspension was transferred to a T75
flask and growth monitored frequently.
3.2.9 Purification of PDX derived cell lines
PDX derived cell lines were routinely tested for mouse cell contamination by pyrosequencing.
Primers for the amplification of species specific single nucleotide polymorphisms (SNPs) were
designed and provided by Dr. M. Volkmar. In a first step, adherent, PDX derived cultures
revealing different cellular phenotypes were separated by differential trypsinisation. For this,
the cells were washed once with PBS. Afterwards, 5 mL StemPro Accutase (Thermo Fisher
Scientific) were added to each flask, the culture incubated for 3-4 min @ 37°C and constantly
monitored under the microscope. Once the first phenotype detached, the supernatant was col-
lected, the flask washed once with 5 mL PBS and fresh accutase added to the flask to detach
the remaining population. In general, two cultures were generated by this approach. One de-
taching early (after 3 - 5 min) and the other detaching considerably late (10 - 20 min). Collected
cells were seeded in separate new flasks and species origin determined by pyrosequencing.
Primers used for pyrosequencing were designed by Dr. M. Volkmar and covered a small region
within the catalytic subunit gamma of the protein phosphatase 1 (PPP1CC) encoding for three
interspecies SNPs (NCBI references: human = NG_030325; mouse = AH006785). Cell lines
tested positive for contamination were afterwards purified by flow cytometry sorting. Here, the
respective cell lines were treated with 330 U/mL IFNγ for 48 h prior to bulk cell sorting. Cells
were sorted for the 5% highest, living population of human MHC-I positive cells into fresh CSC
medium. The sorted population was washed once with 10 mL CSC medium, taken up in fresh
medium and plated in a T25 flask.
3.2.10 Isolation of mononuclear cells from peripheral blood
Buffy coats were provided by the DRK Blutspendedienst Mannheim and the IKTZ Heidelberg
gGmbH. Peripheral blood mononuclear cells (PBMC) were isolated by gradient centrifugation
using Ficoll-Paque PLUS (GE Healthcare). The blood was distributed to 50 mL reaction tubes
(7.5 - 10 mL blood per tube), 35 mL PBS was added and the suspension mixed by pipetting.
Afterwards, the suspension was carefully underlaid with 10 mL ficoll solution and centrifuged
for 22 min at 800 xg with acceleration and break turned off to avoid disruption of the gradient.
The plasma layer was carefully removed and the lymphocyte layer transferred to a fresh 50 mL
reaction tube. The suspension was filled up to 50 mL with PBS and pelleted for 7 min at 450
xg. Subsequently, the pellet was washed twice with 50 mL PBS, resuspended in 30 mL PBS
and cell number, as well as viability were assessed. Cells were aliquoted and cryopreserved
until use.
3.3 Mouse Work
All mouse work was performed under the approval of the German Cancer Research Cen-
ter (DKFZ) in accordance with federal, state and local guidelines. Organ extractions were
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performed under permit number DKFZ303 and xenograft generation under permit number G-
222/15.
3.3.1 Mouse lines used
Ly5.1 [B57BL/6-Ptprca][328], OTI [C57BL/6-Tg(TcraTcrb)1100Mjb/J][329], OTII [B57BL/6-Tg(TcraTcrb)
425Cbn/J][330] and NSG™ [NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ][331] mice were bred in-house
and originated from the Jackson Laboratory. Mice were housed in a SPFP facility with 12h
light/ dark cycle at 25° C and 40 - 60% humidity. Up to 6 mice were kept per individually
ventilated container with food and water being provided ad libitum.
3.3.2 Organ extraction and cell purification
For T cell and splenocyte isolation mice were sacrificed, spleen and lymph nodes (axillary,
inguinal and mesenteric) resected and immediately put in cold PBS. Organs were meshed
through a 100 µm strainer, the strainer flushed with 10 mL cold PBS and the cells pelleted. The
supernatant was discarded and lymph node pellets resuspended in 15 mL PBS. Splenocytes
were resuspended in 5 mL ACK-buffer (Lonza) and incubated for 5 min on ice to lyse erythro-
cytes. The lysis was stopped by adding 10 mL PBS. Cell suspensions from lymph nodes and
spleen were rinsed through a 40 µm strainer, the strainer flushed with 10 mL PBS and the sus-
pensions pelleted. Afterwards, cells were resuspended in 5 mL FACS buffer and cell numbers,
as well as viability, were assessed.
To retrieve pure CD4 (OTII) or CD8 (OTI) T cells, the isolated suspensions were purified by
negative selection using either a CD4+ or the CD8a+ T cell isolation kit (Miltenyi Biotec) follow-
ing the manufacturers instructions. Purified populations were later used for T cell proliferation
analyses.
3.3.3 Xenograft generation, control and harvest
Digest of resected tumor tissue was performed using the human Tumor Dissociation Kit (Mil-
tenyi Biotec), following the manufacturers instructions. Briefly, digestion solution was prepared,
containing 4.7 mL RPMI1640, 200 µL Enzyme H, 100 µL Enzyme R and 25 µL Enzyme A and
transferred to a gentleMACS C tube (Miltenyi Biotec). Tumor tissue was minced and added to
the digestion solution. gentleMACS C tubes were placed onto gentleMACS Octo Dissociator
with heater (Miltenyi Biotec) and digested using the pre-installed program 37C_h_TDK3. After-
wards, a cell strainer (100 µm) was placed inside a 50 mL reaction tube and pre-rinsed with 5
mL PBS. The digested tissue suspension was applied to the strainer, followed by an additional
10 mL PBS to wash the strainer. Subsequently, the cells were pelleted, supernatant removed
and cells taken up in 10 mL fresh PBS. Cell number and viability were assessed, the cells pel-
leted again and the cell concentration adjusted to 2 x 107 cells/mL in PBS. For each injection
100 µL cell suspension were mixed with 100 µL matrigel® matrix (Corning) and constantly kept
on ice until injection to avoid solidification. Prior to injection the right flanks of the mice were
shaved and disinfected with 70% ethanol. Per mouse 200 µL of the cell suspension (2x106
cells) were injected subcutaneously, cranial to the right hind leg using a 26G needle.
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Tumor volume was assessed in three dimensions once per week using a caliper. At 1000 mm3
mice were sacrificed and the tumor tissue resected.
3.4 Immune and biochemical assays
3.4.1 Flow cytometry
In general, multiparametric flow cytometry stainings were subdivided into three consecutive
parts applied as far as needed for the respective assay. For each sample up to 1x106 cells
were placed per sample in a 96-well V-bottom plate. All staining steps were performed in the
dark. Samples were acquired in a final volume of 200 µL FACS-buffer using an LSRFortessa
flow cytometer (BD Bioscience). Analysis was performed using the FlowJo software package
(Treestar).
1. Dead cell staining:
For all samples, cells were first stained with a marker to distinguish live and dead cell
populations. Cells were washed once with PBS and taken up in the respective amount
of dead cell marker in PBS. Samples were incubated for 15 min at 4 °C, diluted with 100
µL FACS-buffer, pelleted and washed twice with 200 µL FACS-buffer. Afterwards, either
extracellular staining was performed or, in the case of GFP transfection/ -duction, cells
were taken up in FACS-buffer and directly analyzed.
2. Extracellular staining:
Antibody master mixes were prepared in FACS-buffer, 20 µL were distributed to each
sample and incubated for 30 min at 4 °C. Subsequently, the samples were washed twice
with 200 µL FACS-buffer and either directly analyzed or stained for intracellular cytokines.
3. Intracellular staining:
To perform intracellular cytokine staining the pre-stained samples were fixed using 100 µL
BD Cytofix/ Cytoperm™ (4.2% formaldehyde [w/w], BD Biosciences) and incubated for 30
min at 4 °C. Cells were washed twice with 200 µL Perm/Wash™ buffer (BD Biosciences).
In order to avoid disruption of the cells, centrifugal forces were lowered from here on to
350 xg for 6 min during the washing steps. Afterwards, cells were stained with 20 µL
antibody master mix prepared in Perm/Wash™ buffer, incubated for 30 min at 4 °C and
washed twice with 200 µL Perm/Wash™ buffer. All samples were washed one additional
time with 200 µL FACS-buffer and subsequently analyzed.
For certain assays cells were stained with CFSE prior to assay setup. Here, respective cells
were pelleted for 6 min at 350 xg, washed once with 10 mL PBS and up to 2x107cells were
taken up in 1 mL 5 µMCFSE in PBS. Subsequently, the tubes were covered in aluminum foil and
gently rocked for 15 min at RT. One volume of FCS was added and the suspension incubated
for 2 min at RT. Afterwards, 10 mL culture medium was added and the cells incubated for 5
min on ice. Viability was again measured to account for cell loss upon staining and the cells
adjusted to the desired concentration.
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3.4.2 Peptide pulse of target cells
Here, target cells were pulsed with 10 µg/mL of the respective peptide unless stated otherwise.
For this, up to 2.5 x 106 cells were taken up in 200 µL of the respective culture medium and
another 50 µL culture medium, containing 25 µg/mL peptide of interest, were added. Suspen-
sions were incubated at 37°C for 1 h, washed once with 10 mL of the respective assay medium
and taken up in assay medium at the desired concentration.
3.4.3 Murine T cell proliferation analyses
Antigen induced activation of murine T cells (OTI and OTII) was assessed by proliferation using
a CFSE dilution [332]. Samples were set up using 1x105 CFSE labeled effector cells and 5x104
(OTI setup) or 1x105(OTII setup) target cells in 200 µL OT culture medium. Samples containing
only T cells served as negative controls. For positive controls T cells were either activated
unspecifically using 20 ng/mL PMA and 50 µg Ionomycine or antigen specific by co-incubation
with BOK cells (OTI) or peptide pulsed, congenic (CD45.1+) splenocytes (OTII). Cell division
was assessed by flow cytometry after 48 - 96 h (OTI - 48 and 72 h; OTII - 72 and 96 h). Total cell
numbers were assessed using CountBright™ Absolute Counting Beads (Invitrogen) according
to the manufacturers protocol.
3.4.4 HLA-binding assay
TAP-deficient T2 cells were harvested, washed once with serum free RPMI1640 medium and
adjusted to 2x106 cells/mL. For each sample 100 µL of the cells were seeded per well into 96-
well U-bottom plates. Peptides were pre-diluted to 20 µg/mL in serum free RPMI1640 and 100
µL were added to each sample. In total five plates, each containing the same sample layout,
were prepared. Four plates were incubated over night at 25°C and 5% CO2, the last plate
was incubated at 37°C and 5% CO2 until harvest. Upon 16h cold pre-incubation, three of the
plates were transferred to 37°C and 5% CO2 in 2h intervals. Two hours after the last plate was
put to 37°C all samples were transferred to 96-well V-bottom plates, washed once with PBS,
stained and analyzed for HLA-A2 surface presentation in the living cell population. From the
point of transfer to the 96-well V-bottom plates, samples were constantly kept at 4°C. Further
characterization of increased HLA-A2 stabilization upon temperature increase was performed
by addition of 5 µg/mL Brefeldin A (BD GolgiPlug™; BD Biosciences) to each sample directly
before transfer to 37°C.
3.4.5 Cytokine production and secretion assessment
Wells containing only T cells served as negative controls. For positive controls T cells were
either unspecifically stimulated with 1 µg/mL Phytohaemagglutinin (PHA) or in the case of T
cell receptor transductions co-incubated with peptide pulsed target cells.
1. ELISpot:
ELISpot analyses were performed using either the Human IFNγ ELISpotBASIC (ALP) kit
(MabTech) or Human TNFα ELISpotBASIC (ALP) kit (MabTech). Capture antibodies (IFNγ:
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1-D1K; TNFα: TNF3/4) were diluted in PBS (IFNγ: 1:500; TNFα: 1:250) and coated to
96-well MAHAS4510 filter plates (75 µL/well) one day prior to co-culture set up. Plates
were incubated over night at 4°C. The next day plates were washed six times with 180
µL sterile ELISpot-wash buffer and blocked with ELISpot-blocking buffer for 120 min at
37°C. In the meantime the effector and target cell suspensions were prepared. MHC
blocking was performed by pre-incubating the respective target cells with 10 µg/mL block-
ing antibody for 1 h at 37°C. Target cells were irradiated with 100 Gy prior to setup of
co-culture. Plates were washed once with 180 µL X-vivo15 medium, 0.5x105 target and
2x105 effector cells were setup in triplicates and incubated for 48 h at 37°C. Following
co-incubation the plates were washed six times with 180 µL ELISpot-wash buffer. The
second antibodies (IFNγ: 7-B6-1 biotin; TNFα: TNF5-biotin) were pre-diluted in PBS +1%
HSA (IFNγ: 1:1000; TNFα: 1:500), 75 µL added to each well and the plates incubated
for 2 h at RT. Plates were again washed six times with 180 µL ELISpot-wash buffer and
75 µL/ well Streptavidin-ALP (1:1000 in PBS + 1% HSA) were added, followed by 1 h
incubation at RT. The supernatant was discarded and the plates washed three times with
180 µL ELISpot-wash buffer followed by two washes with 180 µL PBS. Development of
the spots was performed using one SIGMAFAST™BCIP®/NBT tablet, dissolved in 10 mL
water. 75 µL of the solution were added to each well and the plates incubated in the dark
at RT until first spots became visible. Reactions were stopped under running tab water,
the plates dried and analyzed using an ImmunoSpot® S6 MACRO (Cellular Technology
Limited). Samples with significantly higher spot counts than the respective controls were
considered positive.
2. ELISA:
Each assay was set up in triplicates by plating 0.5x104 effector and 1x105 target cells per
well in a 96-well U-bottom plate in a total volume of 200 µL. Plates were spun down at
130 xg for 1 min and incubated for 20 h at 37°C. Co-culture supernatants were carefully
transferred to a fresh 96-well U-bottom plate and analyzed using the Human IFNγ ELISA
MAX™ kit (BioLegend) according to the manufacturers protocol. Wash steps were fully
automated using an EL406 Combination Washer Dispenser (BioTek). Depending on the
target cells, supernatants were pre-diluted in Assay Diluent (BioLegend) to stay in the lin-
ear range of detection (table 29). Absorbance at 450 nm was measured with an EnVision
2104 Multilabel Reader (PerkinElmer).
Table 29 – Routine, target dependent supernatant dilutions.
Target cells Supernatant predilution
B-cells 1:100
TILs 1:10
3. Intracellular cytokine staining:
Co-cultures were set up using 0.5x105 target and 2x105 effector cells in a total volume of
200 µL. When working with autologous target cells, these were labeled with CFSE prior
to set up of the co-cultures to later distinguish them from the effector population. Samples
were spun down at 130 xg for 1 min and incubated for 1 h at 37°C. Subsequently, 1 µg/mL
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GolgiPlug/ Brefeldin A (BD Bioscience) was added, the cells spun down at 130 xg for 1
min and incubated for another 5 h. Subsequently, samples were transferred to a 96-well
V-bottom plate and stained for flow cytometric analyses.
3.4.6 Polyacrylamide gel electrophoresis
HEK293T cells were transfected by CaPO4co-precipitation. Cells were lysed in 1x Laemmli
buffer (+5% β-mercaptoethanol) and whole protein concentration assessed by photospectrom-
etry using a NanoDrop 8000 Photospectrometer (Thermo Fisher Scientific). Deglycosylation
was performed by transferring 40 µg whole protein per sample to a 1.5 mL reaction tube. Each
sample was diluted 1:1 with H2O and mixed with 1.5 µL of the respective 10x deglycosylation
buffer (G5 = EndoH; G7 = PNGaseF). In the case of PNGaseF, 1.5 µL NP40 (10% stock) was
added to the reaction mix. Afterwards, 0.2 µL Deglycosylase (EndoH or PNGaseF; New Eng-
land Biolabs) was added, each sample filled up to 15 µL total volume, the reaction mixtures
were incubated for 1 h at 37°C and another 5 µL 4x Laemmli buffer (+5% β-mercaptoethanol)
were added. Untransfected cells and untreated lysates served controls.
Samples, as well as a protein ladder, were loaded to a 4-20 % gradient SDS gel and run at 60
V for 15 min, followed by 60 min at 15 mA per gel in SDS running buffer.
3.4.7 Western Blot & Protein detection
Protein was performed using a semi-dry blotting system. PVDF membranes were prepared by
incubating for 15 sec in methanol, 2 min in deionized water and 5 min in transfer buffer. Blotting
was performed for 1.5 h with 100 mA (per gel) at RT.
Membranes were blocked with 5% BSA (Gerbu) in TBS buffer for 1 h at RT on a shaker. Af-
terwards, each membrane was washed for 5 min with TBS buffer and transferred to a 50 mL
reaction tube. Primary antibodies, mouse-α-FLAG (1:1000) and rabbit-α-GAPDH (1:10000),
were added in 5% BSA in TBS buffer per membrane, incubated over night at 4°C while rotating
and the membranes washed three time with TBS buffer (+0.1% Tween-20) for 10 min. Sec-
ondary antibodies, goat-α-mouse-HRP and goat-α-rabbit-HRP (each 1:20000), were added in
TBS buffer (+0.1% Tween-20) and incubated for 60 min at RT while rotating the tubes. Subse-
quently, each membrane was washed three time for 10 min with TBS buffer (+0.1% Tween-20),
followed by one wash with TBS buffer for 10 min.
Membranes were covered with Clarity™ Western ECL Substrate (BioRad) and immediately an-
alyzed using a LAS-3000 (Fujifilm Life Science). Quantification was performed using ImageJ
1.51s [333].
3.5 Molecular biologic methods
3.5.1 Design of Lamp1 constructs
The different Lamp1 constructs were designed together with M. Lemberg. The full length,
canonical Lamp1 sequence (UniProtKB - P11279-1) was retrieved from UniProt [334]. A
3xFLAG tag was added directly C-terminal to the ER localization sequence, between amino
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acid residues 28 and 29. Two BsmBI restriction sites, the first reverse and the second forward
oriented, were used to introduce the desired antigenic sequences between amino acid residues
377 and 378, N-terminal to the transmembrane domain. The final construct was codon opti-
mized for H. sapiens and ordered via the Invitrogen GeneArt® Gene Synthesis service (Thermo
Fisher Scientific). Afterwards, the candidate destabilizing mutations were introduced in the
transmembrane domain via site directed mutagenesis by PCR. The generated constructs were
further adapted for each round of system validation as follows:
1. General functionality:
Inserts were prepared using four overlapping primer pairs encoding the two ovalbumin
peptides SIINFEKL (H-2Kb-restricted) and ISQAVHAAHAEINEAGR (I-Ab-restricted). Prior
to ligation, each primer pair was dimerized and phosphorylated separately (table 30),
leading to primer dimers with matching 3’ and 5’ sticky ends. Here, the samples were
incubated in a Thermocycler for 1 h at 37°C, followed by 5 min incubation at 95°C and
cooling to 10°C. Afterwards, the dimerized primer pairs were ligated, creating an antigen
encoding insert with 3’ and 5’ overhang for insertion into BsmBI digested , dephosphory-
lated (32) Lamp1 constructs.
Table 30 – Sample setup for the generation of phosphorylated primer dimers
Amount (µL)
10 mM ATP 1
PNK Buffer A 2
1 µM Primer (forward & reverse) 1
Nuclease free water 14
T4 PNK 1
Table 31 – Sample setup for primer dimer ligation
Amount (µL)
Each primer pair 2
0.1 M DTT 1
10 mM ATP 0.5
Nuclease free water 12
T4 DNA Ligase 2.5
2. Translation into human setting:
An insert encoding the HLA-A02:01 restricted Mart1 epitope (ELAGIGILTV), as well as
the DDX3Y/HY epitope (HIENFSDIDMGE), interspaced by two BveI restiction sites, the
first reverse and the second forward oriented, was introduced into the Lamp1 constructs.
Target vectors, as well as inserts were digested using BsmBI (table 32), followed by con-
struct ligation.
48 3 METHODS
Table 32 – General protocol for BsmBI digests of inserts and target vectors
Target vector Insert
Template 150 ng 15 ng
Buffer Tango 2 µL 2 µL
100mM DTT 0.2 µL 0.2 µL
BsmBI 1 µL 1 µL
Nuclease free water 10.9 µL 15.8 µL
FastAP 0.5 µL —
Total volume 20 µL 20 µL
3. Patient Screening:
The native, codon optimized sequence of Lamp1 contained one additional BveI restriction
site, which was removed by site directed mutagenesis using PCR.
Introduction of patient derived constructs was performed by restriction digest of target
vector and inserts using BveI (table 33), followed by construct ligation.
Table 33 – Restriction digest patient constructs
Target Vector Insert
Template 100 ng 1000 ng
Buffer O 2 µL 2 µL
50x Oligo Mix 0.4 µL 0.4 µL
BveI 1 µL 1 µL
Nuclease free water 15.6 µL 15.6 µL
FastAP 0.5 µL —
Total volume 20 µL 20 µL
3.5.2 Design of tandem patient constructs
The mRNA RefSeq accession numbers (NM_) [335] of validated mutations from exome and
transcriptome analyses were used to retrieve 30mer wild type amino acid sequences, with the
mutation site at position 16, from UniProt [334]. The respective mutated sequences were re-
verse translated and codon optimized for H. sapiens using Serial Cloner 2.6 (SerialBasics).
Up to six 30mer sequences were put back-to-back, resulting in 180 amino acid long tandem
constructs. The full length constructs were flanked 3’ and 5’ by BveI restriction sites, the first re-
verse and the second forward oriented, and ordered via the Eurofins Genomics Gene Synthesis
service in pEX-A128 vector backbones.
3.5.3 Preparation of bacterial growth media
Media and plates used to grow bacteria were based on lysogeny broth (LB). All media were
autoclaved directly after preparation and stored at 4°C until use. In all cases ampicillin (100
µg/mL) was used for selection. Upon use, all media and plates were handled in close proximity
to a bunsen burner.
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1. Setup of liquid cultures:
For liquid cultures 2% ([w
V
]) LB in deionized water was used. Directly prior to use the
selection antibiotic was added and the solution stirred to evenly distribute it.
2. Setup of LB-agar plates:
LB-agar stocks contained 3.5% ([w
V
]) LB-agar in deionized water. Prior to use solidified
stocks were heated in a microwave until no solid agar was visible and cooled back down
to be hand warm at RT while stirring. Afterwards the selection antibiotic was added, the
mixture shortly stirred to receive an even solution and the medium distributed to 10 cm
petri dishes. Upon solidification the plates were stored at 4°C until use.
3.5.4 Transformation of competent bacteria
Chemically competent E. coli DH5α bacteria were thawed for 20 min on ice. For each sample
50 µL of the bacterial suspension were mixed with 100 ng plasmid DNA for re-transformations
or 5 µL ligation mix. When working with ligation mixes fresh bacteria were used. For re-
transformation, refrozen - according to the manufacturers instructions - bacteria could be used.
After addition of plasmid DNA the suspensions were incubated for 30 min on ice. To perform
the heat shock the reaction mixes were put into a Thermomixer, pre-heated to 42°C, for 40
sec followed by 2 min incubation on ice. Subsequently, 500 µL SOC medium were added and
samples were incubated on a shaker for 50 min at 37°C for bacterial recovery. Afterwards, the
bacterial suspensions were spun down for 3 min at 2400 xg, the majority of supernatant dis-
carded and the pellet resuspended the residual medium. Resuspended bacteria were streaked
onto LB-agar plates containing the respective selection antibiotic.
3.5.5 Plasmid DNA purification
Depending on the desired amount and application plasmid DNA was purified using two dif-
ferent approaches. Concentrations of all purified plasmid solutions were measured by photo
spectrometry using a NanoDrop 8000 Photospectrometer (Thermo Fisher Scientific).
Following protocols were applied:
1. Small scale purification:
Desired bacterial clones were picked late in the afternoon, placed in 5 mL LB-medium
containing the respective selection antibiotic and incubated for 14 - 16 h. Afterwards the
bacteria were pelleted for 7 min at 2400 xg. Plasmid DNA was then purified using the
QIAprep Spin Miniprep kit (Qiagen) according to the manufacturers instructions.
2. Large scale purification (endotoxin free):
Since the plasmids derived from large scale purifications were later used for transfections
and transductions an endotoxin free purification was chosen.
Colonies were picked early in the morning, placed in 5 mL LB-medium containing the
respective selection antibiotic and incubated for 6 - 8 h. Afterwards the pre-culture was
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diluted 1:1000 in 200 mL LB-medium containing the respective selection antibiotic, in-
cubated for 14 - 16h and pelleted for 30 min at 2400 xg. Plasmid DNA was performed
using the Endofree Plasmid Maxi kit (Qiagen) according to the manufacturers instructions.
Plasmid DNA pellets were resolubilized in TE-buffer provided by the kit.
3.5.6 Restriction digest
Digests of plasmid DNA and PCR products were performed using recombinant restriction en-
zymes in their respective buffer system (RE-buffer). Sample master mixes, containing the re-
spective buffer, restriction enzymes, nuclease free water and in some cases oligo additives,
were prepared according to the manufacturers instructions.
In general, two sets of digests were performed during this work:
1. Target vector digest :
Here, target vector, pre-diluted in nuclease free water, was mixed with the respective di-
gestion master mix. The reaction mix was incubated for 16 h at 37°C. Afterwards, the lin-
earized target vector was dephosphorylated by adding FastAP, gently mixing the solution
by pipetting and incubated it for an additional 30 - 60 min at 37°C. The dephosphoryla-
tion reaction was stopped by heat inactivation for 15 min at 85°C. The received digestion
product was later used for construct ligation.
2. Insert digest :
DNA fragments to be inserted into target vectors were digested without dephosphoryla-
tion. The respective reaction mixes were incubated for 16 h at 37°C. Digested inserts
were purified by gel extraction, precipitated and later used for ligation with the target vec-
tor.
3.5.7 Agarose gel electrophoresis
Gels were prepared by mixing 1x TBE buffer with the desired amount of agarose (table 34) in
an erlenmeyer flask and heating up the suspension in a microwave to create an even mixture.
Afterwards 10 µL ethidium bromide solution was added, the mixture gently stirred and poured
into a gel preparation chamber. A sample comb was added and the gel polymerized at RT. In
the meantime the samples were prepared by mixing 10 µL sample with 2 µL loading dye (6x).
Gels were loaded with the prepared samples and 10 µL GeneRuler DNA ladder mix™ (Thermo
Fisher Scientific) for size control. Gels were run for 60 min at 100 V in 1x TBE buffer.
Table 34 – Size dependent agarose gel densities
Product size TBE buffer [mL] Agarose [g] Gel density (% [w/V])
<500 bp 130 2.60 2
500 - 1000 bp 130 1.95 1.5
1000 bp 130 1.30 1
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3.5.8 Gel extraction
Directly after agarose gel electrophoresis gels were illuminated with long wave UV light (366
nm) and bands of interest cut out using an X-tracta Disposable Gel Extraction Tool (STARLAB).
The gel pieces were placed in pre-tared 1.5 mL reaction tubes and weighed. DNAwas extracted
from the gel pieces using a Nucleospin® Gel and PCR Clean-up kit (Macherey-Nagel) following
the manufacturers instructions.
3.5.9 DNA precipitation
Precipitation was performed whenever a switch of buffer was needed. For most instances this
was the case after gel extraction and subsequent construct ligation.
The DNA solution of interest was filled up to 40 µL with nuclease free water. Afterwards 10%
([V
V
]) 5 M NaCl was added to the solution followed by 300 µL ethanol. The reaction mixture
was incubated for 30 min at -20°C and afterwards spun down for 30 min at 20.000 xg and 4°C.
Supernatant was removed, the pellet washed once with 70% ethanol (diluted with nuclease free
water) to remove excess salt and spun down for 5 min at 20.000 xg and 4°C. The supernatant
was again discarded, the pellet air dried and resuspended in the buffer of choice.
3.5.10 Construct ligation
Inserts and target vectors retrieved from sequential digests were ligated using T4 DNA ligase.
Digested and dephosphorylated target vectors were mixed with the complete amount of di-
gested and purified insert, T4 ligase buffer (10x) and filled up to 28.5 µL with nuclease free
water. Afterwards, 1.5 µL T4 DNA ligase were added to the mix, each sample homogenized by
gentle pipetting and incubated for 2 h at RT. Then the samples were transferred to 4°C for at
least 24 h before using them for transformation of competent bacteria.
3.5.11 Primer design
All primers used during this work were ordered as 100 µM HPLC purified stock solutions from
Sigma Aldrich. In the case of pyrosequencing, primers were ordered with a 5’ biotiylation.
1. For cell line mutation validation:
Genomic sequences surrounding the mutated position 200 - 300 bp to each side were
retrieved from the UCSC Genome Browser [336] for reference genome GRCh37/hg19
[337]. Extracted sequences were analyzed for ideal primer pairs with NCBI-primer BLAST
[338], initially using default settings. For sequences yielding off-target amplicons the de-
fault settings (Max Tm difference and # total mismatches) were adjusted. Optimal primer
pairs, most specific for the given loci, were chosen and ordered.
2. For PCR, sanger sequencing and pyrosequencing:
Sequencing primer for regular construct analysis and PCR amplifications were designed
using the respective target sequence as a template. For sanger sequencing, primers were
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chosen between 80 - 100 bp up- or downstream of the region of interest. Each primer
wasmonitored for melting temperature and hairpin formation using IDT Oligo Analyzer 3.1
[339]. Primer pairs for pyrosequencing were designed and provided by Dr. M. Volkmar.
3.5.12 Polymerase chain reaction
Polymerase chain reactions (PCRs) were performed in different ways based on the needs of
the PCR product. Primer stocks were pre-diluted to 5 µM in nuclease free water. All PCR
products were analyzed by agarose gel electrophoresis prior to use in follow up assays.
1. Subcloning and site directed mutagenesis:
Amplification for subcloning and site directed mutagenesis was performed with Pfu DNA
polymerase, using a touchdown PCR program (table 35). Primers for full length construct
amplification included restriction sites for ligation of the PCR product into the respective
target vector.
Site directed mutagenesis PCRs were generally split into two parts using four different
primers. Two primers covering the substitution codon of choice and two primers to am-
plify the full length construct. In a first step, both strands were amplified up to and from
the substitution site. Afterwards, the full length, mutated construct was generated.
Master mixes, containing 0.5 µL dNTP mix (10mM stock), 2.5 µL Pfu-buffer (10x, with
MgSO4), 1 µL of each primer, 2 ng template DNA, 1 µL Pfu-polymerase and 18 µL nucle-
ase free water were used for each amplification. The final PCR products were purified by
gel electrophoresis, digested and ligated into the target vector of choice.
Table 35 – Standard construct amplification PCR program for subcloning and site directed mutage-
nesis
Step Temperature [°C] Time [sec] Cycles
Initial denaturation 95 120 1
Denaturation 95 20 10
Annealing 65⇒ 55 (∆T = -1) 30 10
Extension 72 120 per kb 10
Denaturation 95 20 15
Annealing 55 30 15
Extension 72 120 per kb 15
Final extension 72 600 1
Pause 10 ∞ —
2. Colony PCR:
Colony PCRs were routinely performed to pre-select positive bacterial colonies from con-
struct ligations prior to sending for sequencing. Here, PCR master mixes were prepared
containing 8 µL MyTaq™ HS Mix (Bioline), 7 µL nuclease free water and 1 µL of each
primer. Per sample 16 µL of the master mix were placed in PCR stripes. Afterwards,
colonies were picked, the toothpick shortly stirred in the respective reaction tube and
residual bacteria plated onto a fresh LB-agar plate to re-grow the selected colony. The
respective empty vector served as negative control.
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Sequences of interest were amplified (table 36) and PCR products analyzed by agarose
gel electrophoresis.
Table 36 – Standard colony PCR program
Step Temperature [°C] Time [sec] Cycles
Initial denaturation/ Lysis 95 180 1
Denaturation 95 15 25
Annealing 63 30 25
Extension 72 60 per kb 25
Final extension 72 600 1
Pause 10 ∞ —
3. Cell line mutation validation and pyrosequencing:
For sufficient PCR product sequencing, larger amounts of amplified sequences were
needed. Thus, the total volume for these reactions was 50 µL. For each sample 25 µL
MyTaq™ HS Mix (Bioline), 16 µL nuclease free water, 3.5 µL of each primer and 60 ng
template DNA were mixed. After PCR amplification (table 37), samples used for mutation
validation by sanger sequencing were purified using the MinElute PCR purification kit (Qi-
agen) following the manufacturers instructions. Samples used for pyrosequencing were
directly used.
Table 37 – Standard mutation validation and pyrosequencing PCR program
Step Temperature [°C] Time [sec] Cycles
Initial denaturation/ Lysis 95 120 1
Denaturation 94 20 45
Annealing 58 30 45
Extension 72 60 per kb 45
Final extension 72 300 1
Pause 10 ∞ —
3.5.13 Sequencing of plasmid DNA and PCR products
1. Sanger Sequencing
Sequencing reactions were performed by the Eurofins Tube Sequencing service. Tem-
plate DNA from plasmid purifications or PCR amplifications was provided following the
manufacturers instructions. When using non-standard primers - not available at Eurofins
Genomics - these were always provided in a separate tube. For result analysis the se-
quencing chromatograms were inspected and the received sequences checked using
Serial Cloner 2.6 (SerialBasics).
2. Pyrosequencing
Loci of interest were amplified by PCR using biotinylated primers for later immobiliza-
tion of the PCR product to streptavidin-coated sepharose beads. Pyrosequencing was
performed by J. Rebmann using a PyroMark Q24 (Qiagen), following the manufacturers
instructions.
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3.5.14 Transient transfection
1. Using Electroporation
For electroporation experiments a GenePulser XCell™ (BioRad) was used. All experi-
ments were performed using cuvettes with a 4 mm gap width. A suspension of 5x106
cells and 12 µg total plasmid DNA in 400 µL OptiMEM was prepared for each sample.
Pulse optimization (see table 38) for each cell line was performed using eGFP-N1 [340]
as fluorescence marker. After the pulse, cells were carefully taken out of the cuvette using
a pasteur pipette, placed in 5 mL pre-warmed culture medium per well of a 6-well plate
and incubated over night. Electroporation efficiency for living, GFP transfected cells was
assessed by flow cytometry.
Table 38 – B cell line dependent, optimal electroporation conditions
Cell line Shape Voltage [V] Capacitance [µF] Number of pulses
771 B cells exponential decay 200 500 1
KBV623 B cells exponential decay 250 750 1
TIPC253 B cells exponential decay 250 750 1
TIPC275 B cells exponential decay 250 750 1
2. Using Calcium phosphate co-precipitation
One day prior to transfection cells were seeded. On the day of transfection the super-
natant was removed, fresh culture medium was added and cells incubated at 37°C and
5% CO2 for at least 20 min to stabilize the mediums pH. In the meantime the transfec-
tion solutions were brought to room temperature. Solutions were mixed by adding the
CaCl2/DNA mix to 2x HBS buffer under rigorous pipetting (see table 39). The mix was
immediately added to the cells, evenly distributed and incubated for 6 - 8 h at 37°C. After-
wards the supernatant was discarded and fresh culture medium was added to the cells.
Table 39 – Calculation table for CaPO4 co-precipitation. Calculations are given for single wells.
Solutions need to be tested each time they are prepared.
Dish Medium [mL]
Solution A Solution B
Amount per well/ dish [µL]
2x HBS [µL] CaCl2 (2.5 M) [µL] DNA [µg] H2O ad [µL]
6-well 2 60 6 2 60 120
10 cm 10 300 30 10 300 600
3.5.15 Genomic DNA extraction
Purification of genomic DNA from cell lines and tumor tissue was performed using the DNeasy®
Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions.
3.5.16 Tumor RNA extraction
For RNA extraction frozen tissue samples were constantly kept on dry ice during transportation.
The tissue pieces were homogenized using a pestle. RNA was extracted using the RNeasy®
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Mini Kit (Qiagen) following the producers manual. RNA was quantified using a Qubit (LifeTech-
nologies) and quality was assessed using a BioAnalyzer 2100 (Agilent) with the RNA 6000
Nano Kit (Agilent), both following the respective manufacturers protocol.
3.5.17 Exome and Transcriptome analyses
Next generation sequencing data was collected in the context of the HIPO-15 and HIPO-K28E
projects. Patient sample identifier were provided by the sample processing lab (SPL) of the Hei-
delberg Center for Personalized Oncology (HIPO). Prior to sample preparation, concentrations
were assessed via Qubit (LifeTechnologies), following the manufacturers protocol. Total RNA
and genomic DNA samples were were adjusted to the desired concentrations in fresh nuclease
free water and transferred to the SPL on dry ice.
Whole exome and RNA sequencing were performed by the Genomics and Proteomics core
facility (GPCF) of the DKFZ. Sequencing was performed on an Illumina HiSeq4000 using fol-
lowing submission parameters:
Table 40 – Total RNA and genomic DNA sample submission parameters
Provided Analyte Application Type Sequencing Type Total Amount [µg]
Genomic DNA Low Input Exome - Version 6 without UTRs HiSeq 4000 Paired-End 100 bp 500
Total RNA RNA-Seq HiSeq 4000 Paired-End 100 bp 1500
Analysis of exome and transcriptome data was performed using the Heidelberg Unix Sequence
Analysis Resources (HUSAR) program package. Genome Reference Consortium Human Build
37 (GRCh37/ hg19) [337] was used as the reference genome for all primary and germline
sample analyses during this work. A human-mouse hybrid reference genome (provided by
Dr. M. Volkmar) was applied to all xenograft samples in order to reduce read misalignment of
mouse cell derived reads.
Raw sequencing data of primary tumors, xenograft and germline were retrieved from the GPCF
and prepared for mutation calling, as well as filtering, using to following script (kindly provided
by Dr. M. Volkmar) in the HUSAR environment.
Reads were aligned to the respective reference genome using the Burrows-Wheeler Alignment
Tool (BWA)[341, 342] align function:
1. For the first read file:
bwa aln -t 4 reference.fa sampleXYZ_read1.fastq.gz >
sampleXYZ_read1.sai
2. For the second read file:
bwa aln -t 4 reference.fa sampleXYZ_read2.fastq.gz >
sampleXYZ_read2.sai
Both indexed read files (sampleXYZ_read1.sai and sampleXYZ_read2.sai) were further merged
to a paired-end alignment SAM file using the BWA sampe function:
bwa sampe reference.fa sampleXYZ_read1.sai sampleXYZ_read2.sai
sampleXYZ_read1.fastq.gz sampleXYZ_read2.fastq.gz > sampleXYZ.sam
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The generated Sequence Alignment/Map (SAM) files were sorted and converted to their re-
spective binary counterparts using Picard tools[343] SortSam function:
java -Djava.io.tmpdir =[path to temporary directory] -jar $NGSUTILDIR/
java/SortSam.jar INPUT=[working directory]/ sampleXYZ.sam OUTPUT =[
working directory]/ sampleXYZ_sorted.bam SORT_ORDER=coordinate
Readgroups were added to each sorted Binary Alignment/Map (BAM) using Picard tools Ad-
dOrReplaceReadGroups function:
java -jar $NGSUTILDIR/java/picard -tools -1.78/ AddOrReplaceReadGroups.jar
INPUT=[working directory]/ sampleXYZ_sorted.bam OUTPUT=[working
directory]/ sampleXYZ_AddedReadGroup.bam RGLB=TIPC91GPCF1 RGPL=
Illumina RGPU=1 RGSM=TIPC91GPCF
Duplicate reads in the sorted BAM files were marked as originating from the same DNA frag-
ment without removing them using Picard tools MarkDuplicates tool:
java -Djava.io.tmpdir =[path to temporary directory] -jar $NGSUTILDIR/
java/picard-tools -1.78/ MarkDuplicates.jar INPUT=[ working directory]/
sampleXYZ_AddedReadGroup.bam OUTPUT =[working directory]/
sampleXYZ_markdup.bam METRICS_FILE=TIPC091GPCF_markdup.metrics
REMOVE_DUPLICATES=false ASSUME_SORTED=true VALIDATION_STRINGENCY=
LENIENT CREATE_INDEX=true
Creation of targets for re-alignment around indels was performed using the Genome Analysis
Toolkit (GATK)[344–346] RealignerTargetCreator (RTC):
java -jar GATK.jar -T RealignerTargetCreator -R reference.fa -I
sampleXYZ_markdup.bam -known 1000 genomes_gold_standard.indels.hg19.
vcf -o RTC_sampleXYZ.intervals
Local realignment of target regions around indels retrieved from RTC was performed using the
GATK IndelRealigner function, to decrease overall base mismatches across all reads:
java -jar GATK.jar -T IndelRealigner -R reference.fa -I
sampleXYZ_markdup.bam -targetIntervals RTC_sampleXYZ.intervals -known
1000 genomes_gold_standard.indels.hg19.vcf -o sampleXYZ_markdup_indel
-realigned.bam
Base quality score recalibration (BSQR) was performed using the GATK BaseRecalibrator, in
order to increase variant call accuracy:
java -jar GATK.jar -T BaseRecalibrator -R reference.fa -I
sampleXYZ_markdup_indel -realigned.bam -knownSites 1000 genomes.high -
confidence -SNPs.hg19.vcf -o sampleXYZ_recal.data.grp
RealignmentTargetCreator and BaseRecalibrator output files were thenmerged using the GATK
PrintReads function resulting in a coordinate sorted output BAM file:
java -jar GATK.jar -T PrintReads -R reference.fa -I
sampleXYZ_markdup_indel -realigned.bam -BQSR sampleXYZ_recal.data.grp
-o sampleXYZ_markdup_indel -realigned -recal.bam
Afterwards, the sequencing sample data from tumor and xenograft were compared to the
germline sample for calling of point mutations by MuTect[347]:
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java -jar MuTect -1.1.4.jar --analysis_type MuTect --reference_sequence
reference.fa --dbsnp dbSNP_build144_GRCh37.13_chr.vcf --
downsampling_type NONE --input_file:normal
sampleXYZ_Germline_markdup_indel -realigned -recal.bam --input_file:
tumor sampleXYZ_Tumor_markdup_indel -realigned -recal.bam --out
sampleXYZ_Tumor_MutectSNV_stats .txt --coverage_file
coverage_sampleXYZ.wig.txt --vcf sampleXYZ_Tumor_Mutect.vcf
The output files were then filtered for MuTect quality control passed mutations using the GATK
SelectVariants tool:
java -jar GATK.jar -T SelectVariants -R reference.fa --variant
sampleXYZ_Mutect.vcf -o sampleXYZ_Mutect_filterPASSed.vcf -ef
Transcriptome read depth was manually assessed using the Integtrative Genomics Viewer
(IGV)[348, 349]. Mutations covered with up to as little as a single mutated read were extracted
for further analyses.
All expressed, mutated genes were compared to their respective overall expression in the PDAC
tumor tissue derived subset of National Center for Biotechnology Information’s (NCBI) Gene Ex-
pression Omnibus (GEO)[350, 351] DataSet Record GDS4336[352, 353] (accession number
GSE28735).
3.5.18 HLA genotyping
Patient HLA typing, seq2HLA [354] was performed using either raw RNASeq or whole exome
sequencing data.
3.6 Retroviral transduction
3.6.1 Virus production and transduction
Described here are the steps from seeding of virus producing cells to final transduced cell prod-
uct in a day-by-day manner, since this process takes one week to receive the final transduced
cell product.
• Day 1: ø-NX-Ampho cells were seeded at 0.25x106 cells per well in 2 mL ø-NX culture
medium in a 6-well plate. One 6-well plate yielded enough virus for one transduction of
3x106 cells.
• Day 2: ø-NX-Ampho cells were transfected using the CaPO4method. A 24-well plate was
coated with 500 µL PBS, containing 5 µg/mL αCD3 (OKT3) and 1 µg/mL αCD28, for 2
h at 37°C. Afterwards the supernatant was removed, up to 2x106T cells in TIL-medium,
containing 300 U/mL IL-2, were added to each well and rested for 48 h.
• Day 3: In the late afternoon supernatant was removed from the transfected ø-NX-Ampho
cells and 3 mL fresh ø-NX culture medium per well was added. In addition cells trans-
fected with a GFP construct were screened for transfection efficiency using a fluores-
cence microscope. Afterwards the cells were incubated for another 14 - 16 h. The late
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timepoint for medium exchange was chosen to reduce the amount of empty virus parti-
cles as much as possible. To later co-localize virus particles and target cells, 6-well plates
(non-cellculture treated) were coated with 1 mL RetroNectin (25 µg/mL in PBS) and incu-
bated over night at 4 °C. Here one well is need for the transduction of up to 3x106 target
cells.
• Day 4: RetroNectin was taken up, pooled and transferred to fresh 6-well plates (non-
cellculture treated), which were in turn again incubated over night at 4 °C. Empty wells
were blocked with 1 mL 2% BSA (in PBS) for 30 min at RT. Afterwards the solution was
discarded and each well washed once with 1 mL PBS. On this day the ø-NX-Ampho cells
should have a confluency of 90 - 95%. Virus containing supernatant was taken up from
up from the ø-NX-Ampho cells and filtered (0.45 µm) to remove excess cellular debris,
resulting in 18 mL viral supernatant. Moving on, this suspension was split into two parts.
1. Direct transduction:
PBS was removed from the RetroNectin coated, blocked plates and 3 mL of viral
suspension was added to each well. Plates were immediately centrifuged for 90 min
at 2000 xg and 32 °C. The pre-rested target cells were resuspended, adjusted to
1x106cells/mL in TIL-culture medium, containing 400 U/mL IL-2 and 4 µg/mL pro-
tamin sulfate. Afterwards the supernatant was removed from the virus coated plates
and 3 mL of the cell suspension was added to each well. Subsequently, the target
cells were spun onto the virus for 30 min at 130 xg and 32 °C followed by over night
incubation.
2. Concentration by ultra-centrifugation:
Ultra centrifuge tubes were rinsed with 70% ethanol and dried in a laminar flow hood.
Afterwards the residual viral supernatants were added, the tubes balanced and the
virus concentrated by ultra-centrifugation for 2 h at 111.200 xg (25.000 rpm) in an
SW40Ti rotor and 4°C. The supernatant was discarded and the virus reconstituted
over night at 4 °C with 500 µL PBS.
• Day 5: RetroNectin from the pre-coated plates was discarded and the plates washed
once with 1 mL PBS. The concentrated virus was reconstituted by addition of another
500 µL PBS and careful pipetting. Afterwards the viral suspension was added to the
RetroNectin coated, blocked plate and spun onto the it for 90 min at 2000 xg and 32 °C.
The supernatant was removed, the target cells from day 4 directly transferred to the new
plates, centrifuged onto the virus for 30 min at 130 xg and 32 °C and incubated for 48 - 60
h. Incubation over the weekend and harvest on Monday morning did not appear to harm
target cell activation or transduction efficiency.
• Day 7-8: Cells were resuspended and washed twice with PBS. Afterwards, the cells were
directly used for assay setup or kept in TIL-culture medium, containing 50 U/mL IL-2, for
up to 3 days. Transduction efficiency was monitored by flow cytometry.
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3.6.2 Stable cell line generation
Generation of CIITA or HLA-A02:01 transduced, PDX derived cell lines was performed by the
Genomics and Proteomics core facility of the DKFZ. Briefly, 5x105 cells/well were seeded in
6-well plates and adhered over night. The next day the cells were transferred to the core
facility together with the respective culture medium. In general, cells were ready for pick up
and transfer to an S1 environment about 48 h later. For antibiotic selection 500 µg/mL G418
was routinely used and directly added to the culture medium during medium exchange. When
splitting confluent cultures, the cells were plated and adhered over night in absence of G418
to avoid loss of the culture. After 24h the medium was changed for fresh culture medium,
containing 500 µg/mL G418.
Generation of Bcl-6/XL immortalized B cell lines from patients peripheral blood or spleen was
performed by AIMM Therapeutics (Amsterdam) under a material transfer agreement (MTA).
3.7 Mass spectrometry
3.7.1 Epitope binding prediction
Binding predictions for HLA-A02:01 were performed using netMHC4.0 [355, 356]. Search pa-
rameters were restricted for 8mer - 12mer sequences with thresholds for strong (0.5% rank)
and weak (2% rank) binders. Input sequences were retrieved from UniProt [334] as 30mer
amino acid sequences with the mutation at position 15 using the mRNA RefSeq accession
number (NM_) [335] received from exome and transcriptome analyses. Epitope sequences
with an affinity < 1000 nM were retrieved and synthetic peptides were generated.
3.7.2 Peptide synthesis and handling
The respective sequences were synthesized via solid phase synthesis, purified by HPLC and
controlled by electronspray ionization mass spectrometry by M. Koch. Aliquots of lyophilized
peptides were constantly kept at -20 °C. Upon solubilization peptides were first brought to RT to
avoid moisture uptake from the air. Afterwards, peptides were resolubilized in sterile DMSO at
10 mg/mL working stocks and aliquots kept at -20 °C until use. To avoid repeated freeze-thaw
cycles, working aliquots were prepared fresh for each experiment series.
3.7.3 Lysate generation for mass spectrometry
Due to the expected low abundance of naturally processed and presented HLA-A02:01 bound
neoepitopes within PDX derived cell lines, up to 45 cell culture dishes (10 cm) were prepared
for lysis. In the case of antigen overexpression in HEK293T cells 10 culture dishes were already
sufficient for neoepitope detection. All samples were acquired as biological triplicates.
Cell lines were seeded at 1x106 cells per 10 cm dish in the respective culture medium. HEK293T
cells were transfected with the respective constructs by CaPO4 co-precipitation. At 80 - 85%
confluency, medium was changed to fresh culture medium containing 330 U/mL IFNγ and cells
incubated for another 48 h. HEK293T cells were at 60 - 70% confluency at the time of medium
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exchange and IFNγ addition, as they grew comparably faster. Transfection efficiency, in the
case of HEK293T monitored by GFP, and HLA-A2 upregulation upon IFNγ treatment was as-
sessed by flow cytometry. Prior to starting the lysis, lysis buffer, PBS, cell scraper and collection
tubes were pre-cooled to 4 °C. Culture dishes were taken out of the incubator and immediately
put on ice. It was crucial to constantly keep the dishes in contact with the ice to reduce possible
peptide degradation. Culture medium was removed, each plate rinsed with 5 mL PBS and the
PBS completely removed to avoid sample dilution. Afterwards 1 mL of lysis buffer was used
for lysis of four 10 cm dishes (≈4x107 cells) by adding the buffer to the first plate, scraping off
the cells and transferring the suspension to the next dish to repeat the process. Lysates were
collected, aliquoted to 2 mL tubes and cellular debris was pelleted for 30 min at >20.000 xg and
4 °C. Afterwards up to 5 mL supernatant were pooled and stored at -80 °C until submission for
mass spectrometry analyses.
3.7.4 Mass spectrometry analyses
All lysates and lyophilized peptides were transferred to the group of PD Dr. Dr. A. Riemer on
dry ice. HLA pulldown, peptide elution and mass spectrometry analyses were performed by
them as previously described [357].
3.8 Generation of flow cytometry data
3.8.1 Flow Cytometry Panels
Table 41 – Flow cytometry panels applied for mouse cell experiments. Stainings for the different
markers were performed as described in the method section. Amounts used for each marker can
be found in the material section.
Staining Marker Fluorophore
Panel setup (Volume [µL])
H2-Kb-SIINFEKL OT Assay
CFSE CFSE CFSE —
Dead cell staining DCM_Aqua Aqua
DCM_ZV Zombie Violet — —
DCM_488 488 — —
Extracellular CD45.1 BV711 —
CD45.2 PE/ Dazzle594 —
H2-Kb APC —
H2-Kb- SIINFEKL PE —
CD3 APC —
CD8a APC-Cy7 —
CD4 Pacific Blue —
Additional GFP GFP —
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Table 42 – Flow cytometry panels applied for human cell experiments. Stainings for the different
markers were performed as described in the method section. Amounts of each marker can be found
in the material section. ( ) = Seperate samples with either of the antibodies used.
Staining Marker Fluorophore
Panel setup
T cell
MHC T Cell Cell line Transduction
expression Activation contamination 3xFLAG DMF5 HY TCR GFP
CFSE CFSE CFSE — — — — — — —
Dead cell staining DCM_Aqua Aqua — — — —
DCM_ZV Zombie Violet — — — — —
DCM_488 488 — — — — — — —
Extracellular CD3 BV711 — — — — — —
CD4 APC-Cy7 — — — — — —
CD8 Alf-700 — — — — — —
CD271 (NGFR) APC — — — — — — —
FLAG APC — — — — — — — —
CD326 (EpCAM) APC-Vio770 — — — — — — —
HLA-A2 FITC — ( ) — — — — — —
HLA-A, B, C FITC — ( ) — — — — — —
HLA-DR, DP, DQ FITC — ( ) — — — — — —
mTCR-β BV421 — — — — — — —
CD4 BV510 — — — — — — — —
FLAG APC — — — — — — —
Intracellular TNF-α APC — — — — — — —
IFN-γ PE — — — — — — —
Additional GFP GFP — — — — — — —
3.8.2 Gating strategies
Figure 13 – Gating strategy to determine CD4+/ CD8+ ratios in bulk expanded TIL populations.
Applying the T cell panel.
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Figure 14 – Gating strategy for the OT proliferation assays. Applying the OT assay panel.
Figure 15 – Gating strategy to asess the GFP transduction efficiency. Applying the GFP transduc-
tion panel.
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Figure 16 – Gating strategy for the H2-Kb-SIINFEKL surface staining. Applying the H2-Kb-
SIINFEKL panel.
Figure 17 – Gating strategy to asess the Lamp1 transduction efficiency. Applying the 3xFLAG
transduction panel.
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Figure 18 – Gating strategy for monitoring human T cell activation in an autologous setting. Apply-
ing the T cell activation panel.
Figure 19 – Gating strategy to assess peptide dependent HLA-A2 stabilization. Applying the MHC
expression panel with the HLA-A2_FITC antibody.
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FITC-A :: HLA-A2
HLA-A2
Figure 20 – Gating strategy to assess HLA-A2 upregulation on PDX derived cell lines. Applying the
MHC expression panel with the HLA-A2 antibody.
Figure 21 – Gating strategy to visualize phenotypic differences in mouse contaminated cell lines.
Applying the cell line contamination panel.
Figure 22 – Gating strategy to asess the DMF5 TCR transduction efficiency. Applying the DMF5
transduction panel.
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Figure 23 – Gating strategy to asess the HY TCR transduction efficiency. Applying the HY TCR
transduction panel.
3.9 Statistical analyses
Statistical analyses and plotting of graphs was performed using GraphPad Prism 7 for Mac
OS X, GraphPad software, La Jolla California USA, www.graphpad.com. For the statistical
analyses applied during this work, unpaired t-test and One-way ANOVA with Tukey’s multiple
comparison post-hoc multiple comparisons test were used.
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4 Results
4.1 Strategies towards the identification of TIL-target epitopes in PDAC
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Figure 24 – Complementary strategies for the identification of TIL-target epitopes in PDAC. For
the identification of immunogenic antigens, our main focus was on the validation of an expression
based screening approach. In the case of direct identification of antigens presented on the surface
of tumor cells, we focussed on a targeted proteomics protocol. The main methodologies validated
during this work are highlighted (black arrows).
In order to examine the specificity of PDAC tumor infiltrating lymphocytes (TILs), a general
framework of complementary methodologies can be applied, depending on the starting mate-
rial used (see figure 24). Applying these methodologies to primary PDAC biopsies, this thesis
focused on two main strategies (see figure 24; highlighted by black arrows). On the one hand
on the assessment of immunogenic antigens recognized by PDAC TILs and on the other hand
on the direct identification of antigens presented at the tumor cell surface. Regarding tumor
recognition by TILs, two functional approaches for the identification of immunogenic antigens
may be used which either focus on in vitro expanded TILs, or single cell cloned T cell recep-
tors (TCRs) [141, 143, 144, 358]. However, as the identification of tumor reactive TCRs from
single cells currently remains challenging and cost intensive, we used in vitro expanded TILs
for the implementation of our antigen screening system in this thesis. Especially, since ex-
panded PDAC TILs have been shown to recognize their autologous tumor [279]. Furthermore,
the use of an expression-based or a peptide-based epitope screening were shown to be useful
tools for the identification of immunogenic antigens [146, 175]. Here, we decided to implement
an expression-based screening system, as this approach best resembles the physiological pro-
cessing and presentation of relevant antigens. Given the overall low number of mutations found
in PDAC tumors, in combination with a frequent infiltration of tumor reactive T cells - to a slightly
higher extent by CD4+ than CD8+ cells -, we chose to develop a system, that could potentially
target antigens into the MHC-I, as well as the MHC-II antigen presenting pathway. This allowed
us to screen for CD4+ and CD8+ T cell restricted epitopes in an unbiased (i.e. MHC indepen-
dent) fashion.
The tumor material itself can be used to analyze its genetic profile by next-generation sequenc-
ing, an important step in the process of antigen identification, as it yields crucial information
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on the malignancies’ gene expression profile and tumor mutanome. Based on this, the identi-
fied alterations can afterwards either be used to screen for immunogenic antigens (i.e. using
TILs), to predict potential antigens for in vitro / in vivo immunization (i.e. reverse immunology)
or to directly identify previously predicted epitopes, presented on the tumor cell surface (i.e. by
targeted mass spectrometry). In this thesis, we decided to focus on the direct identification of
antigens presented on the tumor cell surface, using a targeted mass spectrometry approach.
The advantage of this targeted approach, allowing for a highly sensitive detection of low abun-
dant and weaker binding epitopes, was recently shown by the group of PD Dr. Dr. A. Riemer
[357].
4.2 Patient characteristics
4.2.1 Patient sample-sets relevant for this study
In order to design screening methodologies to identify PDAC derived neoepitopes, we analyzed
the available patient material for screening eligibility. For this, we defined the minimal criteria
the patient material had to fulfill to be used for the envisioned approaches. In the case of the
expression based screening, large numbers of expanded TILs, exome and transcriptome data,
as well as patient derived xenografts (PDX) had to be available. For the targeted proteomics
approach, PDX derived cell lines from HLA-A02:01+ patients in combination with the respec-
tive exome and transcriptome data were needed. These criteria led to a total of four patients
that were eligible for an initial application of the screening approaches (table 43; underlined
patients). Out of these patients, three (TIPC102, 222 & 236) could be used for the expression
based screening approach and all four (TIPC102, 113, 222 and 236) for the targeted proteomics
approach. Material of selected patients not meeting the selection criteria (TIPC079, 091, 253
and 275), was used to set up and validate our screening methodologies.
Table 43 – Patient material used to setup the neoepitope screening pipeline. Patients highlighted
(underlined) fullfilled the criteria needed for neoepitope screening by either of the assays indicated.
Material from the residual patients was used for validation and setup of the neoepitope identifica-
tion pipeline. Indicators: = used in the context of this subproject; + = available/ positive; – =
unavailable/ negative.
Patient Setup and Validation
Expression MS
NGS data TILs PDX Cell line HLA-A2+
based based
TIPC079 + + – – +
TIPC091 + + – – –
TIPC102 + + + – +
TIPC113 + – + + +
TIPC222 + + + + +
TIPC236 + + + – +
TIPC253 + – + – +
TIPC275 – + + – –
4.2.2 Assessment of patient specific mutations
The selected set of tumors was analyzed for the expression of non-synonymous single nu-
cleotide variants (nsSNV). These mutations were of special interest, as they are tumor specific
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and the respective T cell pool is unaffected by central tolerance. For this, exome and transcrip-
tome data of the primary tumors, and of low passage PDX samples, were collected, analyzed
and compiled (figure 25). In the case of TIPC113, no primary tumor transcriptome data could
be acquired, due to low RNA quality of the collected sample. In total, the data revealed an
average mutational burden of 80.5 nsSNVs per tumor (range: 72 - 99) (figure 25). However,
looking at the matched transcriptome data, only approximately 33% (average: 27.75 nsSNV;
range: 22 - 39 nsSNV) of these nsSNVs were actually expressed in the respective tumor sam-
ples (figure 25 & table S3-S6).
To establish the targeted proteomics approach, it was necessary to also predict possible HLA-
A02:01 binding epitopes from the fraction of expressed nsSNVs and validate their presence in
the respective PDX derived cell line (figure 25). This resulted in an average of 11 expressed
nsSNVs (range: 9 - 15) per primary tumor for which potentially HLA-A02:01 binding epitopes
could be predicted by netMHC4.0 (figure 25 & table S10-S13). Of these mutations, an average
of 7 nsSNVs (range: 1 - 11) were later found to still be present in the PDX-derived cell line (fig-
ure 25 & table S14-S17). In this context the cell line of TIPC236 needs to be highlighted, since
the mutation validation in this cell line revealed mostly wild type loci, with only the KRAS_G12D
mutation still present (table S17). Therefore implying, that there was a potential mix-up of this
sample during the generation of the PDX-derived cell line. Thus, this patient was excluded from
the targeted proteomics screening approach.
TIPC102 TIPC113 TIPC222 TIPC236
7 67 25 3 64 9Total nsSNV's 5 48 19 18 30 26
of these
expressed nsSNV's
1 1325 1 2190 715 * 19 9
of these
HLA-A02:01 peptide 
generating nsSNV's
5100 1800 37 7 3*
of these
in autol. cell line 11000 27 0 1 07 0*
Figure 25 – Schematic summary of the exome and transcriptome analyses of patient samples used
for neoantigen prediction. Yellow circles represent the number of primary tumor unique mutations
and blue circles xenograft unique mutations. The green overlap indicates the number of mutations
found in both primary tumor and xenograft. *For TIPC113 only xenograft transcriptome data was
available and the expression of primary tumor unique mutations could not be assessed. nsSNV =
non synonymous single nucleotide variant. Detailed summaries can be found in table S3-S6
4.3 Development of an expression based screening system
Due to the overall low number of non-synonymous mutations found in pancreatic cancer, it is
crucial that not a single immunogenic epitope is missed by the applied screening methodology.
Moreover, both, CD8+ and CD4+ T cells, were shown to be important for an anti tumor T cell
response ([142, 144, 220, 221]). Therefore, a screening system capable of simultaneously de-
tecting MHC-I and MHC-II restricted epitopes is desirable, in order to cover the complete range
70 4 RESULTS
of potentially immunogenic antigens. Based on this idea, we chose lysosome-associated mem-
brane glycoprotein 1 (Lamp1; UniProtKB - P11279-1) as a starting point for the development of
such a screening system. In particular, we were aiming to make use of the subcellular localiza-
tion of Lamp1 to the endocytic compartment. This translocation is achieved by a combination of
an N-terminal signal peptide (residues 1 – 28), leading to the translation into the endoplasmic
reticulum (ER), and a C-terminal cytosolic sorting motif (residues 406 – 417; motif Tyr-X-X-Ile),
responsible for lysosomal translocation of Lamp1 [359–361]. It was previously shown, that full
length Lamp1 is capable of targeting antigens to the endocytic compartment, leading to presen-
tation on MHC-II molecules and antigen specific CD4+ T cell activation [362, 363]. Moreover,
truncated variants, encoding only the signal peptide, the antigen of interest and the sorting mo-
tif, were shown to induce antigen specific T cell activation [364, 365]. Due to unknown folding
of the introduced poly-peptide sequences, however, we expected such reduced screening con-
structs to be more negatively affected by the introduction of larger antigen constructs. Thus,
we chose to modify full-length Lamp1 to simultaneously shuttle antigens into the MHC-I and
MHC-II pathway.
4.3.1 Lamp1 construct design
In order to design our expression based screening system, we analyzed the single-spanning
transmembrane helix of Lamp1 for the introduction of destabilizing residues to induce a protein
fallback into the endoplasmic reticulum via ER-associated degradation (ERAD) mediated by in-
tramembrane rhomboid proteases [366]. By introducing such a destabilization we were aiming
to obtain a construct that would overcome sole MHC-II antigen presentation and result in a bal-
anced MHC-I/ MHC-II antigen presentation. We identified two distinct residues (G390 & L395),
that were most likely to destabilize the helix and cause early degradation of Lamp1 (figure 26).
To test our hypothesis we generated two constructs encoding the single destabilizing mutations
(G390R and L395K) and one construct combining both mutations (figure 26). The respective
antigens used to screen for MHC-I and MHC-II presentation were consecutively introduced N-
terminally of the transmembrane helix, between residues L377 & D378 (figure 26). During each
step of the system’s development we took along minigenes – known for efficient MHC-I antigen
presentation [146] – containing only the respective MHC-I and MHC-II epitopes and devoid of
translocation sequences, as a benchmark of T cell activation (figure 26C).
In the following paragraphs the different constructs will be referred to as Wild Type for the non-
modified construct, Mut390/ Mut395 for the respective single mutants and MutGLRK for the
double mutant.
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Figure 26 – General construct design for the establishment of the expression based screening
system. Shown are the wild type Lamp1 construct (A) and the three transmembrane domain (TMD)
destabilizing variants (B), as well as the minigene design used as benchmark (C). Each Lamp1
constuct contains the native ER localization sequence of Lamp1 followed by a 3xFLAG tag for later
detection of the protein. Antigens used for specific activation of CD8+ and CD4+ T cells during
the systems funcionality validation were introduced N-terminally to the TMD. Lysosomal targeting
was achieved by using the native Lamp1 lysosomal targeting sequence. The minigene construct is
devoid of any signal sequence.
4.3.2 Functionality validation of the expression based screening system
For an initial test of the functionality and effects of the destabilization on antigen specific T
cell activation, we used murine, ovalbumin-specific OT-I/ OT-II transgenic T cells as a readout
system. Antigen presentation was achieved by inserting two ovalbumin epitopes, namely SI-
INFEKL (H-2Kb-restricted) and ISQAVHAAHAEINEAGR (I-Ab-restricted), into our Lamp1 vari-
ants combined with transfection of the resulting constructs into the murine 771 B cell line (H-
2Kb+ and I-Ab+, see material section). Co-culture of transfected 771 B cells with ovalbumin
specific CD8+ (OT-I; SIINFEKL specific) [329] and CD4+ (OT-II; ISQAVHAAHAEINEAGR spe-
cific) [330] murine T cells allowed to screen for presentation of antigens via the MHC-I/ MHC-II
pathway.
During these experiments we could not observe significant differences in antigen specific CD8+
T cell activation between the different Lamp1 constructs (figure 27), suggesting that Lamp1,
independent of our modifications, efficiently introduced peptides into the MHC-I pathway. Here,
the formation of defective ribosomal products (DRiPs) of the Lamp1 construct might already
serve as an early source of MHC-I restricted antigen formation ([367, 368]). As expected, the
minigene was capable of specifically activating the OT-I cells (figure 27). Looking at MHC-II
restricted T cell activation, however, we could show the advantage of our Lamp1 screening
system over regular minigene constructs, which were incapable of translocating antigens to the
MHC-II compartment (figure 28). Furthermore, we could show a decrease in CD4+ T cell acti-
vation by our double mutant Lamp1 variant (MutGLRK) compared to the Wild Type construct,
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whereas the single mutants were still capable of activating OT-II cells (figure 28).
Taken together, we could not observe a significant advantage of the TMD destabilizing Lamp1
variants over its wild type form, when looking at the induction of a balanced antigen specific
T cell activation. Furthermore, the double mutant (MutGLRK) even resulted in an undesired
abrogation of CD4+ T cell activation compared to wild type Lamp1, making it the least favorable
construct for neoepitope screening in this context. Nevertheless, we could show, that the ad-
vantage of a Lamp1 based screening approach, compared to a minigene based one, lies in the
increased shuttling of antigens into the MHC-II pathway. Thus, we had a functional approach
to express and screen antigens restricted to the MHC-I, as well as MHC-II antigen presenting
pathway.
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Figure 27 – Validation of MHC-I restricted antigen presentation of the Lamp1 screening system.
(A) Antigen specific activation of OT-I cells monitored by CFSE dilution. For the positive control,
SIINFEKL expressing BOK cells (B7-1+, SigOVA(257-264)+, H2-Kb+ MEC-1 cell line [313, 314])
were used to induce antigen specific T cell activation. Untransfected 771 B cells served as negative
controls to monitor background T cell proliferation. Lamp1 and minigene constructs were transfected
into 771 B cells by electroporation. Readout was performed after 72h coincubation of CFSE labeled
OT-I cells and 5x104 of the respective target cells. (B) Analysis of numbers of divided OT-I cells
in each sample after 72h incubation. Total cell numbers were assessed by normalization to the
aquired number and volume of CountBright™ beads. A representative experiment of n = 4 biological
experiments is shown. Experiments were performed as technical duplicates.
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Figure 28 – Validation of MHC-II restricted antigen presentation of the Lamp1 screening system.
(A) Antigen specific activation of OT-II cells monitored by CFSE dilution. Peptide pulsed (5 µg/ mL
OVA_MHC-II peptide), congeneic (CD45.1+) splenocytes were used as positive control for antigen
specific T cell activation. Lamp1 and minigene constructs were transfected into 771 B cells by
electroporation. Readout was performed after 96h coincubation of CFSE labeled OT-II cells and
1x105 of the respective target cells. (B) Analysis of numbers of divided OT-II cells in each sample
after 96h incubation. Total cell numbers were assessed by normalization to the aquired number
and volume of CountBright™ beads. A representative experiment of n = 4 biological experiments is
shown. Experiments were performed as technical duplicates.
4.3.3 Validation of expanded PDAC derived TILs as antigen presenting cells
After the validation of the systems functionality in murine cells, we set out to confirm this func-
tionality in a fully autologous human setting. Due to the difficulty of obtaining professional
antigen presenting cells from PDAC patients, we tested and used in vitro expanded TILs as
a source of autologous APCs for our screening approach. This approach was supported by
the fact, that activated human T cells are known to express functional MHC-I and MHC-II on
their surface [369–371] (figure 29A). In addition, we were able to obtain TILs from most PDAC
patients in large numbers, as previously described [279].
To set up the screening system in the human setting, we used two T cell receptors (TCRs) with
known antigen specificity and transduced these into TILs from patient TIPC079, expressing
both HLA alleles needed for the presentation and recognition of the antigens of interest (ta-
ble S2). In particular, we used a Mart1-specific TCR (DMF5) recognizing E(A/L)AGIGILTV
bound to HLA-A02:01 [372] and a DDX3Y/ HY specific TCR specific for HIENFSDIDMGE
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presented on HLA-DQB01:05 [316]. Since the TIL population of TIPC079 contained mainly
CD4+ T cells (figure S1), it should be noted, that the Mart1 TCR used here is known to po-
tently activate T cells in a CD8-independent manner [372]. For antigen presentation, we gen-
erated a sequence encoding both epitopes, elongated by their native sequence (Mart1–HY:
YTTAEELAGIGILTVILGV–CPPHIENFSDIDMGEIIMGN), using it either as a minigene or intro-
ducing it into our different Lamp1 constructs. The resulting gene constructs were transduced
into autologous TILs, generating the autologous APC population.
We could show that in the human setting the introduction of transmembrane domain (TMD)
destabilizing mutations into Lamp1 leads to a significant increase in MHC-I restricted T cell
activation compared to the Wild Type variant (figure 29D). In addition, these destabilizations
did not interfere with the MHC-II restricted T cell response (figure 29F), even though the double
mutant construct (MutGLRK) revealed a slight decrease in MHC-II restricted T cell activation
(figure 29F). As in the murine system, the Lamp1-based screening system displayed superior
MHC-II restricted T cell activation compared to the minigene construct (figure 29F).
Taken together, we could show the functionality of the Lamp1 based screening approach, using
PDAC derived TILs as autologous antigen presenting cells. In addition, these results show the
advantage of our Lamp1 screening system over the use of regular minigenes. The function-
ality validation of the Lamp1 screening system revealed that the Mut395 construct was overall
the most robust in balanced MHC-I and MHC-II restricted T cell activation (table 44). Thus,
this construct was chosen as the starting point to screen for patient derived neoepitopes in the
context of PDAC.
Table 44 – Summary of the Lamp1 screening system validation. Depicting the potency of MHC-I and
MHC-II restricted T cell activation during each step of the systems validation. +/++/+++: Objective
strength of T cell activation above background from weak to strong; –: Activation on background
level. Each experimental set was performed as biological triplicates.
Effector cells Antigen presenting cell
Lamp1 construct
Minigene Wild Type Mut390 Mut395 MutGLRK
OTI
771 B cell line
MHC-I ++ ++ ++ ++ ++
OTII MHC-II – ++ ++ ++ –
human PBMC KBV623 cell line
MHC-I + + ++ ++ +++
MHC-II – ++ ++ ++ +
PDAC TIL PDAC TIL
MHC-I ++ + ++ +++ +++
MHC-II – ++ ++ +++ +
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Figure 29 – Lamp1 destabilization leads to a balanced CD4+/CD8+ T cell activation. (A) Sur-
face expression of MHC-I and MHC-II on TILs of TIPC079. (B) Transduction efficiency of both
antigen specific TCRs. Detection of DMF5 TCR transduction efficiency was performed using an
α-mouseTCR-β_BV421 antibody. HY TCR transduction efficiency was assessed via the expression
of truncated NGFR using a α-NGFR_APC antibody. (C/E) Antigen specific activation of TCR trans-
duced TILs for the DMF5 TCR (C) and HY TCR (E). Untransduced, autologous TILs were pulsed
with 10 µg/mL of the respective, synthetic peptide. Irrelevant peptide either represented HY peptide
(C) or Mart1 peptide (E). (D/F) Influence of the Lamp1 expression system and minigene on MHC-I
(D) and MHC-II (F) restricted antigen specific T cell activation. Co-incubation was performed using
0.5x104 TCR transduced effector and 1x105 of the respective target cells per sample. T cell activa-
tion was assessed by ELISA in technical triplicates. Shown is one representative experiment of n =
3 biological replicates. Statistical analysis of the peptide results was performed using an unpaired
t-test, while for the Lamp1 samples a One-way ANOVA with post-hoc Tukey’s multiple comparisons
test was used.
4.3.4 Generation and validation of patient derived constructs
Since the introduction of larger multi-epitope sequences in close proximity to the transmem-
brane helix of Lamp1 could lead to a disruption of the antigen processing and presentation, we
included the Mart1 and HY epitopes in each further construct. This allowed us to control the
functional integrity of each construct after the introduction of patient derived antigens, using the
Mart1 and HY specific TCRs as previously described (figure 30).
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Patient specific multi-epitope constructs were designed by analyzing the respective exome and
transcriptome data for all expressed mutations (figure 25). Sequences encoding up to six mu-
tations were introduced into our Mut395 construct (figure 30 and table S7-S9). Each mutation
was encoded by nucleotides encompassing 30 amino acids with the mutation at position 16,
surrounded by the native sequence (figure 30). For mutations close to the protein’s N- or C-
terminus, the position of the mutation could slightly differ. In order to minimize the generation of
artificial epitopes, due to the decreased spacing between two mutations, we decided to place
the latter sequences either in the first (mutation close to N-term) or last (mutation close to C-
term) position of the respective multi-epitope construct (table S7-S9).
Altogether, we generated 15 patient-derived tandem constructs for a set of three patients,
based on the mutations expressed in the primary tumor and xenograft (table S3, S5-S9). All 15
patient constructs generated were capable of shuttling antigens into the MHC-I, as well as the
MHC-II antigen presenting pathway (figure 31 and 32).
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Figure 30 – Schematic overview of the adaptation of the Lamp1_Mut395 construct for patient de-
rived epitope screening. (A) Layout of the empty Lamp1_Mut395 construct. (B) Lamp1_Mut395
general layout after introduction of patient derived, multi-epitope constructs. (C) multi-epitope con-
struct setup example from TIPC102 (Construct 1). The table indicates the respective gene and
mutation, the chromosomal location of the nsSNV, as well as the mutated sequences used for the
setup of this specific construct. For data from all patients, see table S3 - S9.
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Figure 31 – MHC-I antigen presentation functionality of the Lamp1_Mut395 system after introducing
patient derived, multi-epitope constructs. (A) Antigen specific activation of DMF5 TCR transduced
TILs against peptide pulsed, autologous APCs. Here, the HY peptide (HIENFSDIDMGE) was used
as irrelevant control. (B) Antigen specific, class-I restricted activation of DMF5 TCR transduced TILs
against empty Lamp1_Mut395 transduced, autologous TILs. The empty Lamp1_Mut395 construct
(figure 30) served as a baseline control for the systems functionality. (C) Summary of the MHC-I
restricted, antigen specific activation of DMF5 TCR transduced TILs against the various patient de-
rived, multi-epitope constructs encoding Lamp1_Mut395 constructs.
Staining was performed using the T cell activation panel. Activation was monitored by TNFα ex-
pression in the CD3+ effector (CFSE-) population via intracellular cytokine staining. Day 42 TILs
from patient TIPC079 were used for transduction of the TCR and Lamp1 constructs. Peptides were
pulsed onto GFP transduced d42 TILs. Experiments were performed seperately for each patient.
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Figure 32 – MHC-II antigen presentation functionality of the Lamp1_Mut395 system after introduc-
ing patient derived, multi-epitope constructs. (A) Antigen specific activation of HY TCR transduced
TILs against peptide pulsed, autologous APCs. Here, the Mart1 short peptide (ELAGIGILTV) was
used as irrelevant control. (B) Antigen specific, class-II restricted activation of HY TCR transduced
TILs against empty Lamp1_Mut395 transduced, autologous TILs. The empty Lamp1_Mut395 con-
struct (figure 30) served as a baseline control for the systems functionality. (C) Summary of the
MHC-II restricted, antigen specific activation of HY TCR transduced TILs against the various pa-
tient derived, multi-epitope constructs encoding Lamp1_Mut395 constructs.
Staining was performed using the T cell activation panel. Activation was monitored by TNFα ex-
pression in the CD3+ effector (CFSE-) population via intracellular cytokine staining. Day 42 TILs
from patient TIPC079 were used for transduction of the TCR and Lamp1 constructs. Peptides were
pulsed onto GFP transduced d42 TILs. Experiments were performed seperately for each patient.
4.3.5 Screening of patient TIL using multi-epitope constructs
After assessing the functionality of each patient derived Lamp1 construct, we went on to screen
the respective patient TILs for recognition of the encoded mutations. For this, minimally ex-
panded TILs (expanded for 28 days) from patients TIPC102, 222 and 236 were used as re-
sponder T cells against the respective patients’ Lamp1 multi-epitope constructs. The Lamp1
constructs were transduced into excessively expanded (expanded up to 42 days) TILs from the
same patient to generate the autologous APC population. For each patient, the transduction
efficiencies of the Lamp1 constructs had to be estimated on the basis of GFP and TCR trans-
duction efficiency, since we could not directly assess the transduced Lamp1 using its N-terminal
3x-FLAG tag (figure S5 and S6). Since each patient of this cohort was HLA-A2+, the presence
and functionality of each Lamp1 construct was monitored, within the screening experimetns,
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by coincubation of the autologous APCs with Mart1 TCR (DMF5) transduced TILs. In accor-
dance with the previously published assays to describe recognition of the autologous tumor by
PDAC TILs, we measured the secretion of IFNγ to describe antigen specific TIL reactivity [279].
Overall, screening of TIPC 102 revealed little to no reactivity against the patient derived xenograft
and no reactivity against any of the patient derived mutations (figure 33B - D). Importantly, the
transfection of the multi-epitope constructs was successful, as the MART-1 epitope encoded by
each construct was recognized by DMF5 TCR transduced T cells (figure 33B and D). It should
be noted that the control sample used to test the Mart1 TCR functionality during these experi-
ments was negative, due to loss of HLA-A02:01 in the xenograft (figure 47B).
For patient TIPC222, we had access to responder TILs from two distinct tumor sites (222.2 and
222.3). However, we could neither show recognition of the autologous xenograft, nor reactivity
against any of the mutation encoding Lamp1 constructs (figure 34B - E).
Screening TILs from patient TIPC236 initially appeared more promising, revealing reactivity
against the autologous tumor (figure S4B & D and figure 35B & D). In addition, the IFNγ ELISpot
revealed responder TIL reactivities against all mutation encoding Lamp1 constructs (figure 35C
and D). When we tried to confirm this finding, we included a TNFα ELISpot for an additional
functionality readout. However, the TNFα ELISpot could not confirm results of the IFNγ readout
(figure 35C and D), therefore indicating that the reactivities seen in the IFNγ ELISpot might be
artifacts.
Taken together, we could not show the recognition of mutation derived epitopes by expanded
TIL populations from PDAC patients. However, it should be kept in mind that the overall re-
sponse rate of these cells against the autologous tumor was previously shown to be rather low
(≈1.5%), indicating that the chances of finding neoepitope reactive T cells in bulk expanded
TILs from PDAC patients is generally low [279]. Nevertheless, these findings do not rule out
the initial presence of tumor reactive T cells in pancreatic cancer. They rather show, that the
identification of tumor reactive TILs should start at an earlier stage of tumor material processing
(e.g. ex vivo single cell TCR sequencing of TILs), to avoid the loss of initially tumor reactive T
cell clones during in vitro culture. Furthermore, it should be kept in mind that, though nsSNVs
might harbor an elegant source of potentially immunogenic neoepitopes, they only represent
a limited pool of recognizable antigens. Thus, widening the window of screened epitopes to
antigens derived from peptide and RNA editing or to over-expressed self-antigens might over-
come this limitation. Furthermore, the negative result of the TNFα ELISpot indicates, that the
T cell activation marker panel used for these screenings should be enlarged to include more
than the previously applied IFNγ single readout. In addition, the use of autologous TILs as
antigen presenting cells should be reconsidered for patients with access to professional APCs,
as these could be more potent in complete T cell activation.
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Figure 33 – Screening for patient specific neoepitope reactivity by bulk expanded TILs from patient
TIPC102. (A) Transduction efficiency assessment of TIPC102 autologous APCs and DMF5 TCR
transduced TILs. A combination of GFP and DMF5 TCR served as rough indicator for overall trans-
duction efficiency during the experiments. (B and C) Assessment of responder TIL reactivity by IFNγ
ELISpot. (B) Control samples monitoring the background reactivity and general T cell functionality
after unspecific activation with PHA. In addition, reactivity against the autologous xenograft was as-
sessed. Mart1 TCR (DMF5) transduced TILs were used to monitor functional antigen presentation
and presence of each Lamp1 construct (only shown for multi-epitope construct 1; representative for
all constructs used). Functionality of the DMF5 TCR was assessed by pulsing the xenograft with
Mart1 peptide. PDX = autologous xenograft. PDX/αMHC-I = MHC-I blocked autologous xenograft.
PDX/Mart1 = Mart1 peptide pulsed (Mart1 – ELAGIGILTV), autologous xenograft. (C) Screening for
responder TIL reactivity against Lamp1 construct expressing autologous APCs. Vector Control =
Lamp1_Mut395 screening construct without patient mutations (figure 30). Construct 1 - 4 = Patient
mutation encoding Lamp1 constructs (see table S3 and S7). (D) Spot count for each technical tripli-
cate during one experiment. The screen was performed as biological duplicate. Statistical analysis
of results was performed using a One-way ANOVA with post-hoc Tukey’s multiple comparisons test.
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Figure 34 – Screening for patient specific neoepitope reactivity by bulk expanded TILs from pa-
tient TIPC222. (A) Transduction efficiency assessment of TIPC222 autologous APCs and DMF5
TCR transduced TILs. A combination of GFP and DMF5 TCR served as rough indicator for overall
transduction efficiency during the experiments. (B and C) Assessment of responder TIL reactivity
by IFNγ ELISpot. Samples 222.2 and 222.3 indicate expanded TIL cultures from two different lo-
cations of the autologous tumor material. (B) Control samples monitoring the background reactivity
and general T cell functionality after unspecific activation with PHA. In addition, reactivity against
the autologous xenograft was assessed. Mart1 TCR (DMF5) transduced TILs were used to monitor
functional antigen presentation and presence of each Lamp1 construct (only shown for multi-epitope
construct 1; representative for all constructs used). Functionality of the DMF5 TCR was assessed
by pulsing the xenograft with Mart1 peptide. PDX = autologous xenograft. PDX/αMHC-I = MHC-I
blocked autologous xenograft. PDX/Mart1 = Mart1 peptide pulsed (Mart1 – ELAGIGILTV), autol-
ogous xenograft. (C) Screening for responder TIL reactivity against Lamp1 construct expressing
autologous APCs. Vector Control = Lamp1_Mut395 screening construct without patient mutations
(figure 30). Construct 1 - 7 = Patient mutation encoding Lamp1 constructs (see table S5 and S8).
(D) Spot count for each technical triplicate during one experiment. The screen was performed once.
Statistical analysis of results was performed using a One-way ANOVA with post-hoc Tukey’s multiple
comparisons test.
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Figure 35 – Screening for patient specific neoepitope reactivity by bulk expanded TILs from pa-
tient TIPC236. (A) Transduction efficiency assessment of TIPC236 autologous APCs and DMF5
TCR transduced TILs. A combination of GFP and DMF5 TCR served as rough indicator for overall
transduction efficiency during the experiments. (B and C) Assessment of responder TIL reactivity
by IFNγ and TNFα ELISpot. (B) Control samples monitoring the background reactivity and general
T cell functionality after unspecific activation with PHA. In addition, reactivity against the autologous
xenograft was assessed. Mart1 TCR (DMF5) transduced TILs were used to monitor functional anti-
gen presentation and presence of each Lamp1 construct (only shown for multi-epitope construct 1;
representative for all constructs used). Functionality of the DMF5 TCR was assessed by pulsing the
xenograft with Mart1 peptide. PDX = autologous xenograft. PDX/αMHC-I = MHC-I blocked autolo-
gous xenograft. PDX/Mart1 = Mart1 peptide pulsed (Mart1 – ELAGIGILTV), autologous xenograft.
(C) Screening for responder TIL reactivity against Lamp1 construct expressing autologous APCs.
Vector Control = Lamp1_Mut395 screening construct without patient mutations (figure 30). Con-
struct 1 - 4 = Patient mutation encoding Lamp1 constructs (see table S6 and S9). (D) Spot count
for each technical triplicate during one experiment. The upper default detection limit of the counting
software was 500 spots/ well. The IFNγ ELISpot was performed as biological duplicate. The TNFα
ELISpot was measured once, in parallel with the second IFNγ ELISpot screening, to further evalu-
ate reactivities seen in the IFNγ readout. Statistical analysis of results performed using a One-way
ANOVA with post-hoc Tukey’s multiple comparisons test.
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4.3.6 Alternative neoepitope screening approaches for PDAC
Comparison of the Lamp1 screening system to a MITD expression system
In 2017, Sahin and coworkers (BioNTech) published an RNA-based vaccine construct capable
of inducing neoantigen specfic CD4+ and CD8+ T cell activation, leading to reduced post resec-
tion disease recurrence in melanoma patients [176]. For this vaccination study they made use
of a gene construct - distinct from our expression vector - capable of directing T cell epitope
presentation to MHC-I and -II. In the case of their vector, we decided to compare the efficiency
of the two constructs for MHC-I/ -II antigen presentation to check if the BioNTech construct
would be more efficient. Based on published information, we generated a construct encoding
the N-terminal signal peptide (SP) and MHC-I transmembrane domain (MITD) [252] used in
their RNA vaccination constructs and compared it to our Lamp1 based screening system (fig-
ure 36). For this approach, each gene construct was introduced into TILs from patient TIPC079
and encoded the Mart1 and HY epitopes to monitor MHC-I, as well as MHC-II restricted T cell
activation. In addition, Mart1 TCR and HY TCR transduced TILs served again as responder
T cell population. Moreover, we wanted to assess the stability of each systems functionality
upon the introduction of larger multi-epitope constructs. Here, we introduced two patient de-
rived multi-epitope constructs (TIPC102_TC1 and TIPC102_TC2) in between the Mart1 and
HY epitopes to monitor their influence on antigen specific T cell activation.
Our results indicate that both systems are equally efficient in simultaneously inducing MHC-I,
as well as MHC-II restricted T cell activation (figure 37C and 38C). In addition, the introduction
of larger multi-epitope constructs did not appear to disrupt this functionality in either of the two
approaches (figure 37C and 38C).
In view of these findings, we decided to continue with the Lamp1 screening approach, as we
had already extensively validated this system, which worked well in our hands.
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Figure 36 – Schematic overview of the MITD construct design. (A) Layout of the empty MITD
construct. Sequences for the signal peptide (SP) and MHC-I transmembrane domain (MITD) were
retreived from [252]. (B) MITD construct after the insertion of patient derived multi-epitope con-
structs. (C) multi-epitope construct setup example from TIPC102 (Construct 1) used for one of the
tested MITD constructs. The table indicates the respective gene and mutation, the chromosomal
location of the nsSNV, as well as the mutated sequences used for the setup of this specific construct
(compare to table S3 & S7)
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Figure 37 – Comparison of MHC-I restricted T cell activation between the Lamp1 expression system
and the MITD construct. (A) Transduction efficiency of the DMF5 TCR. Detection was performed
using an α-mouseTCR-β_BV421 antibody. (B) Antigen specific DMF5 TCR transduced T cell acitva-
tion. Autologous, peptide pulsed TILs served as target cells. The irrelevant peptide is represented
by the HY short peptide (HIENFSDIDMGE). (C) Antigen specific activation of DMF5 transduced
TILs by autologous TILs transduced with the respective expression system. Activation was moni-
tored by TNFα expression in the CD3+ effector (CFSE-) population via intracellular cytokine staining.
(D) Summary of the MHC-I restricted, antigen specific activation of DMF5 TCR transduced TILs
against the respective expression system. Lamp1_Control = Lamp1_Mut395 screening construct
without patient multi-epitope constructs (figure 30); MITD_Control = MITD construct without patient
multi-epitope constructs (figure 36). TIPC102_TC1 and TIPC102_TC2 represent the respective ex-
pression system combined with multi-epitope constructs from patient TIPC102. Day 42 TILs from
patient TIPC079 were used for transduction. Peptides were pulsed onto GFP transduced d42 TILs.
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Figure 38 – Comparison of MHC-II restricted T cell activation between the Lamp1 expression sys-
tem and the MITD construct. (A) Transduction efficiency of the HY TCR. Detection was performed
using an α-NGFR_APC antibody. (B) Antigen specific HY TCR transduced T cell acitvation. Au-
tologous, peptide pulsed TILs served as target cells. The irrelevant peptide is represented by the
Mart1 short peptide (ELAGIGILTV). (C) Antigen dependent activation of HY transduced TILs by
autologous TILs transduced with the respective expression system. Activation was monitored by
TNFα expression in the CD3+ effector (CFSE-) population via intracellular cytokine staining. (D)
Summary of the MHC-II restricted, antigen specific activation of HY TCR transduced TILs against
the respective expression system. Lamp1_Control = Lamp1_Mut395 screening construct without
patient multi-epitope constructs (figure 30); MITD_Control = MITD construct without patient multi-
epitope constructs (figure 36). TIPC102_TC1 and TIPC102_TC2 represent the respective expres-
sion system combined with multi-epitope constructs from patient TIPC102. Day 42 TILs from patient
TIPC079 were used for transduction. Peptides were pulsed onto GFP transduced d42 TILs.
Comparison of the Lamp1 screening system to peptide pulsed, autologous B cells
One way to overcome the fact that autologous, expanded TIL might not be the best possible
APC would be the use of immortalized B cells for patient samples where we have access to an
adequate source of B cells (e.g. resected spleen or blood). Unfortunately, access to autolo-
gous spleen or blood samples from patients was rather limited. To test an alternative screening
approach, we used spleen samples from two patients (TIPC253 and 275) for the immortaliza-
tion of B cells. We successfully over-expressed antiapoptotic endogenous proteins (Bcl-6/XL)
to immortalize the B cells as previously described [175, 318], since overexpression of Bcl-6/XL
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in B cells was recently shown to significantly reduce background T cell activation compared to
commonly used EBV immortalized B cells, when screening for neoepitope reactive T cells in a
peptide-based screening approach [175].
We tested the applicability of the Lamp1 based screening approach in Bcl-6/XL immortalized B
cells. Furthermore, we compared the Lamp1 system to the use of synthetic peptide-based
screening approaches applied when using B cells as APCs [175]. Mart1 (DMF5) and HY
TCRs transduced TILs from patient TIPC091 were used as responder T cells. Immortalized
B cells from TIPC253 were used as positive controls for antigen presentation, as this patient
expressed both HLA-A02:01 and HLA-DQB01:05, needed for presentation and recognition of
our antigens (table S2), whereas B cells from TIPC275 served as negative control, since this
patient expressed neither HLA-A02:01 nor HLA-DQB01:05 (table S2). To use the B cell lines
as APCs, we either pulsed them with the Mart1 or HY core peptides, an elongated version of
these or transduced them with our Lamp1_Mut395 screening construct. Here, the elongated
peptides were used to monitor a potential loss of T cell responses in the context of peptide
processing and cross-presentation.
The results first and foremost revealed, that the Lamp1 screening system is still functional in si-
multaneous MHC-I and MHC-II antigen presentation when introduced into immortalized B cells
(figure 39 and 40). We could further show a loss of antigen specific T cell reactivity against
elongated, MHC-I restricted peptides compared to the core epitope recognized by the TCR
(figure 39), most likely due to a limited capability of antigen cross presentation by the B cells
into MHC-I [373]. In the context of the Lamp1 system, however, elongated epitope variants
could still induce MHC-I restricted T cell reactivities (figure 39). In the case of MHC-II restricted
responses, the core HY peptide, as well as its elongated version, and the Lamp1 system ap-
peared equally potent in T cell activation (figure 40). Background reactivity of the HY TCR
against TIPC253 B-cells was observed as could have been expected, as these cells derive
from a male patient potentially expressing endogenous HY antigen.
Taken together, these results enlarge the pool of potential autologous APCs that could be used
with the Lamp1 based screening approach. In addition, the Lamp1 screening system appeared
superior to a peptide based screening approach, when looking at MHC-I restricted epitopes.
Here, the use of too large or falsely designed peptides will certainly result in overlooking of
potential immunogenic epitopes, whereas the use of long peptides seems less critical for the
detection of MHC-II restricted epitopes.
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Figure 39 – Comparing MHC-I restricted T cell activation between a peptide based and the Lamp1
screening system. (A) Assessment of transduction efficiency. DMF5 TCR was transduced into ex-
panded TILs from patient TIPC091. Transduction efficiency of immortalized B cells was monitored
by HY TCR control transduction. Staining of the DMF5 TCR was performed using an α-mouseTCR-
β_BV421 antibody. HY TCR expression was monitored using an α-NGFR_APC antibody. (B and
C) Monitoring activation of DMF5 TCR transduced TILs from patient TIPC091. (B) Assessment
of the general functionality of the TCR transduced effector cells by unspecific activation with 1 µg/
mL PHA. (C) Reactivity of DMF5 TCR transduced TILs against the respective peptide or the empty
Lamp1_Mut395 construct (see figure 30). B-cell lines were pulsed for 20h with 20 µg/ mL of the pep-
tide as described in [175] or transduced with the empty Lamp1_Mut395 construct (see figure 30).
The HY peptide served as irrelevant peptide control. (D) Summary of antigen specific reactivi-
ties. Reactivities were assessed by intracellular cytokine staining on TNFα. Peptides used Mart1 =
ELAGIGILTV; Mart1_long = KGHGHSYTTAEELAGIGILTVILGVLLLIG; HY = HIENFSDIDMGE.
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Figure 40 – Comparing MHC-II restricted T cell activation between a peptide based and the Lamp1
screening system. (A) Assessment of transduction efficiency. HY TCR was transduced into ex-
panded TILs from patient TIPC091. Transduction efficiency of immortalized B cells was monitored
by HY TCR control transduction. Staining was performed using an α-NGFR_APC antibody. (B
and C) Monitoring activation of HY TCR transduced TILs from patient TIPC091. (B) Assessment
of the general functionality of the TCR transduced effector cells by unspecific activation with 1 µg/
mL PHA. (C) Reactivity of HY TCR transduced TILs against the respective peptide or the empty
Lamp1_Mut395 construct (see figure 30). B-cell lines were pulsed for 20h with 20 µg/ mL of the
peptide as described in [175] or transduced with the empty Lamp1_Mut395 construct (see fig-
ure 30). The Mart1 peptide served as irrelevant peptide control. (D) Summary of antigen specific
reactivities. Reactivities were assesed by intracellular cytokine staining on TNFα. Peptides used HY
= HIENFSDIDMGE; HY-long = EATGSNCPPHIENFSDIDMGEIIMGNIELT; Mart1 = ELAGIGILTV.
4.3.7 Effects of Lamp1 destabilizing mutations on antigen trafficking and presentation
In order to get a better understanding of the underlying effects on antigen presentation upon
destabilization of Lamp1, we monitored MHC-I antigen presentation and subcellular localization
of our different Lamp1 constructs.
Destabilization of Lamp1 leads to an increase in MHC-I restricted antigen presentation
To obtain an insight into the influence of Lamp1 destabilization on MHC restricted antigen
presentation, we directly monitored the surface presentation of the respective antigens. For
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this, we co-transfected the ovalbumin antigen (SIINFEKL; H-2Kb-restricted and ISQAVHAA-
HAEINEAGR; I-Ab-restricted) encoding Lamp1 constructs, as well as GFP for transfection
control (figure 41A), into the murine 771 B cell line. MHC-I restricted surface expression of
SIINFEKL was monitored using a H-2Kb-SIINFEKL specific antibody. In the case of MHC-II re-
stricted antigen presentation, however, there was no I-Ab-Ovalbumin specific antibody available
and we could not assess the surface presentation of ISQAVHAAHAEINEAGR.
We could show that MHC-I antigen presentation was not significantly increased by either of the
single mutants compared to wild type Lamp1 (figure 41B and C). However, the combination of
both TMD destabilizing mutations revealed a significant increase in MHC-I restricted antigen
presentation, indicating an improved early degradation of this construct (figure 41B and C).
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Figure 41 – Destabilization of the Lamp1 expression system results in increased MHC-I antigen pre-
sentation. (A) Transfection efficiency control by cotransfection of 771 B cells with pEGFP_N1 and
the respective ovalbumin antigen encoding Lamp1 constructs. (B) Monitoring the influence Lamp1
destabilitzation on surface the presentation of SIINFEKL using a H2-Kb-SIINFEKL_PE specific an-
tibody. (C) Summary of the influence on MHC-I antigen presentation upon Lamp1 destabilization.
n=4 biological replicates. Statistical analysis of results performed using a One-way ANOVA with
post-hoc Tukey’s multiple comparisons test.
Effects of TMD destabilization on subcellular localization
Another aspect influencing antigen presentation upon TMD destabilization of Lamp1 is the
subcellular localization of the protein in combination with an early protein degradation. Thus,
we analyzed the increase in early protein degradation resulting from the TMD destabilization by
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monitoring protein accumulation (signal at 45 kDa) upon proteasome inhibition using the small
molecule inhibitor MG132. In addition, we examined the subcellular localization of our different
Lamp1 variants, by taking advantage of the high number of N-linked gylcosylation sites (18
in total) spread over the whole luminal domain of Lamp1 [360]. Due to glycan maturation in
the golgi network, Lamp1 should become resistant to EndoH digest upon shuttling from the
ER through the golgi and to the MHC-II compartment. Thus, comparing EndoH digested to
PNGaseF digested Lamp1 (signal at 120 kDa) in turn reveals the portion of protein passing the
golgi network. Since experiments were independent of surface antigen presentation, we used
HEK293T cells for the expression of the different Lamp1 constructs.
Proteasome inhibition did not reliably lead to Lamp1 accumulation, despite the presence of
over-expressed, incompletely processed (EndoH sensitive) protein (figure 42). However, our
results indicate, that the introduction of TMD destabilizing mutations can lead to a disruption
of subcellular trafficking of Lamp1. While the MutGLRK construct appeared to mainly reside in
the ER, both single mutants, as well as the wild type variant still appeared to cross the golgi
network (figure 42).
These results suggest that Lamp1 TMD destabilization is not critical for shuttling antigens into
the MHC-I presentation pathway, due to the accumulation of highly overexpressed protein in the
ER. Nevertheless, the introduction of these mutations appears to influence MHC-II restricted
antigen presentation by disrupting the subcellular trafficking of the protein.
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Figure 42 – Destabilization of Lamp1 indicates disruption of subcellular trafficking. A) Analysis of
subcellular trafficking of the respective Lamp1 construct by western blot. Arrows indicate: Top = En-
doH resistant Lamp1; Middle = EndoH sensitive Lamp1 and Bottom = loading control (GAPDH). B)
Analysis of EndoH resistant and PNGaseF sensitive Lamp1 signal intensities (120 kDa). Signal in-
tensities were first normalized to the loading control. Quantification was performed by normalization
to the signal intensity of the non-deglycosylised sample. C) Ratio of normalized signal intensities of
EndoH to PNGaseF digested Lamp1. The Lamp1 constructs were introduced into HEK293T cells
via Calcium phosphate coprecipitation. A representative experiment of n=3 biological replicates is
shown.
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4.4 Using targeted proteomics to identify PDAC neoepitopes
An alternative method to identify mutation derived epitopes is direct identification of antigens
presented on the tumor cell surface by mass spectrometry [180, 181, 357]. In this context,
Bassani-Sternberg and coworkers could recently show the potential benefit (i.e. antigen spe-
cific T cell priming) and current hurdles (i.e. sensitivity) of direct neoepitope identification from
resected melanoma tissue using an untargeted (MHC allele independent) screening approach
[181]. Since the success of such an untargeted approach seems highly dependent on state-of-
the-art technologies - which are currently difficult to access - combined with the risk of missing
low abundant epitopes, we aimed for a targeted mass spectrometry approach to verify the
presentation of predicted mutation-derived epitopes. The advantage of such a targeted pro-
teomics approach, looking for low abundant and weaker binding epitopes, was recently shown
by the group of PD Dr. Dr. A. Riemer [357]. By combining epitope-derived reference spectra
with mass spectrometry data of a samples HLA-ligandome we aimed to directly identify PDAC-
derived epitopes.
In cooperation with the group of PD Dr. Dr. A. Riemer, we set up a pipeline to identify neoepi-
topes presented on the surface of pancreatic cancer cells (figure 43). For the initial testing
of the pipeline we focused on neoepitopes predicted to bind HLA-A02:01, keeping the current
limitations of epitope prediction algorithms in mind [182, 183].
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Figure 43 – Schematic overview of the targeted proteomics approach.
4.4.1 Validation of the targeted proteomics pipeline by detection of overexpressed epi-
topes
In order to test the setup and sensitivity of the screening pipeline, we initially screened a set
of well characterized HLA-A02:01 binding epitopes, which we over-expressed in HEK293T
cells. The epitopes chosen for this approach (CSNK1A1: GLFGDIYLAI; GAS7: SLADEAEVYL;
HAUS3: ILNAMIAKI) were previously shown to be restricted to HLA-A02:01 and immunogenic
in melanoma patients [325]. However, to validate their binding to HLA-A02:01 we applied
two assays monitoring either their general HLA-binding in combination with the HLA:peptide
complex stability over time (low stringency assay) or by measuring the formation of stable
HLA:peptide complexes at a physiological temperature (high stringency assay). Here, pep-
tides binding to HLA-A02:01 at a physiological temperature indicate an increased likelihood of
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these epitopes to be endogenously processed and presented at the cell surface. Therefore,
these epitopes might be more relevant in an actual anti-tumor T-cell response.
For the low stringency assay we induced the accumulation and potential stabilization of HLA-
A02:01 at the cell surface by pre-incubating TAP-deficient T2 cells together with the respective
peptide at a low temperature (25°C for 16 h), as previously described [374, 375]. Afterwards,
the cells were transferred to a higher temperature (37°C) for different time spans, leading to an
increased internalization of unstable HLA-A02:01. Peptide-stabilized MHCmolecules remained
on the cell surface for an extended period of time, allowing the assessment of epitopes bind-
ing to and stabilizing HLA-A02:01 over time (figure 44A - C). Furthermore, the high stringency
assay was performed by co-incubation of each peptide with TAP-deficient T2 cells at 37°C
over night, indicating a strong and lasting stabilization of HLA-A02:01(figure 44D & E). To con-
trol and compare the binding strength of each peptide, we took along well characterized viral
reference peptides [320, 321], three binding (EBV, GAG77-85 and NEF136-145) and four not
binding (GAG20-28, NEF73-82, GAG240-249 and NEF120-128) to HLA-A02:01 during each
assay (figure 44B and E). Taken together, we could validate HLA-A02:01 binding of all three
melanoma epitopes (figure 44C), with GAS7 showing the strongest binding among these (fig-
ure 44D and E).
Based on this, we screened for the endogenous presentation and detectability of these epitopes
using direct identification by targeted mass spectrometry. We first designed two minigene con-
structs expressing all three epitopes, either as elongated versions of the epitopes (figure 45A)
or the core sequences separated by a triple alanine linker (figure 45B). These constructs were
transfected into HEK293T cells, followed by a 48 h IFNγ treatment of the cells to increase
the overall antigen processing and HLA-A02:01 surface expression (figure 46A and B). After-
wards, the cells were lysed, the HLA-A02:01-bound peptides extracted and analyzed for the
presence of the three melanoma epitopes by comparing the mass spectrometry data of HLA-
A02:01 bound epitopes to the reference spectra of the respective synthetic peptide. We could
detect two (GAS7 and HAUS3) of the three epitopes presented on the surface of transfected
HEK293T cells (figure 46D - F). Looking at the differences in detectability of both, the GAS7
and the HAUS3, epitopes, the GAS7 epitope was detected with a higher abundance than the
HAUS3 epitope (figure 46D). Here, the increased detectability of the GAS7 peptide, compared
to the HAUS3 peptide, likely derives from physico-chemical properties influencing the peptides
behavior during acquisition (e.g. polarity), which is also seen when measuring both synthetic
peptides at equimolar concentrations (figure 46C). In combination with suboptimal antigen pro-
cessing, this difference in epitope abundance likely led to the loss of detectability of the HAUS3
epitope in the 25mer gene construct (figure 46D). The third epitope (CSNK1A1) was neither
detectable as a synthetic peptide nor in the biological sample.
Taken together, these results indicate that we now have a functional pipeline to detect HLA-
A02:01 binding epitopes using targeted mass spectrometry. In addition, the validation of HLA-
A02:01 binding might be a critical step in this pipeline, considering that epitopes used for future
patient screenings might not bind as well as previously predicted. Furthermore, an enhanced
stabilization of HLA-A02:01 at 37°C might indicate a stronger MHC binding and result in a
higher chance to detect these epitopes by mass spectrometry. This hypothesis was supported
by the correlation of the enhanced HLA-A02:01 binding of the GAS7 epitope at 37°C with a
higher abundance in the mass spectrometry readouts, compared to the HAUS3 epitope.
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Figure 44 – Assessing HLA-A2 binding of the overexpressed epitopes. (A) Analysis example for
peptide derived HLA-A2 stabilization on T2 cells upon increase of incubation temperature. (B and
C) Analysis of HLA-A2 stabilization on T2 cells by 10 µg/mL of the respective pepitde compared to
a matched sample without peptide. Colour scale indicates the time incubated at 37°C. Mean fluo-
rescence intensity (MFI) change of the peptide sample to a DMSO treated sample was assessed.
(D) Analysis example HLA-A02:01 stabilization after coincubation of T2 cells with the respective
peptide over night at 37°C. (E) MFI change in HLA-A2 surface stabilization by the respective pep-
tide compared to a DMSO sample. Reference Peptides: HLA-A02:01 binders: EBV = GLCTLVAML;
GAG77-85 = SLYNTVATL; NEF136-145 = PLTFGWCYKL. Non-HLA-A02:01 binders: GAG20-28 =
RLRPGGKKK; NEF73-82 = QVPLRPMTYK; GAG240-249 = TSTLQEQIGW; NEF120-128 = YF-
PDWQNYT. Melanoma peptides: CSNK1A1 = GLFGDIYLAI; GAS7 = SLADEAEVYL; HAUS3 =
ILNAMIAKI. Each peptide was measured as biological triplicate.
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Figure 45 – Gene construct design for the detection of overexpressed HLA-A02:01 binding epi-
topes. Two versions were designed encoding three previously published HLA-A02:01 binding epi-
topes (see [325]) fused head-to-tail into the pcDNA3.1 vector. (A) The 25mer variant encoding each
core epitope, elongated N- and C-terminally by its native sequence, with the published mutation at
position 13 (arrow). (B) The minimal variant encoding the core sequences of the published epitopes
connected by triple alanine linkers.
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Figure 46 – Detection of overexpressed HLA-A02:01 epitopes using a targeted mass spectrometry
approach. (A) Transfection efficiency of HEK293T cells using CaPO4 co-precipitation. Efficiency
was assessed by GFP expression in a seperate sample three days after transfection, on the day of
cell lysate generation. (B) Upregulation of HLA-A2 upon 48 h IFNγ treatment of HEK293T cells. (C
and D) Total ion chromatograms of the respective synthetic peptides at equimolar concentrations
(C) and the HLA-A2 pulldown samples (D). (E and F) Extracted-ion chromatograms for measured
MS3 fragment transitions and their underlying MS3 spectra in the pulldown samples (top) and the
synthetic peptides (bottom) of the GAS7 (E), as well as HAUS3 (F) epitopes. Fragments are indi-
cated with their respective m/z ratio.
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4.4.2 Selection of patient samples to screen for presentation of neoepitopes
In order to validate the targeted proteomics pipeline with patient samples, we identified a set of
four patients who were HLA-A02:01+ with exome and transcriptome data, as well as a growing
cell line available (TIPC102, 113, 222 and 236). Of these, TIPC236 was later excluded as we
could not validate the mutations, identified in the primary tumor and xenograft, in the cell line
(table S17; table 43). For the remaining patients we confirmed HLA-A02:01 surface expression,
as well as its upregulation upon treatment of each xenograft derived cell line with IFNγ for 48 h
(figure 47).
Notably, we encountered two examples of immune editing influencing the HLA-A02:01 surface
expression in cell lines TIPC102 and 222. In the case of TIPC102, xenograft expansion led
to the outgrowth of a clone devoid of the chromosome 6 p-arm encoding for HLA-A02:01 (fig-
ure 47B). Since this patient initially expressed HLA-A02:01, we decided to reintroduce the HLA
molecule, generating a cell line stably expressing HLA-A02:01 (figure 47A). For the TIPC222
cell line we could identify a general unresponsiveness to the IFNγ treatment, caused by a
functional loss of JAK2 during xenograft expansion (figure 47D and E). Nevertheless, due to a
reasonably high endogenous expression of HLA-A02:01, we decided to include this patient for
the targeted proteomics approach. The cell line of patient TIPC113 did not reveal any abnor-
mality affecting HLA-A02:01 expression or upregulation (figure 47C).
These results demonstrate the necessity of testing each xenograft derived cell line for functional
HLA-A02:01 expression. The high incidence of abnormalities calls for a deeper characterization
(i.e. validation of mutations) of every cell line after xenograft expansion, due to the outgrowth
of certain subclones.
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Figure 47 – Upregulation of HLA-A2 on cell lines upon IFNγ treatment. Shown are PDX derived
cell lines selected for the targeted mass spectrometry approach. (A) HLA-A2 suface expression
of TIP102 before (top) and after (bottom) stable transduction with HLA-A02:01. (B) Loss of HLA-
A*02 locus in TIPC102 upon xenograft passaging. (C) Increase of HLA-A2 surface expression in the
TIPC113 cell line after IFNγ treatment. (D) Unresponsivness of TIPC222 cell line to IFNγ treatment.
(E) TIPC222 transcriptome analysis of the JAK2 locus. Shown is the read coverage of exon 1 & 2,
as well as exons 5 - 14, in the xenograft transcriptome. (FACS plot colors: red = FMO; orange = no
IFNγ; blue = 330 U/mL IFNγ).
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4.4.3 Prediction of HLA-A02:01 binding epitopes from expressed mutations
Using the exome and transcriptome data of three patients (TIPC102, 113 and 222), we an-
alyzed the expressed mutations for potential HLA-A02:01 binding epitopes using netMHC 4.0
with an affinity cut-off of 1000 nM. Overall, these predictions revealed mutations generating one
or more HLA-A02:01 binding epitopes, as well as mutations yielding no binding epitopes within
the given binding affinity range of <1000 nM (example in table 45). Compiling these results led
to a total of 51 epitopes (range 13 - 19) within 27 mutations (range 7 - 11) across all three pa-
tients (table S10 - S12). Approximately 40.1% of the expressed mutations (range 35.7 - 45.4%)
led to predicted HLA-A02:01 binding epitopes within the applied affinity range (figure 25).
Table 45 – Example for the prediction of HLA-A2 binding epitopes from expressed nsSNVs. Shown
here for patient TIPC102 samples. The predicted affinity cutoff for the mutated epitope was set to
≤1000 nM. Posititions of amino acid changes are highlited in bold & underlined. Lists of predicted
HLA-A02:01 binding epitopes for all patients can be found in the table S10 - S13.
Gene Mutation Location Sequence Length Predicted affinity [nM]
ADCY6 G535V chr12:49170065 — — —
ALDH16A1 R493Q chr19:49967929 — — —
ATAD2 R913C chr8:124351668 FICDYGEIFNV 11 32.2
ELFICDYGEI 10 807.4
CCDC71 R269Q chr3:49200836 — — —
CDC16 L447V chr13:115027386 VTVDKWEPV 9 502.1
DNM3 R369H chr1:172011262 — — —
DOCK1 E1316 chr10:129201400 — — —
DTNBP1 A123V chr6:15615618 MTANLTHLEV 10 297.4
SMTANLTHLEV 11 594.9
FILIP1L F109V chr3:99648801 ALLEAQYGV 9 4.3
LALLEAQYGV 10 22.1
ALLEAQYGVV 10 28.9
LLEAQYGV 8 173.2
DLALLEAQYGV 11 174.9
LALLEAQYGVV 11 288.2
FOXJ2 D4G chr12:8192439 GLESSLTSI 9 312.2
GBAS G203D chr7:56052562 TMIEWDNYWA 10 44.1
GTMIEWDNYWA 11 758.3
GNG2 P60L chr14:52433368 — — —
KRAS G12D chr12:25398284 KLVVVGADGV 10 498.0
LIMCH1 T760K chr4:41673607 — — —
LPIN1 M78I chr2:11907930 — — —
LRP12 R330H chr8:105509791 KLLHVLTAF 9 655.1
KLLHVLTA 8 779.2
MAP2K4 G294R chr17:12028677 SLRITLYEL 9 436.5
SLRITLYELA 10 854.8
NFKBIZ G405E chr3:101572584 — — —
NR1I2 G36R chr3:119526203 — — —
NSD1 L2063F chr5:176715855 — — —
RASSF6 A238V chr4:74447542 FALHIIFVT 9 312.4
FALHIIFV 8 329.7
SRGAP2D Q97R chr1:121116733 — — —
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4.4.4 Validation of mutations present in xenograft derived cell lines
Following HLA-A02:01 binding epitope prediction, we validated the underlying mutations, found
in the primary tumor and xenograft, in each respective xenograft-derived cell line, to avoid
screening of mutations lost due to the outgrowth of certain subclones (i.e. as a result of tumor
heterogeneity). We first identified the mutated locus from the exome and transcriptome data.
Based on this, we designed primer pairs to amplify and sequence the respective mutated locus
(figure 48). For three of the patients (TIPC102, 113 and 222) the majority of HLA-A02:01
epitope yielding mutations (average: 80%; range: 70 - 90%) were still present in the respective
cell line (table S14 - S16). As mentioned before, this step of validation revealed the absence of
most mutations, except for KRAS_G12D, in the cell line of patient TIPC236 (table S17). Thus,
we excluded this cell line from any additional experiments, due to a likely sample mix-up during
cell line generation.
A
B
T CTT T
Figure 48 – Example of the assessment of patient specific mutations in the PDX derived cell line.
Shown here for the cell line TIPC102_A2. Using either pyrosequencing (A) or sanger sequencing
(B) to assess the presence of mutations in the respective cell line. (C) Summary of the mutation
validation results for the TIPC102_A2 cell line. Detailed lists for validated mutations in the cell lines
used for the targeted proteomics approach can be found in table S14 - S17.
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4.4.5 Validation of HLA-A02:01 binding of predicted patient epitopes
In order to avoid screening of predicted epitopes that do not truly bind to HLA-A02:01, we val-
idated each peptide using both T2 cell-based HLA-A02:01 stabilization assays - see results
section 4.4.1 - (figure 49 and 50). We could show, that the majority of predicted epitopes (av-
erage 88.8%; range 76.9 - 100%) bound with varying strength to HLA-A02:01, using the low
stringency assay (figure 49C - E). In addition, the correlation between predicted binding affin-
ity and experimentally determined epitope binding was poor (figure 49C - E and table S10 -
S12). Compared to the viral reference peptides, the predicted patient epitopes could be further
divided into four groups. The first group of peptides stabilized HLA-A02:01 as good as the ref-
erence peptides and induced lasting complex formation (e.g. ATAD2; figure 49 C). The second
group of epitopes revealed HLA-A02:01 stabilization comparable to the reference peptides (e.g.
FILIP1L_2; figure 49 C). The third group of peptides weakly bound to HLA-A02:01, resulting in
a fast complex internalization (e.g. FOXJ2; figure 49 C). The last group of peptides did not bind
to HLA-A02:01 (e.g. LRP12_1; figure 49 C). Furthermore, the high stringency assay revealed
a small set (average: 20.9%; range: 15.4 - 31.6%) of 9 epitopes forming strong peptide:MHC
complexes at physiological temperatures (figure 50C - E). This strong HLA-A02:01 binding cor-
related with the first group of peptides identified by the low stringency assay (figure 49 C-E
and 50 C - E). Due to the strong and lasting formation of peptide:MHC complexes at physio-
logical temperature, this small set of 9 epitopes (highlighted in figure 50C - E) was considered
to include the best candidates for mass spectrometry analyses. However, as we are currently
lacking further information on epitope characteristics essential for the detection by this targeted
MS approach, we decided to screen all epitopes exceeding a general HLA binding and sta-
bilization at 25°C beyond one standard deviation of the non-HLA-A02:01 binding reference
epitopes (figure 49; σ. = 0.07 indicated by the red line).
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Figure 49 – Assessing HLA-A2 binding of predicted epitopes. (A) Analysis example for peptide
derived HLA-A2 stabilization on T2 cells over time at 37° C. (B-E) HLA-A2 MFI fold change of
epitope pulsed T2 cells compared to the respective DMSO control sample was used to assess
HLA-A2 binding. (B) HLA-A2 stabilization profile of the control peptides used in each experiment.
(C - E) HLA-A2 stabilization of the various predicted peptides for the patient indicated. Peptides
are sorted by decreasing predicted binding affinity. Dotted lines indicate normalization to DMSO
sample (black line; MFI fold change = 1) and the standard deviation of the four non HLA-A2 binding
control peptides (red line; σ% = 0.07). All peptides were measured as biological triplicates.
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Figure 50 – Assessment of strong HLA-A2 binding peptides at 37°C. (A) Visualization of HLA-
A2 stabilization on T2 cells by two of the control peptides and one predicted peptide (ATAD2_1;
TIPC102) after over night incubation at 37° C. (B-E) HLA-A2 MFI fold change compared to the
respective DMSO sample was used to assess HLA-A2 binding. (B) Stabilization of HLA-A2 by
the control peptides. (C - E) HLA-A2 stabilization of the various predicted peptides for the patient
indicated. Peptides are sorted by decreasing predicted binding affinity. Dotted lines indicate nor-
malization to DMSO sample (black line; MFI fold change = 1) and the standard deviation of the four
non HLA-A2 binding control peptides (red line; σ% = 0.07). All peptides were measured as biological
triplicates. Statistical analysis of results performed using a One-way ANOVA with post-hoc Tukey’s
multiple comparisons test. Asterisks indicate significance compared to DMSO sample.
4.4.6 In depth analysis of strong HLA-A02:01 binding epitopes
After we found that only a small set of predicted epitopes led to an enhanced stabilization of
HLA-A02:01, we wanted to get a better understanding of the underlying mechanisms of this
stabilization. Using the T2-based assay, we analyzed the peptide dependent stabilization of
de novo synthesized HLA-A02:01 by blocking its transport to the cell surface with Brefeldin A
upon transfer of the samples to 37°C. Here, the absence or suboptimal binding of stabilizing
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peptides would result in the internalization of unstable HLA molecules, resulting in an overall
decrease of HLA-A02:01 surface presentation. We tested each of the eight previously identified
epitopes showing the strongest MHC binding (figure 50C - E) for their capabilities of stabilizing
de novo synthesized HLA-A02:01.
We could show that some epitopes indeed directly stabilize de novo synthesized HLAmolecules,
indicated by a decrease in HLA-A02:01 surface presentation following the addition of Brefeldin
A (figure 51A and C). These effects were most prominent for the peptides SARM1_1 and AG-
PAT6_4 (figure 51A and C). In addition, these results show a prolonged HLA-A02:01 stabiliza-
tion by some epitopes, indicating a lasting surface presentation of the respective neoepitopes
(figure 51C).
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Figure 51 – Brefeldin A treatment indicates direct stabilization of de novo synthesized HLA-A2 by
strong binding peptides. (A) Effect of HLA-A2 stabilization in DMSO and peptide samples in the
absence or presence of 5 µg/ mL Brefeldin A upon increase of incubation temperature. (B and
C) Effect of HLA-A2 stabilization by the control peptides (B) and selected strong binding peptides
(assessed in figure 50) (C). MFI increase compared to the respective DMSO sample was used to
assess HLA-A2 binding. Peptides are sorted by decreasing predicted binding affinity. Dotted lines
indicate normalization to DMSO sample (black line; MFI fold change = 1) and the standard deviation
of the four non HLA-A2 binding control peptides (red line; σ% = 0.07). All peptides were measured as
biological triplicates.
104 4 RESULTS
4.4.7 Detection of epitopes on xenograft derived cell lines
To validate the targeted MS-based screening approach for PDAC patient samples, we gener-
ated whole cell lysates from three PDX-derived cell lines (TIPC102_A2, 113 and 222) and gave
the samples to the group of PD Dr. Dr. A. Riemer. We were not able to detect any of the in total
45 validated HLA-A02:01 binding epitopes in these samples. These results do not rule out the
presence of immunogenic neoepitopes on PDAC tumor cells. The problems of epitope detec-
tion might rather result from technical issues (i.e. limit of detection by MS) in combination with
low antigen abundance on the cell surface and the subsequent loss during sample process-
ing. Moreover, the use of current standard epitope prediction algorithms (i.e. NetMHC4.0) and
affinity cut-offs introduces additional limitations on the choice of epitopes screened. Therefore,
the current technical issues, as well as the prediction bias, should be thoroughly revised during
future applications of the targeted proteomics pipeline.
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5 Discussion
Pancreatic cancer still forms a disease with no cure available. Currently the majority of pancre-
atic cancer patients experiences relapse within less than 24 months post surgery and ultimately
succumbs to the disease [38, 39]. The limited progression in increasing the overall survival of
PDAC patients by various treatment regimen reveals a high unmet medical need to combat this
malignancy.
In this context, the increasing clinical relevance of neoepitope specific T cell therapies against
various solid malignancies, including those with low mutational burden, represents a promising
approach for the treatment of PDAC [142–145, 264]. Still, it should be kept in mind that, while
the specificity of neoepitope reactive T cells appears highly effective, targeting single epitopes
in the context of MHC-I antigen presentation likely results in immunoediting and leads to es-
cape by the tumor due to selective pressure [144]. Therefore, the use of multi-epitope reactive
T cells, including both CD4+ and CD8+ cells, could offer a remedy to the single epitope immune
evasion [253]. In this context, especially the use of multi-epitope RNA vaccination was shown
to be effective in suppressing disease recurrence in metastatic melanoma [176]. This approach
might also be considered to counter tumor recurrence in patients with primary resectable pan-
creatic cancer, when applied as adjuvant treatment. Nevertheless, a functional proof of TIL
reactivity against characterized PDAC epitopes is still missing. The presented thesis focused
on the development of screening methodologies to hopefully provide this missing information.
The implementation of an epitope screening approach for PDAC patients is supported by the
recognition of autologous, xenograft-derived tumor material by in vitro expanded PDAC TILs
[279]. Furthermore, despite the low and mainly patient specific mutational landscape, it was re-
cently shown bioinformatically that PDAC frequently contains potentially immunogenic neoepi-
topes [178]. Therefore, we validated two screening methodologies, which can be applied to
identify and characterize the frequency, as well as the origin of antigens recognized by PDAC
TILs. Both methodologies may be employed to overcome the current lack of functional infor-
mation on immunogenic antigens recognized by PDAC TILs. Taken together, this study may
provide the foundation for the screening of immunogenic antigens in larger pancreatic cancer
patient cohorts, facilitating insights into the applicability of antigen specific T cell therapies in
the context of PDAC in the future.
5.1 Development of an expression based screening system
Until now, most studies focussed on the characterization of either MHC-I (i.e. tandem mini-
genes) or MHC-II (i.e. long peptides) restricted antigens recognized by the respective tumor
reactive T cell population [142–145, 175]. In the context of the low mutational burden of pan-
creatic cancer in combination with a frequent infiltration of tumor reactive T cells, we developed
a screening system capable of identifying MHC-I and MHC-II epitopes in parallel, independent
of the HLA type of the patient. Furthermore, due to the restricted access to professional APCs
from PDAC patients, we focussed the application of this system on using autologous TILs as
APCs, as we were able to expand these to large numbers. This approach was supported by
the functional expression of both, MHC-I and MHC-II, on the surface of activated human T-cells
[369, 371].
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We developed an expression-based screening system based on the protein Lamp1, since it
was previously shown that full length chimeric Lamp1:antigen proteins are able to induce anti-
gen specific CD4+ T cell responses [362]. However, this rendered the risk that MHC-I epitopes
could be missed, as the introduced antigens may preferably be processed through the MHC-II
pathway. Working from here, the modification of two candidate residues in its transmembrane
domain led to a destabilization of Lamp1, increasing the presentation of incorporated MHC-I
restricted epitopes, while keeping the MHC-II antigen presentation functional (figure 29). We
showed that these TMD destabilizing mutations induced a disruption of subcellular Lamp1 traf-
ficking through the golgi network (figure 42). Thus, we could increase the MHC-I antigen pre-
sentation by destabilization of the Lamp1 transmembrane domain, which was likely induced by
an increased ER associated degradation (i.e. by intramembrane proteases [366]) of the protein.
Furthermore, our single mutant construct Lamp1_Mut395 was the most robust in simultaneous
MHC-I and MHC-II antigen presentation (table 44) and was therefore used for patient epitope
screenings.
In addition, our Lamp1 screening approach appeared equally potent in shuttling antigens into
both, the MHC-I and MHC-II presentation pathway, compared to a RNA vaccine construct re-
cently published by Sahin and coworkers [176, 253] (figure 37 and 38).
We futher compared the functionality of the Lamp1 system with short (core epitopes) and long
synthetic peptides (30mer) loaded onto APCs. Here, we were able to highlight the advantage
of an expression-based screening approach over an approach focussing on synthetic peptides
(figure 39 and 40). While the use of synthetic peptides to screen for MHC-II restricted anti-
gens seems feasible, it appears suboptimal for screening MHC-I restricted epitopes, especially,
when using suboptimal or long peptides during these approaches, as potential antigen specific
responses could be missed (figure 39).
Because of the afore-mentioned clinical relevance of mutation derived epitopes as targets of
TIL reactivity [142–145, 176], we focussed our screening approach on expressed neoepitopes
identified by exome and transcriptome analyses of the primary tumor, as well as low passage
patient derived xenografts. Furthermore, we chose to work with in vitro expanded TILs as
responder populations, as these populations were previously described to recognize their au-
tologous tumor [279] and currently form the most commonly used population for adoptive T cell
therapy [142, 144, 145, 261, 264, 358]. For the small cohort used in this work, we could only
detect weak to no recognition of the autologous tumor by the TILs (figure 33 - 35). Furthermore,
we were not able to show TIL reactivity against any of the mutations encoded by the expression
based system (figure 33 - 35).
Taken together, these results indicate certain considerations need to be taken into account for
future applications of the expression based screening system. On the one hand, bulk expanded
TILs might not yield the optimal material to screen for neoepitope specific responses. Here, in-
sights into the initial T cell repertoire within the primary tumor, focussing on the identification
of tumor reactive T cell receptors of large T cell clones, might yield greater success to later
identify the recognized epitopes. In addition, a loss of large tumor reactive T cell clones dur-
ing unspecific in vitro expansion would further support such an approach [279, 376]. On the
other hand, keeping in mind the overall low frequency of tumor reactive TILs (≈1%) in the ex-
panded population [279], the sole focus on mutation derived epitopes might be another reason
for the poor screening outcome within this study. For future large scale screening approaches
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one should further consider taking into account additional sources of antigens, such as InDels
(base insertion/ deletion) [377, 378], over-expressed self-antigens [172, 247, 264], as well as
cancer testis antigens, and epitopes derived from RNA editing [379–383] and peptide splicing
[384–387], as these yield additional potential targets of TIL reactivity in the context of PDAC
and other cancers.
5.2 Using targeted proteomics to identify PDAC neoepitopes
Another key question to be answered in the context of PDAC is the tumors capability to present
mutation-derived epitopes. One way to address this question is the direct characterization of
neoantigens presented on the surface of tumor cells using mass spectrometry. In combina-
tion with exome-based in silico epitope prediction, it is now possible to detect neoepitopes
presented on the cell surface by targeted mass spectrometry [179–181, 357, 388]. In order to
apply these findings to pancreatic cancer, we established a pipeline based on the targeted iden-
tification of previously predicted, mutation derived epitopes. Even though, pancreatic cancer
was previously bioinformatically described to frequently yield potential neoepitopes, the overall
cell surface abundance of these is currently not known [178].
Therefore, we validated a streamlined mass spectrometry pipeline, based on known control
epitopes (figure 44 and 46), which can be applied to directly identify PDAC epitopes.
Following the basic workflow validation by the melanoma epitopes, we identified a small cohort
of four PDAC patients for an initial application of the pipeline. For the screening of patient-
derived material, however, the initial pipeline had to be adapted to include the validation of
HLA-A02:01 surface presentation and upregulation by IFNγ on the tumor cells (figure 47), as
well as validation of cell line purity (figure S7) and the presence of mutations after xenograft
passaging (table S14 - S17). We could validate HLA-A02:01 binding for the majority of the
predicted epitopes, with a minor fraction of the epitopes revealing strong and lasting HLA-
stabilization (figure 49 and 50). Deeper characterization of the strongest HLA-A02:01 binding
patient epitopes (figure 50) indicated a direct binding and stabilization of de novo synthesized
MHC molecules on the cell surface (figure 51). The final targeted mass spectrometry screening
of PDAC epitopes from three patients did not confirm HLA-A02:01 surface presentation for any
of the peptides tested. This result does not rule out the presence of immunogenic antigens on
the surface of PDAC cells, but merely indicates the need of further optimization of the protocols
procedure.
Here, several adaptations should be considered: First of all, we validated the presence of each
mutation in the respective patient cell line on the DNA level. However, silencing of mutated
loci is missed with this approach, resulting in unnecessary screening of unexpressed muta-
tions. Thus, it might be worthwhile to include a mutation validation on the RNA level, to ensure
functional expression of the respective mutations in each cell line and thus only screen for mu-
tations truly expressed. In addition, we validated the targeted mass spectrometry sensitivity on
over-expressed epitopes, that may not represent physiological antigen abundance within a cell
line. Thus, the sensitivity of the mass spectrometry protocol should be further refined with a cell
line expressing known immunogenic epitopes. Here, especially the patient-derived melanoma
cells expressing the three melanoma epitopes used for validation of this targeted proteomics
pipeline would be of interest [325], as these cells were shown to induce antigen specific T cell
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activation against physiological levels of the respective epitopes. This readout would in the end
yield the necessary information on the sensitivity of the targeted proteomics approach in the
context of physiological levels of known immunogenic epitopes.
Taken together, we show the development of a pipeline that can be applied to directly identify
antigens on the surface of xenograft-derived cell lines. By implementing a first proof of prin-
ciple approach, using over-expressed melanoma antigens, we carefully monitored each step
necessary for a streamlined and straight forward screening of patient-derived antigens. An ap-
plication of this pipeline to a small patient cohort revealed certain issues (i.e. immune editing,
detection sensitivity) and chances for improvement, that should be kept in mind and tested in
future screenings. Furthermore, the protocol implemented here might allow for the functional
characterization of the origin (e.g. mutation-derived or over-expressed self antigens), as well
as frequency, of potentially immunogenic antigens in the context of PDAC.
5.3 Concluding remarks and Outlook
In summary, we show the development of an expression-based screening system with the ad-
vantage of an HLA independent, simultaneous identification of MHC-I and MHC-II restricted
epitopes in a fully autologous system. In addition, this methodology has the advantage of an
unbiased screening for immunogenic epitopes, independent of artificial epitope prediction algo-
rithms. Moreover, we describe an initial protocol including the minimum prerequisites needed
for the screening of an enlarged patient cohort. It should be noted that the negative results
during the screening of the initial small patient cohort in this work do not rule out the general
recognition of tumor-derived antigens by PDAC TILs. These results merely emphasize the
complexity and difficulty of identifying targets of TIL reactivity in the context of PDAC.
The presented work highlights that in vitro expanded PDAC TILs may not represent an optimal
T-cell population to characterize immunogenic target antigens in PDAC. Here, using single cell
cloned TCRs from primary PDAC tissue instead might, indeed, be a more promising approach,
as these TCRs resemble the initial T-cell repertoire more accurately. In this case the most dom-
inant T-cell clones would be of special interest, as they are most likely to be tumor reactive.
Furthermore, a combination of cloned TCRs showing reactivity against their autologous tumor
with the expression-based screening might then reveal the functional proof of concept currently
needed to move forward with a T-cell based therapy for PDAC patients. However, even if these
in vitro experiments yield positive results, they do not provide information on PDAC directed T-
cell responses in a complex tumor microenvironment. For this, a pre-clinical in vivo assessment
of TCR functionality against the autologous tumor (e.g. PDX model) would probably achieve
the most reliable results. Assuming these pre-clinical experiments are successful, the next step
would be to assess the safety of the most dominant TCR clones in a small patient cohort to
monitor the frequency of potential off-target effects (e.g. self-antigen reactivity). The results of
such a trial will be crucial to apply a T-cell based therapy to a greater cohort of PDAC patients.
Importantly, since the short therapeutic window for PDAC patients might not allow for an epi-
tope characterization prior to the start of the treatment. Nevertheless, once the chosen TCRs
appear to induce tumor regression or disease stabilization, the antigen identification might be
performed afterwards.
In conclusion, the pipelines and screening modalities developed in the course of the presented
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thesis may be applied to achieve further insight into and functional proof of the antigens rec-
ognized by PDAC TILs, therefore laying the foundation for the functional applicability of T-cell
based therapy in PDAC patients.
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6 Supplementary Data
6.1 Patient characteristics
6.1.1 General information
Table S1 – Patient characteristics of the cohort used for this study. *Tumor content of the tissue
sample received for xenograft generation and TIL expansion. T cell tumor infiltrate calculations,
based on immunohistochemistry stainings, were kindly provided by C. Lauenstein, as previously
described [279].
Patient Gender Diagnosis (Location) TNM-Stage Grade R-classification Neoadjuvant Tumor Content* [%]
T cell tumor infiltrate
CD3/mm2 CD8/mm2 FoxP3/mm2
079 female PDAC (whole organ) T3/N1/M0 N/A R1 Chemo 95 256.56 42.82 103.38
091 male PDAC (whole organ) T3/N1/M0 G2 R1 — 100 162.96 101.06 18.85
102 female PDAC (whole organ) T3/N3/M1 G2 R1 — 65 262.46 14.73 71.11
113 male PDAC (tail) T3/N0/M1 G2 R0 — 90 222.96 44.36 173.66
222 male PDAC (head) T3/N3/M0 G3 R1 — 50 438.35 378.42 358.50
236 female PDAC (whole organ) T3/N3/M1 G2 R1 — 100 280.83 3.31 N/A
253 male PDAC (tail) T3/N3/M0 G3 R1 — 100 N/A 5.56 6.57
275 female PDAC (head) T3/N3/M0 G3 R1 — 90 374.88 21.29 247.98
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6.1.2 Patient HLA Typing
Table S2 – HLA typing of the patient cohort used for this work. Allele 1 and 2 represent the most
likely HLA-alleles of the patient. p-value indicates the confidence score of correct read mapping
between the true HLA allele and background noise. Values converging to 0 represent an increase
in confidence. N/A = reads could not be mapped to a specific HLA allele above background.
Patient Allele 1 p-value Allele 2 p-value
TIPC079 MHC-I A A*03 6.65e-05 A*02 0.00614
B B*18 0.00146 B*35 0.03462
C C*04 2.57e-06 C*12 0.29450
MHC II DQA A1*01 1.29e-12 A1*05 0.32802
DQB B1*05 0.05419 B1*03 0
DRB B1*01 0.00095 B1*11 0.13036
TIPC091 MHC-I A A*34 0.00196 A*11 0.00661
B B*35 5.67e-05 B*07 0.02532
C C*04 0.00221 C*15 0.03976
MHC II DQA A1*05 0.18852 A1*01 0.24163
DQB B1*02 0.00557 B1*05 0.24548
DRB B1*03 0.01622 B1*01 0.05113
TIPC102 MHC-I A A*25 1.748e-09 A*02 0.00420
B B*39 0.00017 B*13 1.68e-05
C C*06 0.01815 C*12 0.12397
MHC II DQA A1*05 0.06901 A1*01 0.32802
DQB B1*02 0.01256 B1*05 0.42202
DRB B1*03 0.07152 B1*01 0.08453
TIPC113 MHC-I A A*25 0.00047 A*02 0.00762
B B*13 8.90e-12 B*27 0.00012
C C*01 0.07024 C*02 0.01983
MHC II DQA A1*01 7.15e-05 A1*02 0.24175
DQB B1*02 0.01707 B1*05 0.32804
DRB B1*01 0.00285 B1*07 0.01430
TIPC222 MHC-I A A*01 1.70e-05 A*02 0.02454
B B*08 0.07709 B*39 0.00856
C C*12 0.00505 C*07 0.02530
MHC II DQA A1*01 6.83e-12 A1*05 0.32899
DQB B1*05 0.01226 B1*02 0.42202
DRB B1*16 0.07197 B1*03 0.08998
TIPC236 MHC-I A A*03 0.00042 A*02 0.02379
B B*27 0.00279 B*07 0.00264
C C*02 4.12e-03 C*07 0.02582
MHC II DQA A1*01 2.33e-09 A1*04 0.53423
DQB B1*06 0.00568 B1*04 0.42202
DRB B1*08 0.31896 B1*15 0.09091
TIPC253 MHC-I A A*24 0.01071 A*02 0.01354
B B*13 2.42e+00 B*58 0.00182
C C*06 0.01283 C*03 0.03700
MHC II DQA A1*01 0.01054 A1*02 0.32802
DQB B1*05 0.00051 B1*02 0
DRB B1*01 0.00060 B1*07 0.20127
TIPC275 MHC-I A A*01 0.00155 A*29 0.13250
B B*08 2.73e-05 B*08 0.00906
C C*07 0 C*07 0.00011
MHC II DQA A1*05 0.00063 A1*05 0.05748
DQB B1*02 N/A B1 N/A
DRB B1*03 7.17e-08 B1*12 0.62962
112 6 SUPPLEMENTARY DATA
6.1.3 Composition of bulk expanded TILs
TIPC079 TIPC091
TIPC102 TIPC222 TIPC222
A
B TIPC236
Figure S1 – CD4+/ CD8+ composition of bulk expanded TIL populations (d28/42 = TILs expanded
for 28 or 42 days) used during this study. (A and B) Patient TILs used to establish the expression
based screening pipeline (A) and screen for neoepitope reactivity (B). Stainings were performed
using the T cell panel. *For TIPC236 the data of d28 bulk expanded cells was unfortunately lost and
could not be restored without unnecessary thawing of patient material.
6.1.4 Exome and transcriptome analyses
Table S3 – Expressed mutations identified from the exome and transcriptome data of TIPC102.
Highlighted amino acid in mutated sequence indicates the position of the mutated residue. *indi-
cates the first or last amino acid residue of the respective protein.
Gene Mutation NCBI Reference Mutation Location Mutated sequence Tumor MAF exome PDX MAF exome RNASeq MAF (read count) Expression percentile (GDS4336)
ADCY6 G535V NM_015270 chr12:49170065 TLQYLNGDYEVEPGRVGERNAYLKEQHIET 0.221 0.478 89% (8 of 9 reads) 81st
ALDH16A1 R493Q NM_153329 chr19:49967929 PDGLYEYLRPSGTPAQLSCLSKNLNYDTFG 0.193 0.345 2 mutant reads 57th
ATAD2 R913C NM_014109 chr8:124351668 KPHSALPEEVQELFICDYGEIFNVQLPDKE 0.190 0.422 42% (39 of 92 reads) 75th
CCDC71 R269Q NM_022903 chr3:49200836 HQSKTNRATGSPSVRQMKGGSALGTKTAQA 0.191 0.355 50% (1 of 2 reads) 70th
CDC16 L447V NM_003903 chr13:115027386 IKAIGNEVTVDKWEPVLNNLGHVCRKLKKY 0.416 0.996 100% (99 mutant reads) 92nd
DNM3 R369H NM_015569 chr1:172011262 LELSGGAKINRIFHEHFPFEIVKMEFNEKE 0.154 0.620 75% (3 of 4 reads) 44th
DOCK1 E1316K NM_001380 chr10:129201400 AEQYENEMFDYEQLSKLLKKQAQFYENIVK 0.223 0.571 52% (25 of 48 reads) 91st
DTNBP1 A123V NM_032122 chr6:15615618 IADLESMTANLTHLEVSFEEVENNLLHLED — 0.979 90% (9 of 10 reads) 83rd
FILIP1L F109V NM_182909 chr3:99648801 KAEKMDLALLEAQYGVVTPKKVLEALQRDA 0.159 0.646 71% (5 of 7 reads) 64th
FOXJ2 D4G NM_018416 chr12:8192439 *MASGLESSLTSIDWLPQL 0.217 0.538 47% (9 of 19 reads) 31st
GBAS G203D NM_001483 chr7:56052562 ELRSYQLRPGTMIEWDNYWARAIRFRQDGN — 0.289 26% (14 of 54 reads) 83rd
GNG2 P60L NM_053064 chr14:52433368 AKEDPLLTPVPASENLFREKKFFCAIL* 0.248 0.460 1 mutant read 60th
KRAS G12D NM_004985 chr12:25398284 *MTEYKLVVVGADGVGKSALTIQLIQNHFVD 0.228 0.495 40% (22 of 55 reads) 89th
LIMCH1 T760K NM_014988 chr4:41673607 NSQVDSPSSEKSPVMKPQFKFWAWDPEEER — 0.592 53% (24 of 45 reads) 61st
LPIN1 M78I NM_145693 chr2:11907930 KVVDIEINGESVDLHIKLGDNGEAFFVQET — 0.253 14% (6 of 42 reads) 84th
LRP12 R330H NM_013437 chr8:105509791 VKIYDGLEENPHKLLHVLTAFDSHAPLTVV — 0.300 75% (3 of 4 reads) 75th
MAP2K4 G294R NM_003010 chr17:12028677 ASRQGYDVRSDVWSLRITLYELATGRFPYP 0.369 1.00 100% (23 mutant reads) 76th
NFKBIZ G405E NM_031419 chr3:101572584 MASDSSNTSLPFSNMENPMNTTQLGKSLFQ 0.212 0.621 76% (77 of 101 reads) 93rd
NR1I2 G36R NM_003889 chr3:119526203 ESVPGKPSVNADEEVRGPQICRVCGDKATG — 0.249 5% (1 of 20 reads) 48th
NSD1 L2063F NM_022455 chr5:176715855 IKAGTELTFNYNLECFGNGKTVCKCGAPNC 0.208 0.477 46% (32 of 70 reads) 87th
RASSF6 A238V NM_177532 chr4:74447542 KIENSPQDFALHIIFVTGEQRRLKKTDIPL 0.235 0.635 60% (76 of 126 reads) 62nd
SRGAP2D Q97R NM_001271887 chr1:121116733 RQAKYTENKLKAIKARNEYLLALEATNASV — 0.107 55% (12 of 22 reads) 97th
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Table S4 – Expressed mutations identified from the exome and transcriptome data of TIPC113.
Highlighted amino acid in mutated sequence indicates the position of the mutated residue. *indi-
cates the first or last amino acid residue of the respective protein.
Gene Mutation NCBI Reference Mutation Location Mutated sequence Tumor MAF exome PDX MAF exome RNASeq MAF (read count) Expression percentile (GDS4336)
ABCA12 Y629C NM_015657 chr2:215866305 AAKTIDEMEREAKRLCKSNELFGSVIFKLP 0.093 0.455 1 mutant read 32nd
AGMO P414L NM_001004320 chr7:15405161 MFLMLYRFGHLKPLVLSLSSAFEIVFSICI 0.079 0.274 14% (2 of 14 reads) 44th
ANXA2 T208N NM_004039 chr15:60644641 QDARDLYDAGVKRKGNDVPKWISIMTERSV — 0.424 51%(2278 of 4455 reads) 99th
BRAT1 L168R NM_152743 chr7:2583524 QGDSSLFVASAASQLRVHVLALSMRGGAEG — 0.624 73%(8 of 11 reads) 60th
CDH1 R90W NM_004360 chr16:68835677 FKVGTDGVITVKRPLWFHNPQIHFLVYAWD — 0.034 12%(134 of 1097 reads) 95th
CDKN2A P114R NM_000077 chr9:21971017 RAGARLDVRDAWGRLRVDLAEELGHRDVAR 0.120 1.00 100%(7 of 7 reads) 51st
DCAF6 A242V NM_018442 chr1:167962500 RATGNYAGRGTTGMVVRFIPSHLNNKSCRV 0.100 0.286 38%(106 of 280 reads) 91st
FAM193B I530V NM_001190946 chr5:176951894 LPPSNLSGSSEQQPDVNLDLSPLTLGSPQN 0.144 0.181 20%(8 of 41 reads) 62nd
GUCY1A3 E246K NM_000856 chr4:156632053 VEVSLMPPCFHNDCSKFVNQPYLLYSVHMK 0.120 1.00 100%(12 of 12 reads) 89th
KIFC1 P435L NM_002263 chr6:33373176 MEGGPGGDPQLEGLILRALRHLFSVAQELS 0.110 0.404 42%(14 of 33 reads) 53rd
KLF4 W435R NM_004235 chr9:110248169 HTGEKPYHCDWDGCGRKFARSDELTRHYRK 0.092 1.00 99%(362 of 365 reads) 76th
KRAS G12V NM_004985 chr12:25398284 *MTEYKLVVVGAVGVGKSALTIQLIQNHFVD 0.122 0.411 49%(69 of 142 reads) 89th
MAP6 M598T NM_033063 chr11:75298753 DEGPMVSASVKDQGPTVSAPVKDQGPIVPA 0.108 0.518 1 mutant read 49th
NEMF L1070F NM_004713 chr14:50251377 LSRNIPGKVKVSAPNFLNVKRK* 0.153 0.480 54%(91 of 168 reads) 79th
PEX16 A20S NM_004813 chr11:45939305 RLLGLRYQEYVTRHPSATAQLETAVRGFSY 0.179 0.635 50%(7 of 14 reads) 55th
PGM3 L156F NM_015599 chr6:83892687 IDGVTVLGGQFHDYGFLTTPQLHYMVYCRN — 0.357 39%(35 of 90 reads) 84th
RPS6KA1 D44V NM_001006665 chr1:26872522 QTSLPVPGPGSGPQRVSDEGVLKEISITHH — 1.00 1 mutant read 71st
SARM1 F591L NM_015077 chr17:26715411 ASLLKVHLQLHGFSVLIDVEKLEAGKFEDK — 0.476 52%(17 of 33 reads) 55th
TLE4 S48G NM_007005 chr9:82188700 DRIKEEFQFLQAQYHGLKLECEKLASEKTE — 0.989 92%(12 of 13 reads) 69th
TMC4 Y109H NM_144686 chr19:54673367 RRAHRQRNASRDQVVHGSGTKTDRWARLLR 0.098 0.434 45%(120 of 265 reads) 83rd
TMEM8A V416I NM_021259 chr16:425414 TISLRANKTEMRNETIVVACVNAASPFLGF 0.110 0.529 47%(60 of 128 reads) 79th
TP53 C275Y NM_000546 chr17:7577114 SSGNLLGRNSFEVRVYACPGRDRRTEEENL 0.177 1.00 100%(137 of 137 reads) 77th
UGT1A6 H54N NM_001072 chr2:234601810 WLSMKDIVEVLSDRGNEIVVVVPEVNLLLK 0.100 0.437 59%(48 of 82 reads) 62nd
XPNPEP1 S548T NM_020383 chr10:111630542 GVGSFLNVHEGPCGITYKTFSDEPLEAGMI 0.084 0.556 53%(273 of 513 reads) 93rd
ZNF28 R589Q NM_006969 chr19:53303332 TGEKPYKCKVCDKAFQRDSHLAQHQRVHTG — 0.103 1%(1 of 173 reads) 73rd
Table S5 – Expressed mutations identified from the exome and transcriptome data of TIPC222.
Highlighted amino acid in mutated sequence indicates the position of the mutated residue. *indi-
cates the first or last amino acid residue of the respective protein.
Gene Mutation NCBI Reference Mutation Location Mutated sequence Tumor MAF exome PDX MAF exome RNASeq MAF (read count) Expression percentile (GDS4336)
AGPAT6 T344I NM_178819 chr8:41472545 TSVMMFKKGSFEIGAIVYPVAIKYDPQFGD 0.133 0.962 100%(388 of 388 reads) 92nd
ANKRD32 N938D NM_032290 chr5:94030652 KEELFAITKIEDTVEDFHAQAEKHFHYQQL 0.111 0.923 100%(22 of 22 reads) 41st
ANKRD32 L1010R NM_032290 chr5:94030869 SHKETTSVHTDWLLDRYAGNIKTLQKLPHI 0.139 0.983 100%(47 of 47 reads) 41st
AUTS2 R1154C NM_015570 chr7:70255662 PRREHERGGHLDERECLHMLREDYEHTRLH 0,19 0.437 43%(32 of 75 reads) 60th
BARD1 R150Q NM_000465 chr2:215646149 DAGNKKNSIKMWFSPQSKKVRYVVSKASVQ 0.163 0.359 33%(15 of 46 reads) 67th
C8orf47 P115L NM_173549 chr8:99101589 STEKTQPGEGLEESGLPQPGGKEDAPAAEG 0.2 0.544 47%(59 of 125 reads) 51st
CACNA1C V2052I NM_199460 chr12:2797733 TPPATPGSRGWPPQPIPTLRLEGVESSEKL — 0.386 50%(3 of 6 reads) 63rd
CDC27 I493P NM_001114091 chr17:45219311 GYLALCSYNCKEAINPLSHLPSHHYNTGWV 0.082 — 0% (1 of 280 reads) 87th
CEP44 A153T NM_001040157 chr4:175225470 SSGKSEPPLGNEKISTEAVGVDISGRFMTS 0.204 0.404 52%(38 of 73 reads) 57th
CMYA5 A3318V NM_153610 chr5:79034541 GEGESVDHVETVGNVVMQKKAPITEDVRVA 0.14 0.967 1 mutant read 39th
CPSF1 D1275N NM_013291 chr8:145619364 FMVDNAQLGFLVSDRNRNLMVYMYLPEAKE 0.147 0.445 39%(279 of 714 reads) 70th
CPSF2 V535F NM_017437 chr14:92624010 TKCISTTESIEIKARFTYIDYEGRSDGDSI 0.113 0.628 53%(206 of 388 reads) 95th
CSNK1A1 E60D NM_001892 chr5:148929688 VKLESQKARHPQLLYDSKLYKILQGGVGIP — 0.494 52%(371 of 708 reads) 98th
DDX5 R263S NM_004396 chr17:62499327 DEADRMLDMGFEPQISKIVDQIRPDRQTLM 0.158 0.242 20%(679 of 3456 reads) 99th
GAK D1222V NM_005255 chr4:843849 QDLAKDTDPLKLKLLVWIEGKERNIRALLS — 0.231 17%(205 of 1241 reads) 81st
IL17RE R519C NM_153483 chr3:9956449 ALLTLLGVVLALTCRCPQSGPGPARPVLLL 0.232 0.940 99%(219 of 220) 56th
IMPA2 T143M NM_014214 chr18:12014310 LEFGVIYHCTEERLYMGRRGRGAFCNGQRL 0.186 0.612 76%(524 of 694 reads) 69th
KDM6B P272S NM_001080424 chr17:7750239- PPPPPPPPLPGLATSSPFQLTKPGLWSTLH 0.203 1.0 100%(17 of 17 reads) 67th
KLHL13 R336M NM_033495 chrX:117043623 MPYMQPVMQSDRTAIMSDTTHLVTLGGVLR — 0.381 64%(21 of 33 reads) 40th
KLHL13 F301S NM_033495 chrX:117043728 LMTPQELINYVQTVDSMRTDNTCVNLLLEA — 0.398 59%(23 of 39 reads) 40th
KPNA7 P371S NM_001145715 chr7:98782575 PCHHIQQLLAYDVLPSLVALLKNGEFKVQK — 0.043 8%(7 of 88 reads) 46th
KRAS G12D NM_033360 chr12:25398284 *MTEYKLVVVGADGVGKSALTIQLIQNHFVD 0.203 0.603 68%(315 of 461 reads) 89th
LIG1 I707B NM_000234 chr19:48626460 EFVFATSLDTKDIEQNAEFLEQSVKDSCEG 0.226 0.985 100%(265 of 265 reads) 61st
MAPRE2 S222Y NM_001143827 chr18:32707002 SRPSSAKRASSSGSAYKSDKDLETQVIQLN 0.198 0.988 100%(203 of 203 reads) 83rd
N4BP2 D1482N NM_018177 chr4:40127867 KLLKTLTASEMLPLLNHWNTQTKKVSLREI — 0.413 46%(11 of 24 reads) 67th
PCDHGB7 D184N NM_018927 chr5:140797976 KYQLSPNEYFSLVEKNNPDGGKYPELVLQK 0.084 0.320 28%(11 of 39 reads) 43rd
PCLO V927M NM_014510 chr7:82764087 ITDAPKSQPTTPQETMTGKLFGFGASIFSQ — 0.213 2 mutant reads 34th
PDLIM1 M61V NM_020992 chr10:97031457 IGDVITAIDGENTSNVTHLEAQNRIKGCTD 0.133 0.486 55%(460 of 840 reads) 94th
PIK3CA I788F NM_006218 chr3:178942555 SSAKRPLWLNWENPDFMSELLFQNNEIIFK 0.188 0.460 55%(54 of 98 reads) 92nd
PPM1D N242S NM_003620 chr17:58711237 RIEGLGGSVMNKSGVSRVVWKRPRLTHNGP 0.174 0.313 27%(23 of 86 reads) 68th
RALBP1 P628R NM_006788 chr18:9535850 WRGGAVQPPRDGVLERKAAKEQPKAGKEPA 0.136 0.569 69%(153 of 223 reads) 88th
SMARCA2 R1531Q NM_139045 chr9:2191317 SVKVKIKLNKKDDKGQDKGKGKKRPNRGKA — 0.155 20%(76 of 376 reads) 89th
STEAP1 T64S NM_012449 chr7:89790224 TAHADEFDCPSELQHSQELFPQWHLPIKIA — 0.032 2%(9 of 439 reads) 66th
TP53 H20D NM_001276699 chr17:7578395 QSQHMTEVVRRCPHDERCSDSDGLAPPQHL 0.254 0.985 99%(550 of 551 reads) 77th
TROAP M465L NM_005480 chr12:49724021 VGGQCVPLNGGSSLDLVELQPLLTEISRTL — 0.344 40%(49 of 121 reads) 43rd
TSKU T121P NM_001258210 chr11:76507021 RLRYLESLDLSHNGLPALPAESFTSSPLSD 0.156 0.463 47%(358 of 752 reads) 89th
UQCRC2 V358L NM_003366 chr16:21987512 QATAAGDVIKAAYNQLKTIAQGNLSNTDVQ — 0.417 40%(602 of 1511 reads) 97th
WDR43 R252Q NM_015131 chr2:29140767 LSGAVHDRLLNVWQVQSENKEKSAVMSFTV — 0.193 18%(105 of 597 reads) 89th
Table S6 – Expressed mutations identified from the exome and transcriptome data of TIPC236.
Highlighted amino acid in mutated sequence indicates the position of the mutated residue. *indi-
cates the first or last amino acid residue of the respective protein.
Gene Mutation NCBI Reference Mutation Location Mutated sequence Tumor MAF exome PDX MAF exome RNASeq MAF (read count) Expression percentile (GDS4336)
CCDC88C F27L NM_001080414 chr14:91883162 FLQSPLVTWVKTFGPLGSGSQDNLTMYMDL 0.205 0.450 39%(21 of 54 reads) 73rd
CDKN2A G55V NM_001195132 chr9:21971194 APNSYGRRPIQVMMMVSARVAELLLLHGAE 0.341 0.994 99%(886 of 889 reads) 51st
CIC R190H NM_015125 chr19:42791588 SALPKERDSSSEKDGHSPNKREKDHIRRPM 0.364 0.609 62%(141 of 228 reads) 68th
COPS7A T224M NM_001164095 chr12:6839869 IESEVANLKKTIKVTMAAAAAATSQDPEQH 0,22 0.519 46%(240 of 517 reads) 80th
IGSF3 M75T NM_001542 chr1:117158899 YLPSSPEREVQIVSTTDSSFPYAIYTQRVR 0.062 — 0% (1 of 244 reads) 48th
KCTD5 G215S NM_018992 chr16:2752447 EFLCVVSKELHNTPYSTASEPSEKAKILQE 0.256 0.467 50%(227 of 455 reads) 79th
KRAS G12D NM_033360 chr12:25398284 *MTEYKLVVVGADGVGKSALTIQLIQNHFVD 0.255 0.488 42%(121 of 287 reads) 89th
LCA5 T596A NM_001122769 chr6:80197029 RNSMEKLSKDGVDLIARKEKKANLMEQLFG 0.373 0.515 58%(22 of 38 reads) 58th
N4BP1 M173T NM_153029 chr16:48596036 REFKQFVEAHADNYTTDLLILPTSLKKELL 0.218 0.493 48%(171 of 360 reads) 85th
PCDHGA10 A582V NM_018913 chr5:140794487 LYPALPTDGSTGVELVPRSAEPGYLVTKVV 0.209 0.496 50%(2 of 4 reads) 43rd
PLXNB2 D766N NM_012401 chr22:50722387 SKLHVTLYNCSFGRSNCSLCRAANPDYRCA 0.272 0.543 52%(680 of 1299 reads) 89th
PRKACB W185S NM_001242858 chr1:84663455 QVTDFGFAKRVKGRTSTLCGTPEYLAPEII 0.237 0.508 46%(391 of 853 reads) 81st
RBL2 V539A NM_005611 chr16:53498193 EQDAFHRSLLACCLEAVTFSYKPPGNFPFI 0.238 0.440 52%(134 of 259 reads) 95th
RORC R57Q NM_005060 chr1:151789268 HYGVITCEGCKGFFRQSQRCNAAYSCTRQQ 0.292 0.480 45%(24 of 53 reads) 61st
SLC43A1 V86M NM_001198810 chr11:57268701 QQDEMLNLGFTIGSFMLSATTLPLGILMDR 0.276 0.441 46%(11 of 24 reads) 71st
SMARCA4 G784R NM_001128848 chr19:11123700 YNNNLNGILADEMGLRKTIQTIALITYLME 0.351 0.984 99%(243 of 245 reads) 81st
SMG7 A38T NM_001174061 chr1:183486881 FKNQITTLQGQAKNRTNPNRSEVQANLSLF 0.233 0.500 46%(117 of 253 reads) 80th
SYBU E423K NM_001099752 chr8:110587860 DTMADGLSLEEQVTGKGADRELLVGDSIAN 0.242 0.424 52%(51 of 99 reads) 65th
SYNE1 A5379V NM_033071 chr6:152640038 LTEATNHRQNIEKMAVEQKEKYLGLYTILP — 0.404 40%(2 of 5 reads) 72nd
TGFBRAP1 T121M NM_001142621 chr2:105924397 NLEPVPSGARIKGAAMFALNENPVSGDPFC — 0.090 20%(14 of 71 reads) 73rd
TNXB G3330R NM_019105 chr6:32016191 VSGLDPARKYKFLLFRLQNGKRHGPVPVEA 0.303 0.448 25%(1 of 4 reads) 51st
TP53 H20R NM_001276699 chr17:7578394 KQSQHMTEVVRRCPHRERCSDSDGLAPPQH 0.406 0.992 10%(164 of 164 reads) 77th
WDR45B D86G NM_019613 chr17:80585155 GGKKPKYPPNKVMIWGDLKKKTVIEIEFST 0.235 0.427 47%(642 of 1359 reads) 94th
114 6 SUPPLEMENTARY DATA
6.2 Expression based screening system
6.2.1 Validation of Lamp1 functionality in human B cells
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Figure S2 – Validation of Lamp1 functionality in human B cells. (A) Transduction efficiency of both
antigen specific TCRs into donor PBMC. Detection of DMF5 TCR transduction efficiency was per-
formed using an α-mouseTCR-β_BV421 antibody. HY TCR transduction efficiency was assessed
by expression of truncated NGFR using a α-NGFR_APC antibody. Both TCRs shown in the CD3+
population (B/D) Antigen specific activation of TCR transduced PBMCs for the DMF5 TCR (B) and
HY TCR (D). Untransfected B cells (KBV623) were pulsed with 10 µg/mL of the respective, synthetic
peptide. Irrelevant peptide either represented HY peptide (B) or Mart1 peptide (D). (C/E) Influence
of the Lamp1 expression system and minigene on MHC-I (C) and MHC-II (E) restricted antigen
specific T cell activation. Co-incubation was performed using 0.5x104 TCR transduced PBMCs and
1x105 of Lamp1 transfected B cells per sample. T cell activation was assessed by ELISA in technical
triplicates. Lamp1 was introduced into the B cells by electroporation. Shown is one representative
experiment of n = 3 biological replicates. Statistical analysis of the peptide results was performed
using an unpaired t-test, while for the Lamp1 samples a One-way ANOVA with post-hoc Tukey’s
multiple comparisons test was used.
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6.2.2 Setup of Lamp1 multi-epitope constructs
The Lamp1 multi-epitope encoding constructs were designed by first fusing the sequences
found in table S3, S5 and S6 head-to-tail, followed by introducing the resulting tandem con-
structs into the Lamp1_Mut395 screening system as depicted in figure 30. For TIPC113 no
constructs were generated, since bulk expanded TILs from this patient neither recognized the
autologous xenograft, nor the PDX derived cell line.
Table S7 – Lamp1 tandem construct setup for TIPC102. Indicated are the respective positions
of each mutation in the final construct. The indicated mutations are encoded by the mutated se-
quences found in table S3.
Tandem Construct
Encoded mutations (by position)
1 2 3 4 5 6
1 ADCY6_G535V ALDH16A1_R493Q ATAD2_R913C CCDC71_R269Q CDC16_L447V DNM3_R369H
2 FOXJ2_D4G DOCK1_E1316K DTNBP1_A123V FILIP1L_F109V GBAS_G203D GNG2_P60L
3 KRAS_G12D LIMCH1_T760K LPIN1_M78I LRP12_R330H MAP2K4_G294R NFKBIZ_G405E
4 NR1I2_G36R NSD1_L2063F RASSF6_A238V SRGAP2D_Q97R — —
Table S8 – Lamp1 tandem construct setup for TIPC222. Indicated are the respective positions
of each mutation in the final construct. The indicated mutations are encoded by the mutated se-
quences found in table S5.
Tandem Construct
Encoded mutations (by position)
1 2 3 4 5 6
1 AGPAT6_T344I ANKRD32_N938D ANKRD32_L1010R AUTS2_R1154C BARD1_R150Q C8orf47_P115L
2 CACNA1C_V2052I CEP44_A153T CMYA5_A3318V CPSF_D1275N CPSF2_V535F CSNK1A1_E60D
3 DDX5_R263S GAK_D1222V IL17RE_R519C IMPA2_T143M KLHL13_R336M CDC27_I493P
4 KRAS_G12D KDM6B_P272S KLHL13_F301S KPNA7_P371S LIG1_I707N —
5 MAPRE2_S222Y N4BP2_D1482N PCDHGB7_D184N PCLO_V927M PDLIM1_M61V —
6 PIK3CA_I788F PPM1D_N242S RALBP1_P628R SMARCA2_R1531Q STEAP1_T64S —
7 TP53_H20D TROAP_M465L TSKU_T121P UQCRC2_V358L WDR43_R252Q —
Table S9 – Lamp1 tandem construct setup for TIPC236. Indicated are the respective positions
of each mutation in the final construct. The indicated mutations are encoded by the mutated se-
quences found in table S6.
Tandem Construct
Mutation position in the construct
1 2 3 4 5 6
1 KRAS_G12D CCDC88C_F27L CDKN2A_G55V CIC_R190H COPS7A_T224M KCTDS_G215S
2 LCA5_T596A N4BP1_M173T PCDHGA10_A582V PLXNB2_D766N PRKACB_W185S RBL2_V539A
3 RORC_R57Q SLC43A1_V86M SMARCA1_G784R SMG7_A38T SYBU_E423K SYNE1_A5379V
4 TGFBRAP1_T121M TNXB_G3330R TP53_H20R WDR45B_D86G IGSF3_M75T —
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6.2.3 Screening of patient derived constructs
The remaining screening results of samples where a duplicate measurement yielded conclusive
results are given in the following figures. For TIPC222 the repeated screening was inconclusive,
as the responder TIL samples revealed reactivities indistinguishable from remaining signals.
Thus, this approach was not included in this work.
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Figure S3 – Additional screening for patient specific neoepitope reactivity by bulk expanded TILs
from patient TIPC102. (A) Transduction efficiency assessment of TIPC102 autologous APCs and
DMF5 TCR transduced TILs. A combination of GFP and DMF5 TCR served as rough indicator
for overall transduction efficiency during the experiments. (B and C) Assessment of responder TIL
reactivity by IFNγ ELISpot. (B) Control samples monitoring the background reactivity and general T
cell functionality after unspecific activation with PHA. In addition, reactivity against the autologous
xenograft was assessed. PDX = autologous xenograft. PDX/αMHC-I = MHC-I blocked autolo-
gous xenograft. (C) Screening for responder TIL reactivity against Lamp1 construct expressing
autologous APCs. Vector Control = Lamp1_Mut395 screening construct without patient mutations.
Construct 1 - 4 = Patient mutation encoding Lamp1 constructs. (D) Spot count for each technical
triplicate during one experiment. The screen was performed as biological duplicate. Statistical anal-
ysis of results was performed using a One-way ANOVA with post-hoc Tukey’s multiple comparisons
test.
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Figure S4 – Additional screening for patient specific neoepitope reactivity by bulk expanded TILs
from patient TIPC236. (A) Transduction efficiency assessment of TIPC236 autologous APCs and
DMF5 TCR transduced TILs. A combination of GFP and DMF5 TCR served as rough indicator
for overall transduction efficiency during the experiments. (B and C) Assessment of responder TIL
reactivity by IFNγ and TNFα ELISpot. (B) Control samples monitoring the background reactivity
and general T cell functionality after unspecific activation with PHA. In addition, reactivity against
the autologous xenograft was assessed. Mart1 TCR (DMF5) transduced TILs were used to monitor
functional antigen presentation and presence of each Lamp1 construct. Functionality of the DMF5
TCR was assessed by pulsing the xenograft with Mart1 peptide. PDX = autologous xenograft.
PDX/αMHC-I = MHC-I blocked autologous xenograft. PDX/Mart1 = Mart1 peptide pulsed (Mart1 –
ELAGIGILTV), autologous xenograft. (C) Screening for responder TIL reactivity against Lamp1 con-
struct expressing autologous APCs. Vector Control = Lamp1_Mut395 screening construct without
patient mutations. Construct 1 - 4 = Patient mutation encoding Lamp1 constructs. (D) Spot count
for each technical triplicate during one experiment. The upper default detection limit of the counting
software was 500 spots/ well. The IFNγ ELISpot was performed as biological duplicate. The TNFα
ELISpot was measured once, in parallel with the second IFNγ ELISpot screening, to further evalu-
ate reactivities seen in the IFNγ readout. Statistical analysis of results performed using a One-way
ANOVA with post-hoc Tukey’s multiple comparisons test.
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6.2.4 Assessment of Lamp1 transduction efficiency by 3xFLAG tag
Initially the 3xFLAG tag included in our Lamp1 screening system was supposed to serve as a
transfection or transduction marker. However, we were not able to reliably detect Lamp1 after
introduction into the cells. An initial attempt to stain the 3xFLAG tag intracellularly could not
indicate any Lamp1 population (figure S5).
Considering that Lamp1 could potentially traffic throughout the cell, we expected it to also reach
the cell surface. Therefore, we later performed a surface staining, that appeared to detect a
small portion of introduced Lamp1 control vector (figure S6A). Nevertheless, this population
decreased after the introduction of patient derived tandem constructs (figure S6B).
3x FLAG3x FLAG
0.63
Untra Lamp1_Mut395
Figure S5 – Assessment of Lamp1 transduction efficiency by intracellular staining. Lamp1_Mut395
was transduced into TILs from patient TIPC079. 3xFLAG tag staining was performed by intracellular
staining. The experiment was performed as biological triplicate.
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Figure S6 – Assessment of Lamp1 transduction efficiency by surface staining. (A) Control sam-
ples. Vector control = Lamp1_Mut395 empty construct (see figure 30). (B) Lamp1 tandem construct
transduction efficiency. 3xFLAG tag staining was performed on the cell surface. Here, tandem con-
structs from TIPC102 were used. All constructs were transduced into TILs from patient TIPC079.
The experiment was performed as biological triplicate.
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6.3 Targeted proteomics
6.3.1 Prediction of HLA-A02:01 binding epitopes from patient samples
Table S10 – HLA-A02:01 epitope prediction for expressed mutations of patient TIPC102. Mutated
positions are highlited in bold & underlined. Peptides sorted by predicted binding affinity of the
mutated epitope to HLA-A02:01. The respective peptide name is derived from the mutated gene
followed by an arbitrary running number.
Peptide name Sequence Length
Predicted affinity [nM]
RNASeq MAF & Read Count Expression percentile (GDS4336)
mutated wild type
FILIP1L_1 ALLEAQYGV 9 4.3 320.4 71% (5 of 7 reads) 64th
FILIP1L_2 LALLEAQYGV 10 22.1 2555.3 71% (5 of 7 reads) 64th
FILIP1L_6 ALLEAQYGVV 10 28.9 14.2 71% (5 of 7 reads) 64th
ATAD2_1 FICDYGEIFNV 11 32.2 39.4 42% (39 of 92 reads) 75th
FILIP1L_3 LLEAQYGV 8 173.2 13795.7 71% (5 of 7 reads) 64th
FILIP1L_4 DLALLEAQYGV 11 174.9 12300.6 71% (5 of 7 reads) 64th
FILIP1L_5 LALLEAQYGVV 11 288.2 101.4 71% (5 of 7 reads) 64th
DTNBP1_1 MTANLTHLEV 10 297.4 3067.6 90% (9 of 10 reads) 83rd
FOXJ2 GLESSLTSI 9 312.1 10691.9 47% (9 of 19 reads) 31st
RASSF6_1 FALHIIFVT 9 312.4 126.7 60% (76 of 126 reads) 62nd
RASSF6_2 FALHIIFV 8 329.8 2448.6 60% (76 of 126 reads) 62nd
MAP2K4_1 SLRITLYEL 9 436.5 63.3 100% (23 mutant reads) 76th
KRAS_G12D KLVVVGADGV 10 498.0 506.9 40% (22 of 55 reads) 89th
CDC16 VTVDKWEPV 9 502.1 1924.7 100% (99 mutant reads) 92nd
DTNBP1_2 SMTANLTHLEV 11 594.9 5871.5 90% (9 of 10 reads) 83rd
LRP12_1 KLLHVLTAF 9 655.1 1215.2 75% (3 of 4 reads) 75th
LRP12_2 KLLHVLTA 8 779.2 1539.4 75% (3 of 4 reads) 75th
ATAD2_2 ELFICDYGEI 10 807.5 2863.2 42% (39 of 92 reads) 75th
MAP2K4_2 SLRITLYELA 10 854.8 564.9 100% (23 mutant reads) 76th
Table S11 – HLA-A02:01 epitope prediction for expressed mutations of patient TIPC113. Mutated
positions are highlited in bold & underlined. Peptides sorted by predicted binding affinity of the
mutated epitope to HLA-A02:01. The respective peptide name is derived from the mutated gene
followed by an arbitrary running number.
Peptide name Sequence Length
Predicted affinity [nM]
RNASeq MAF & Read Count Expression percentile (GDS4336)
mutated wild type
KIFC1_1 ILRALRHLFSV 11 60.6 5149.4 42% (14 of 33 reads) 54th
SARM1_1 VLIDVEKLEA 10 155.5 9209.6 52% (17 of 33 reads) 55th
SARM1_2 QLHGFSVLI 9 174.4 77.0 52% (17 of 33 reads) 55th
SARM1_3 LQLHGFSVLI 10 284.5 133.8 52% (17 of 33 reads) 55th
KRAS_G12V KLVVVGAVGV 10 300.2 506.9 49% (69 of 142 reads) 89th
UGT1A6_1 VLSDRGNEI 9 430.5 178.1 59% (48 of 82 reads) 62nd
CDKN2A RLRVDLAEEL 10 523.3 487.6 100% (7 of 7 reads) 51st
SARM1_4 QLHGFSVLIDV 11 592.3 749.1 52% (17 of 33 reads) 55th
UGT1A6_2 VLSDRGNEIV 10 785.8 863.5 59% (48 of 82 reads) 62nd
KIFC1_2 LRALRHLFSV 10 792.2 1689.8 42% (14 of 33 reads) 54th
SARM1_5 LQLHGFSVL 9 902.6 13661.6 52% (17 of 33 reads) 55th
FAM193B VNLDLSPLTL 10 916.2 572.5 20% (8 of 41 reads) 62nd
DCAF6 MVVRFIPSHL 10 971.9 642.5 38% (106 of 280 reads) 92nd
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Table S12 – HLA-A02:01 epitope prediction for expressed mutations of patient TIPC222. Mutated
positions are highlited in bold & underlined. Peptides sorted by predicted binding affinity of the
mutated epitope to HLA-A02:01. The respective peptide name is derived from the mutated gene
followed by an arbitrary running number.
Peptide name Sequence Length
Predicted affinity [nM]
RNASeq MAF & Read Count Expression percentile (GDS4336)
mutated wild type
AGPAT6_3 FEIGAIVYPV 10 22.7 35.3 100% (388 of 388 reads) 94th
KLHL13_1 AIMSDTTHLV 10 45.5 632.3 64% (21 of 33 reads) 40th
KLHL13_2 AIMSDTTHL 9 84.8 9698.3 64% (21 of 33 reads) 41st
PIK3CA_1 WLNWENPDFM 10 122.9 948.9 55% (54 of 98 reads) 92nd
KLHL13_3 IMSDTTHLVT 10 174.3 30725.4 64% (21 of 33 reads) 42nd
AGPAT6_1 SFEIGAIVYPV 11 186.1 309.2 100% (388 of 388 reads) 92nd
KDM6B GLATSSPFQL 10 202.8 237.6 100% (17 of 17 reads) 67th
KLHL13_4 IMSDTTHLVTL 11 395.7 23672.4 64% (21 of 33 reads) 43rd
BARD1 KMWFSPQSKKV 11 399.0 1560.2 33% (15 of 46 reads) 67th
CEP44 KISTEAVGV 9 410.8 260.9 52% (38 of 73 reads) 57th
AGPAT6_4 EIGAIVYPV 9 426.3 809.0 100% (388 of 388 reads) 95th
KLHL13_5 TAIMSDTTHLV 11 467.7 7036.3 64% (21 of 33 reads) 44th
KRAS_G12D KLVVVGADGV 10 498.0 506.9 68% (315 of 461 reads) 89th
PIK3CA_2 FMSELLFQN 9 572.3 3329.9 55% (54 of 98 reads) 93rd
AGPAT6_2 FEIGAIVYPVA 11 626.6 1033.6 100% (388 of 388 reads) 93rd
DDX5 MLDMGFEPQIS 11 828.9 826.3 20% (679 of 3456 reads) 99th
PPM1D VMNKSGVSRV 10 888.9 842.3 27% (23 of 86 reads) 68th
AUTS2 HLDERECLHML 11 958.3 3064.3 43% (32 of 75 reads) 60th
ANKRD32 LLDRYAGNI 9 988.5 680.1 100% (47 of 47 reads) 41st
Table S13 – HLA-A02:01 epitope prediction for expressed mutations of patient TIPC236. Mutated
positions are highlited in bold & underlined. Peptides sorted by predicted binding affinity of the
mutated epitope to HLA-A02:01. The respective peptide name is derived from the mutated gene
followed by an arbitrary running number. The peptides for this patient were not ordered in the end,
due to the negative results from the mutation validation (see table S17).
Peptide name Sequence Length
Predicted affinity [nM]
RNASeq MAF & Read Count Expression percentile (GDS4336)
mutated wild type
SLC43A1_1 FMLSATTLPL 10 6.14 13.3 46% (11 of 24 reads) 71st
SLC43A1_2 MLSATTLPL 9 6.87 17.6 46% (11 of 24 reads) 71st
CDKN2A_1 VMMMVSARV 9 8.35 8.1 99% (886 of 889 reads) 51st
RBL2_1 LLACCLEAV 9 9.25 17.9 52% (134 of 259 reads) 95th
TGFBRAP1_1 AMFALNENPV 10 19.5 623.7 20% (14 of 71 reads) 73rd
RBL2_2 SLLACCLEAV 10 19.6 22.1 52% (134 of 259 reads) 95th
RBL2_3 SLLACCLEA 9 21.4 6.4 52% (134 of 259 reads) 95th
SLC43A1_3 SFMLSATTLPL 11 31.9 114.7 46% (11 of 24 reads) 71st
CDKN2A_2 QVMMMVSARV 10 57.6 80.6 99% (886 of 889 reads) 51st
CDKN2A_3 MMMVSARV 8 91.7 146.4 99% (886 of 889 reads) 51st
CDKN2A_4 MMVSARVAEL 10 96.4 151.7 99% (886 of 889 reads) 51st
SLC43A1_4 MLSATTLPLG 10 96.5 461.5 46% (11 of 24 reads) 71st
SLC43A1_5 FMLSATTLPLG 11 97.1 360.6 46% (11 of 24 reads) 71st
RBL2_4 RSLLACCLEA 10 104.6 23.8 52% (134 of 259 reads) 95th
RBL2_5 LLACCLEAVT 10 113.1 239.9 52% (134 of 259 reads) 95th
CDKN2A_5 MMMVSARVAEL 11 118.9 73.8 99% (886 of 889 reads) 51st
RBL2_6 RSLLACCLEAV 11 134.9 138.0 52% (134 of 259 reads) 95th
SLC43A1_6 FMLSATTL 8 151.8 4365.4 46% (11 of 24 reads) 71st
CDKN2A_6 VMMMVSARVA 10 161.7 286.7 99% (886 of 889 reads) 51st
SLC43A1_7 FTIGSFMLSA 10 162.6 173.8 46% (11 of 24 reads) 71st
TGFBRAP1_2 AAMFALNENPV 11 178.1 6405.7 20% (14 of 71 reads) 73rd
CDKN2A_7 IQVMMMVSARV 11 220.9 395.6 99% (886 of 889 reads) 51st
CDKN2A_8 MVSARVAEL 9 242.3 10574.7 99% (886 of 889 reads) 51st
RBL2_7 LACCLEAV 8 331.7 747.2 52% (134 of 259 reads) 95th
SLC43A1_8 MLSATTLPLGI 11 341.1 1585.3 46% (11 of 24 reads) 71st
RBL2_8 SLLACCLEAVT 11 364.1 371.5 52% (134 of 259 reads) 95th
PRKACB STLCGTPEYL 10 398.9 298.8 46% (391 of 853 reads) 81st
SLC43A1_9 FMLSATTLP 9 440.5 8695.1 46% (11 of 24 reads) 71st
KRAS_G12D KLVVVGADGV 10 498.0 506.9 42% (121 of 287 reads) 89th
N4BP1 TDLLILPTSL 10 621.0 120.7 48% (171 of 360 reads) 85th
CDKN2A_9 MMMVSARVA 9 624.7 248.2 99% (886 of 889 reads) 51st
TGFBRAP1_3 AMFALNENPVS 11 646.8 12777.9 20% (14 of 71 reads) 73rd
RBL2_9 LLACCLEA 8 657.8 80.6 52% (134 of 259 reads) 95th
RBL2_10 HRSLLACCLEA 11 767.6 767.6 52% (134 of 259 reads) 95th
CCDC88C VTWVKTFGPL 10 823.9 9648.2 39% (21 of 54 reads) 73rd
COPS7A KTIKVTMAA 9 886.5 2395.5 46% (240 of 517 reads) 80th
SLC43A1_10 TIGSFMLSA 9 907.7 932.2 46% (11 of 24 reads) 71st
6.3 Targeted proteomics 121
6.3.2 Cell line mutation validation
Mutations yielding potentially HLA-A02:01 binding epitopes (table S14-S17) were validated in
each respective cell line to avoid unnecessary screening of mutations lost during xenograft and
cell line propagation. Due to a loss of HLA-A02:01 during xenograft outgrowth, as mentioned
in section 4.4.2, the mutation validation of the PDX-derived cell line from patient TIPC102 was
performed on the respective, HLA-A02:01 transduced cell line (TIPC102_A2; figure 47).
Table S14 – TIPC102_A2 cell line mutation validation. *Pyrosequencing primers were readily avail-
able for a part of the mutations and kindly provided by Dr. M. Volkmar.
Gene Mutation
Exome MAF
PDX RNASeq MAF (read count)
Cell line
Primary PDX Pyro Sequencing* Sanger Sequencing
ATAD2 R913C 0.190 0.422 42% (39 of 92 reads) 49% mutated heterozygous
CDC16 L447V 0.416 0.996 100% (99 mutant reads) — homozygous mutated
DTNBP1 A123V — 0.979 90% (9 of 10 reads) 98% mutated —
FILIP1L F109V 0.159 0.646 71% (5 of 7 reads) 70% mutated —
FOXJ2 D4G 0.217 0.538 47% (9 of 19 reads) — heterozygous
GBAS G203D — 0.289 26% (14 of 54 reads) — wild type
KRAS G12D 0.228 0.495 40% (22 of 55 reads) 33% mutated —
LRP12 R330H — 0.300 75% (3 of 4 reads) — heterozygous
MAP2K4 G294R 0.369 1.0 100% (23 mutant reads) — homozygous mutated
RASSF6 A238V 0.235 0.635 60% (76 of 126 reads) 69% mutated —
Table S15 – TIPC113 cell line mutation validation.
Gene Mutation
Exome MAF
PDX RNASeq MAF (read count)
Cell line
Primary PDX Sanger Sequencing
CDH1 R90W — 0.034 12% (134 of 1097 reads) wild type
CDKN2A P114R 0.120 1.0 100% (7 of 7 reads) homozygous mutated
DCAF6 A242V 0.100 0.268 38% (106 of 280 reads) heterozygous
FAM193B I530V 0.144 0.181 20% (8 of 41 reads) heterozygous
KIFC1 P435L 0.110 0.404 42% (14 of 33 reads) homozygous mutated
KRAS G12V 0.122 0.411 49% (69 of 142 reads) heterozygous
PGM3 L156F — 0.357 39% (35 of 90 reads) wild type
SARM1 F591L — 0.476 52% (17 of 33 reads) subclonal mutated
TLE4 S48G — 0.989 92% (12 of 13 reads) wild type
UGT1A6 H54N 0.100 0.437 59% (48 of 82 reads) heterozygous
Table S16 – TIPC222 cell line mutation validation. *Sanger sequencing did not reveal a conclusive
result and the mutation was assumed to be present in the cell line.
Gene Mutation
Exome MAF
PDX RNASeq MAF (read count)
Cell line
Primary PDX Sanger Sequencing
AGPAT6 T344I 0.133 0.962 100% (388 of 388 reads) homozygous mutated
ANKRD32 L1010R 0.139 0.983 100% (47 of 47 reads) homozygous mutated
AUTS2 R1154C 0,19 0.437 43% (32 of 75 reads) heterozygous
BARD1 R150Q 0.163 0.359 33% (15 of 46 reads) heterozygous
CEP44 A153T 0.204 0.404 52% (38 of 73 reads) heterozygous
CSNK1A1 E60D — 0.494 52% (371 of 708 reads) wild type
DDX5 R263S 0.158 0.242 20% (679 of 3456 reads) heterozygous
KDM6B P272S 0.203 1.0 100% (17 of 17 reads) —*
KLHL13 R336M — 0.385 64% (21 of 33 reads) homozygous mutated
KPNA7 P371S — 0.052 8% (7 of 88 reads) wild type
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Table S17 – TIPC236 cell line mutation validation.
Gene Mutation
Exome MAF
PDX RNASeq MAF (read count)
Cell line
Primary PDX Sanger Sequencing
CCDC88C F27L 0.205 0.450 39% (21 of 54 reads) wild type
CDKN2A G55V 0.341 0.994 99% (886 of 889 reads) wild type
COPS7A T224M 0.22 0.519 46% (240 of 517 reads) wild type
KRAS G12D 0.255 0.488 42% (121 of 287 reads) heterozygous
N4BP1 M173T 0.218 0.493 48% (171 of 360 reads) wild type
PRKACB W185S 0.237 0.508 46% (391 of 853 reads) wild type
RBL2 V539A 0.238 0.440 52% (134 of 259 reads) wild type
SLC43A1 V86M 0.276 0.441 46% (11 of 24 reads) wild type
TGFBRAP1 T121M — 0.090 20% (14 of 71 reads) wild type
6.4 Purification of PDX derived cell lines
Since there was high chance of contaminating xenograft derived cell lines with mouse fibrob-
lasts during setup of the cultures, we designed a protocol to test each line for mouse cell
contamination. During the initial setup of the protocol we microscopically monitored each PDX
derived line for the appearance of multiple phenotypes in combination with human EpCAM
expression (figure S7A and B). We tried to separate these phenotypes by differential trypsin-
isation. However, this approach led to the outgrowth of mouse cells after several passages.
In order to overcome this issue, we later treated each cell line with IFNγ for 48h, followed by
flow cytometry sorting of the top 5% pan-MHC-I+ (human) population (figure S7C). To get a
better insight into the species origin of each cellular phenotype monitored, we designed a fast
sequencing approach focused on three interspecies (human and mouse) SNPs (figure S7D).
The final combination of sequencing and flow cytometry sorting allowed for a robust and fast
depletion of mouse cell contaminations in PDX derived cell lines.
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Sequence to analyse:
TAT/CTGAT/CTTTGAA/-TTTTACATGTACA
A
l culture Early ment Late ta ent
C l culture
SNP 1 2 3
Quality Passed Passed Passed
A (%) - - -
C (%) 74 74 -
G (%) - - -
T (%) 26 26 -
Insertion
(%)
- - 50
Deletion
(%)
- - 50
Sequence to analyse:
TAT/CTGAT/CTTTGAA/-TTTTACATGTACA
1 2 3
SNP 1 2 3
Quality Passed Passed Passed
A (%) - - -
C (%) 3 1 -
G (%) - - -
T (%) 97 99 -
Insertion
(%)
- - 100
Deletion
(%)
- - 0
1 2 3
A ture
M
- I
+ I
B
Figure S7 – Example for the purification of mouse cell contaminated cell lines. (A) Cellular phe-
notype of the initial PDX cell line and the two resulting populations after differential trypsinisation.
Early = fast detachment after addition of trypsin (≈3 min). Late = slow detachment after addition of
trypsin (≈20 min). (B) Surface staining for human EpCAM on the three cell line cultures following
differential trypsinisation. Staining performed using the cell line contamination panel. (C) Illustration
of human MHC-I upregulation after 48 h treatment with IFNγ on the initial and panMHC-I+ (human)
sorted culture. Stainings performed using the MHC expression panel. (D) Species PCR on the initial
PDX derived cell line (left) and its panMHC-I+ (human) sorted cell line (right). Species specific SNP
positions are highlighted in blue. For a pure human cell line SNP_1 = T, SNP_2 = T and SNP_3 =
A (insertion).
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6.5 Stable cell line selection using G418
To ensure proper selection of stably transduced cell lines, the respective parental cell lines were
first titrated against increasing amounts of G418. For all cell lines stably transduced during this
work a concentration of 500 µg/ mL G418 in the culture medium was sufficient for selection
(see figure S8).
A Untreat
125 g/mL 250 g/mL 500 g/mL 100 g/mLB
Figure S8 – G418 titration example for the generation of stably transduced cell lines. Shown here
the untransduced TIPC102 cell line. (A) Regular culture without G418. (B) Culture with an increased
concentration of G418 to determine the neccessary selection concentration .
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6.6 Vector used in this study
SgrDI(6677)  
SspI(6560)  
ScaI(6236)  
PvuI(6126)  
AhdI(5756)  
PciI(4866)  
CAP binding site
lac operator
BstZ17I(4487)  
BsmI(4435)  
BstBI(4197)  
RsrII(4031)  
BssHII(3912)  
PflFI - Tth111I(3633)  
EagI(3421)  
BglII  (12)
MfeI  (161)
NruI  (208)
MluI  (228)
SpeI  (249)
CMV enhancer
NdeI  (484)
SnaBI  (590)
Eco53kI  (816)
SacI  (818)
NheI  (895)
BmtI  (899)
EcoRV  (1023)
BamHI  (1051)
BstXI  (1065)
BsrGI  (1328)
KflI - PpuMI  (1914)
SbfI  (1958)
PmlI  (2001)
BsmBI  (2099)
HindIII  (2111)
BsmBI  (2124)
PspOMI  (2248)
ApaI  (2252)
PmeI  (2257)
BbsI  (2468)
AvrII  (3305)
pcDNA3.1_Lamp1
6679 bp
Figure S9 – pcDNA3.1(+)_Lamp1 vector map
CAP binding site
lac operator
Kozak sequence
pcDNA3.1_Minigene
5677 bp
Figure S10 – pcDNA3.1(+)_Minigene vector map
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NdeI(6957)  
PfoI(6819)  
SspI(6590)  
BspQI - SapI(4777)  
PaeR7I - XhoI(4528)  
AfeI(3872)  
RsrII(3635)  
BsaBI*  (662)
SacII  (679)
SfiI  (741)
PspOMI  (742)
ApaI  (746)
HpaI  (773)
NotI  (1030)
BsmI  (1398)
XcmI  (1424)
AleI  (1518)
PmlI  (1553)
DraIII  (2476)
BstXI  (2522)
BfuAI - BspMI  (2800)
PshAI  (2813)
EcoRI  (2829)
AccI  (2888)
BstZ17I  (2889)
SwaI  (2896)
BsiWI  (3144)
BtgZI  (3329)
EcoNI  (3526)
BbsI  (3555)
pMP71-TCR-DMF5-(b13m-p-a2m)c
7244 bp
Figure S11 – DMF5/ Mart1 TCR vector map (as described in [372, 389])
ScaI
FspI 
AfeI
MluI
NsiI
SgrAI
SbfI(7771
BsiWI(7631
SrfI
BtgZI  (1799
BamHI
SwaI
BstBI
EcoRI
NotI
BspQI - SapI
RsrII  (7572
HY TCR (α-T2A-β -δNGFR
2 bp
Figure S12 – pLZRS_HY-TCR(α-T2A-β)_IRES_δNGFR vector map (as described in [316])
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(5946)  
(5944)  
NarI(5943)  
KasI(5942)  
(5891)  
SspI(5524)  
BspQI - SapI(3711)  
7I - I(3462)  
(2905)  
  (566)
  (611)
NaeI  (613)
  (657)
BsaBI*  (662)
Sa   (679)
  (741)
  (742)
ApaI  (746)
HpaI  (773)
BsaAI  (823)
  (926)
  (1030)
BsrGI  (1752)
  (1763)
I  (1822)
  (1823)
  (1830)
  (2078)
  (2202)
  (2460)
  (2489)
RsrII  (2569)
AfeI  (2806)
  (2808)
NheI  (2901)
6178 bp
Figure S13 – pMP71_GFP vector map
(6656)  
SspI(6289)  
BspQI - SapI(4476)  
7I - I(4227)  
(3670)  
NheI(3666)  
BlpI(3573)  
BglII  (657)
Sa   (679)
  (741)
  (742)
ApaI  (746)
HpaI  (773)
  (1030)
  (1207)
BspMI  (1320)
III  (1933)
KflI  (2056)
  (2100)
  (2143)
BspMI  (2304)
BspMI  (2335)
  (2528)
I  (2587)
BstZ17I  (2588)
  (2595)
BsiWI  (2843)
PflMI  (2967)
BtgZI  (3028)
EcoNI  (3225)
BbsI  (3254)
RsrII  (3334)
AfeI  (3571)
pMP71_Lamp1
6943 bp
Figure S14 – pMP71_Lamp1 vector map
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PluTI(5395)  
SfoI(5393)  
NarI(5392)  
KasI(5391)  
NdeI(5340)  
PfoI(5202)  
SspI(4973)
BspQI - SapI(3160)  
7I - I(2911)  
  (566)
BglII  (657)
BsaBI*  (662)
Sa   (679)
  (741)
  (742)
ApaI  (746)
HpaI  (773)
BsaAI  (823)
  (926)
  (1030)
BsrGI  (1048)
AarI  (1139)
  (1212)
I  (1271)
BstZ17I  (1272)
  (1279)
BsiWI  (1527)
PflMI  (1651)
BtgZI  (1712)
EcoNI (1909)
BbsI  (1938)
RsrII  (2018)
BsgI  (2064)
AfeI  (2255)
BlpI  (2257)
NheI  (2350)
BmtI  (2354)
pMP71_Minigene
5627 bp
Figure S15 – pMP71_Minigene vector map. The minigenes Mart1 and HY are represented by their
core sequence: Mart1 = ELAGIGILTV; HY = HIENFSDIDMGE.
CAP binding site
lac operator
AAA
AAA
bGH poly(A) signal
pcDNA3.1_Targeted_Minimal
5539 bp
Figure S16 – pcDNA3.1_Minimal vector for targeted proteomics. The sequences of CSNK1A1,
GAS7 and HAUS3 are represented by their core sequence separated by triple alanine linkers:
CSNK1A1 = GLFGDIYLAI; GAS7 = SLADEAEVYL; HAUS3 = ILNAMIAKI.
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CAP binding site
lac operator
omoter
pcDNA3.1_Tar
7 bp
Figure S17 – pcDNA3.1_25mer vector for targeted proteomics
T7 promoter
ng site
T3 promoter
rwpLX305-GW-HLA_A2-IRES-NeoR
9 bp
Figure S18 – rwpLX305-GW-HLA_A2-IRES-NeoR gateway vector for stable cell line generation.
The vector was kindly provided by Dr. R. Will from the Genomics and Proteomics core facility at the
DKFZ.
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omoter
T7 promoter
ng site
lac promoter
lac operator
T3 promoter
rwpLX305-GW-CIITA-IRES-NeoR
Figure S19 – rwpLX305-GW-CIITA-IRES-NeoR gateway vector for stable cell line generation. The
vector was kindly provided by Dr. R. Will from the Genomics and Proteomics core facility at the
DKFZ.
4733 bp
Figure S20 – pEGFP-N1 vector map
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6.7 Sequences
>Lamp1 (Nucleotide Sequence)
(including 3x FLAG-Tag; [] = indication of TMD mutation variants; () = multi epitope insertion
site)
ATGGCTGCCCCTGGCAGCGCCAGAAGGCCCCTGCTTCTGCTCCTTTTGCTCCTGCTGCTGGGCCTGATGCACTGCGCC
AGCGCCGACTACAAGGACCACGACGGCGATTACAAGGATCACGATATCGACTATAAGGACGACGATGACAAGGGATCC
GCCATGTTCATGGTGAAAAACGGCAACGGCACCGCCTGCATCATGGCCAACTTCAGCGCCGCCTTCAGCGTGAACTAC
GACACCAAGAGCGGCCCCAAGAACATGACCTTCGACCTGCCCAGCGACGCCACCGTGGTGCTGAACAGAAGCAGCTGC
GGCAAAGAGAACACCAGCGACCCCAGCCTGGTGATCGCCTTCGGCAGAGGCCACACCCTGACCCTGAACTTCACCCGG
AACGCCACCCGGTACAGCGTGCAGCTGATGAGCTTCGTGTACAACCTGAGCGACACCCACCTGTTCCCCAACGCCAGC
AGCAAAGAAATCAAGACCGTGGAATCCATCACCGACATCCGGGCCGACATCGACAAAAAGTACAGATGCGTGTCCGGC
ACCCAGGTGCACATGAACAACGTGACCGTGACCCTGCACGACGCCACCATCCAGGCCTACCTGAGCAACAGCAGCTTC
AGCAGAGGCGAGACAAGATGCGAGCAGGACCGGCCCAGCCCTACCACAGCTCCTCCAGCCCCTCCAAGCCCCAGCCCT
AGCCCTGTGCCTAAGAGCCCCAGCGTGGACAAGTACAACGTGTCCGGGACCAACGGCACCTGTCTGCTGGCCTCCATG
GGCCTGCAGCTGAACCTGACCTACGAGCGGAAGGACAACACCACCGTGACCCGGCTGCTGAACATCAACCCCAACAAG
ACCAGCGCCAGCGGCAGCTGTGGCGCCCACCTGGTGACACTGGAACTGCACAGCGAGGGCACCACCGTGCTGCTGTTC
CAGTTCGGCATGAACGCCAGCTCCAGCCGGTTCTTTCTGCAAGGCATCCAGCTGAACACCATCCTGCCCGACGCCCGG
GACCCTGCCTTTAAGGCCGCCAATGGCTCCCTGAGAGCCCTGCAGGCCACCGTGGGCAACAGCTACAAGTGCAACGCC
GAGGAACACGTGCGCGTGACCAAGGCCTTCTCCGTGAACATCTTCAAAGTGTGGGTGCAGGCCTTCAAGGTGGAAGGC
GGCCAGTTCGGCTCCGTGGAAGAGTGCCTGCTG(GGAGACGAAGCTTCCGTCTCG)GACGAGAACAGCATGCTGATCC
CTATCGCCGTGGGC[GGA/AGA]GCCCTGGCTGGA[CTG/AAG]GTGCTGATCGTGCTGATTGCCTACCTGGTCGGAC
GGAAGCGGAGCCACGCCGGCTACCAGACCATCTGA
>Lamp1 (Amino acid Sequence)
(including 3x FLAG-Tag; [] = indication of TMD mutation variants; () = multi epitope insertion
site)
MAAPGSARRPLLLLLLLLLLGLMHCASADYKDHDGDYKDHDIDYKDDDDKGSAMFMVKNGNGTACIMANFSAAFSVNY
DTKSGPKNMTFDLPSDATVVLNRSSCGKENTSDPSLVIAFGRGHTLTLNFTRNATRYSVQLMSFVYNLSDTHLFPNAS
SKEIKTVESITDIRADIDKKYRCVSGTQVHMNNVTVTLHDATIQAYLSNSSFSRGETRCEQDRPSPTTAPPAPPSPSP
SPVPKSPSVDKYNVSGTNGTCLLASMGLQLNLTYERKDNTTVTRLLNINPNKTSASGSCGAHLVTLELHSEGTTVLLF
QFGMNASSSRFFLQGIQLNTILPDARDPAFKAANGSLRALQATVGNSYKCNAEEHVRVTKAFSVNIFKVWVQAFKVEG
GQFGSVEECLL(GDEASVS)DENSMLIPIAVG[G/R]ALAG[L/K]VLIVLIAYLVGRKRSHAGYQTI
Lamp1 multi epitope construct inserts:
>TIPC102_TC1 Insert
ACCCTGCAGTACCTGAACGGCGACTACGAGGTGGAGCCCGGCAGAGTGGGCGAGAGAAACGCCTACCTGAAGGAGCAG
CACATCGAGACCCCCGACGGCCTGTACGAGTACCTGAGACCCAGCGGCACCCCCGCCCAGCTGAGCTGCCTGAGCAAG
AACCTGAACTACGACACCTTCGGCAAGCCCCACAGCGCCCTGCCCGAGGAGGTGCAGGAGCTGTTCATCTGCGACTAC
GGCGAGATCTTCAACGTGCAGCTGCCCGACAAGGAGCACCAGAGCAAGACCAACAGAGCCACCGGCAGCCCCAGCGTG
AGACAGATGAAGGGCGGCAGCGCCCTGGGCACCAAGACCGCCCAGGCCATCAAGGCCATCGGCAACGAGGTGACCGTG
GACAAGTGGGAGCCCGTGCTGAACAACCTGGGCCACGTGTGCAGAAAGCTGAAGAAGTACCTGGAGCTGAGCGGCGGC
GCCAAGATCAACAGAATCTTCCACGAGCACTTCCCCTTCGAGATCGTGAAGATGGAGTTCAACGAGAAGGAG
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>TIPC102_TC2 Insert
ATGGCCAGCGGCCTGGAGAGCAGCCTGACCAGCATCGACTGGCTGCCCCAGCTGGCCGAGCAGTACGAGAACGAGATG
TTCGACTACGAGCAGCTGAGCAAGCTGCTGAAGAAGCAGGCCCAGTTCTACGAGAACATCGTGAAGATCGCCGACCTG
GAGAGCATGACCGCCAACCTGACCCACCTGGAGGTGAGCTTCGAGGAGGTGGAGAACAATCTGCTGCACCTGGAGGAC
AAGGCCGAGAAGATGGACCTGGCCCTGCTGGAGGCCCAGTACGGCGTGGTGACCCCCAAGAAGGTGCTGGAGGCCCTG
CAGAGAGACGCCGAGCTGAGAAGCTACCAGCTCAGACCCGGCACCATGATCGAGTGGGACAACTACTGGGCCAGAGCC
ATCAGATTCAGACAGGACGGCAACGCCAAGGAGGACCCCCTGCTGACCCCCGTGCCCGCCAGCGAGAACCTGTTCAGA
GAGAAGAAGTTCTTCTGCGCCATCCTG
>TIPC102_TC3 Insert
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGATCCAGAAC
CACTTCGTGGACAACAGCCAGGTGGACAGCCCCAGCAGCGAGAAGAGCCCCGTGATGAAGCCCCAGTTCAAGTTCTGG
GCCTGGGACCCCGAGGAGGAGAGAAAGGTGGTGGACATCGAGATCAACGGCGAGAGCGTGGATCTGCACATCAAGCTG
GGCGACAACGGCGAGGCCTTCTTCGTGCAGGAAACCGTGAAGATCTACGACGGCCTGGAGGAGAACCCCCACAAGCTG
CTGCACGTGCTGACCGCCTTCGACAGCCACGCCCCCCTGACCGTGGTGGCCAGCAGACAGGGCTACGACGTGAGAAGC
GACGTGTGGAGCCTGAGAATCACCCTGTACGAGCTGGCCACCGGCAGATTCCCCTACCCCATGGCCAGCGACAGCAGC
AACACCAGCCTGCCCTTCAGCAACATGGAGAACCCCATGAACACCACCCAGCTGGGCAAGAGCCTGTTCCAG
>TIPC102_TC4 Insert
GAGAGCGTGCCCGGCAAGCCCAGCGTGAACGCCGACGAGGAGGTGAGAGGCCCCCAGATCTGCAGAGTGTGCGGCGAC
AAGGCCACCGGCATCAAGGCCGGCACCGAGCTGACCTTCAACTACAACCTGGAGTGCTTCGGCAACGGCAAGACCGTG
TGCAAGTGCGGCGCCCCCAACTGCAAGATCGAGAACAGCCCCCAGGACTTCGCCCTGCACATCATCTTCGTGACCGGC
GAGCAGAGAAGACTGAAGAAGACCGACATCCCCCTGAGACAGGCCAAGTACACCGAGAACAAGCTGAAGGCCATCAAG
GCCAGAAACGAGTATCTGCTGGCCCTGGAGGCCACCAACGCCAGCGTG
>TIPC222_TC1 Insert
ACCAGCGTGATGATGTTCAAGAAGGGCAGCTTCGAGATCGGCGCCATCGTGTACCCCGTGGCCATCAAGTACGACCCC
CAGTTCGGCGACAAGGAGGAGCTGTTCGCCATCACCAAGATCGAGGACACCGTGGAGGACTTCCACGCCCAGGCCGAG
AAGCACTTCCACTACCAGCAGCTGAGCCACAAGGAGACCACCAGCGTGCACACCGACTGGCTGCTGGACAGATACGCC
GGCAACATCAAGACCCTGCAGAAGCTGCCCCACATCCCCAGAAGAGAGCACGAGAGAGGCGGCCACCTGGACGAGAGA
GAGTGCCTGCACATGCTGAGAGAGGACTACGAGCACACCAGACTGCACGACGCCGGCAACAAGAAGAACAGCATCAAG
ATGTGGTTCAGCCCCCAGAGCAAGAAGGTGAGATACGTGGTGAGCAAGGCCAGCGTGCAGAGCACCGAGAAGACCCAG
CCCGGCGAGGGCCTGGAGGAGAGCGGCCTGCCCCAGCCCGGCGGCAAGGAGGACGCCCCCGCCGCCGAGGGC
>TIPC222_TC2 Insert
ACCCCCCCCGCCACCCCCGGCAGCAGAGGCTGGCCCCCCCAGCCCATCCCCACCCTGAGACTGGAGGGCGTGGAGAGC
AGCGAGAAGCTGAGCAGCGGCAAGAGCGAGCCCCCCCTGGGCAACGAGAAGATCAGCACCGAGGCCGTGGGCGTGGAC
ATCAGCGGCAGATTCATGACCAGCGGCGAGGGCGAGAGCGTGGACCACGTGGAGACCGTGGGCAACGTGGTGATGCAG
AAGAAGGCCCCCATCACCGAGGACGTGAGAGTGGCCTTCATGGTGGACAACGCCCAGCTGGGCTTCCTGGTGAGCGAC
AGAAACAGAAACCTGATGGTGTACATGTACCTGCCCGAGGCCAAGCCCACCAAGTGCATCAGCACCACCGAGAGCATC
GAGATCAAGGCCAGATTCACCTACATCGACTACGAGGGCAGAAGCGACGGCGACAGCATCGTGAAGCTGGAGAGCCAG
AAGGCCAGACACCCCCAGCTGCTGTACGACAGCAAGCTGTACAAGATCCTGCAGGGCGGCGTGGGCATCCCC
>TIPC222_TC3 Insert
GACGAGGCCGACAGAATGCTGGACATGGGCTTCGAGCCCCAGATCAGCAAGATCGTGGACCAGATCAGACCCGACAGA
CAGACCCTGATGCAGGACCTGGCCAAGGACACCGACCCCCTGAAGCTGAAGCTGCTGGTGTGGATCGAGGGCAAGGAG
AGAAACATCAGAGCCCTGCTGAGCGCCCTGCTGACCCTGCTGGGCGTGGTGCTGGCCCTGACCTGCAGATGCCCCCAG
6.7 Sequences 133
AGCGGCCCCGGCCCCGCCAGACCCGTGCTGCTGCTGCTGGAGTTCGGCGTGATCTACCACTGCACCGAGGAGAGACTG
TACATGGGCAGAAGAGGCAGAGGCGCCTTCTGCAACGGCCAGAGACTGATGCCCTACATGCAGCCCGTGATGCAGAGC
GACAGAACCGCCATCATGAGCGACACCACCCACCTGGTGACCCTGGGCGGCGTGCTGAGAGGCTACCTGGCCCTGTGC
AGCTACAACTGCAAGGAGGCCATCAACCCCCTGAGCCACCTGCCCAGCCACCACTACAACACCGGCTGGGTG
>TIPC222_TC4 Insert
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGACGGCGTGGGCAAGAGCGCCCTGACCATCCAGCTGATCCAGAAC
CACTTCGTGGACCCCCCCCCCCCCCCCCCCCCCCCCCTGCCCGGCCTGGCCACCAGCAGCCCCTTCCAGCTGACCAAG
CCCGGCCTGTGGAGCACCCTGCACCTGATGACCCCCCAGGAGCTGATCAACTACGTGCAGACCGTGGACAGCATGAGA
ACCGACAACACCTGCGTGAACCTGCTGCTGGAGGCCCCCTGCCACCACATCCAGCAGCTGCTGGCCTACGACGTGCTG
CCCAGCCTGGTGGCCCTGCTGAAGAACGGCGAGTTCAAGGTGCAGAAGGAGTTCGTGTTCGCCACCAGCCTGGACACC
AAGGACATCGAGCAGAACGCCGAGTTCCTGGAGCAGAGCGTGAAGGACAGCTGCGAGGGC
>TIPC222_TC5 Insert
AGCAGACCCAGCAGCGCCAAGAGAGCCAGCAGCAGCGGCAGCGCCTACAAGAGCGACAAGGACCTGGAGACCCAGGTG
ATCCAGCTGAACAAGCTGCTGAAGACCCTGACCGCCAGCGAGATGCTGCCCCTGCTGAACCACTGGAACACCCAGACC
AAGAAGGTGAGCCTGAGAGAGATCAAGTACCAGCTGAGCCCCAACGAGTACTTCAGCCTGGTGGAGAAGAACAACCCC
GACGGCGGCAAGTACCCCGAGCTGGTGCTGCAGAAGATCACCGACGCCCCCAAGAGCCAGCCCACCACCCCCCAGGAG
ACCATGACCGGCAAGCTGTTCGGCTTCGGCGCCAGCATCTTCAGCCAGATCGGCGACGTGATCACCGCCATCGACGGC
GAGAACACCAGCAACGTGACCCACCTGGAGGCCCAGAACAGAATCAAGGGCTGCACCGAC
>TIPC222_TC6 Insert
AGCAGCGCCAAGAGACCCCTGTGGCTGAACTGGGAGAACCCCGACTTCATGAGCGAGCTGCTGTTCCAGAACAACGAG
ATCATCTTCAAGAGAATCGAGGGCCTGGGCGGCAGCGTGATGAACAAGAGCGGCGTGAGCAGAGTGGTGTGGAAGAGA
CCCAGACTGACCCACAACGGCCCCTGGAGAGGCGGCGCCGTGCAGCCCCCCAGAGACGGCGTGCTGGAGAGAAAGGCC
GCCAAGGAGCAGCCCAAGGCCGGCAAGGAGCCCGCCAGCGTGAAGGTGAAGATCAAGCTGAACAAGAAGGACGACAAG
GGCCAGGACAAGGGCAAGGGCAAGAAGAGACCCAACAGAGGCAAGGCCACCGCCCACGCCGACGAGTTCGACTGCCCC
AGCGAGCTGCAGCACAGCCAGGAGCTGTTCCCCCAGTGGCACCTGCCCATCAAGATCGCC
>TIPC222_TC7 Insert
CAGAGCCAGCACATGACCGAGGTGGTGAGAAGATGCCCCCACGACGAGAGATGCAGCGACAGCGACGGCCTGGCCCCC
CCCCAGCACCTGGTGGGCGGCCAGTGCGTGCCCCTGAACGGCGGCAGCAGCCTGGACCTGGTGGAGCTGCAGCCCCTG
CTGACCGAGATCAGCAGAACCCTGAGACTGAGATACCTGGAGAGCCTGGACCTGAGCCACAACGGCCTGCCCGCCCTG
CCCGCCGAGAGCTTCACCAGCAGCCCCCTGAGCGACCAGGCCACCGCCGCCGGCGACGTGATCAAGGCCGCCTACAAC
CAGCTGAAGACCATCGCCCAGGGCAACCTGAGCAACACCGACGTGCAGCTGAGCGGCGCCGTGCACGACAGACTGCTG
AACGTGTGGCAGGTGCAGAGCGAGAACAAGGAGAAGAGCGCCGTGATGAGCTTCACCGTG
>TIPC236_TC1 Insert
ATGACCGAGTACAAGCTGGTGGTGGTGGGCGCCGGCGACGTGGGCAAGAGCGCCCTGACCATCCAGCTGATCCAGAAC
CACTTCGTGGACTTCCTGCAGAGCCCCCTGGTGACCTGGGTGAAGACCTTCGGCCCCCTGGGCAGCGGCAGCCAGGAC
AACCTGACCATGTACATGGACCTGGCCCCCAACAGCTACGGCAGAAGACCCATCCAGGTGATGATGATGGTGAGCGCC
AGAGTGGCCGAGCTGCTGCTGCTGCACGGCGCCGAGAGCGCCCTGCCCAAGGAGAGAGACAGCAGCAGCGAGAAGGAC
GGCCACAGCCCCAACAAGAGAGAGAAGGACCACATCAGAAGACCCATGATCGAGAGCGAGGTGGCCAACCTGAAGAAG
ACCATCAAGGTGACCATGGCCGCCGCCGCCGCCGCCACCAGCCAGGACCCCGAGCAGCACGAGTTCCTGTGCGTGGTG
AGCAAGGAGCTGCACAACACCCCCTACAGCACCGCCAGCGAGCCCAGCGAGAAGGCCAAGATCCTGCAGGAG
>TIPC236_TC2 Insert
AGAAACAGCATGGAGAAGCTGAGCAAGGACGGCGTGGACCTGATCGCCAGAAAGGAGAAGAAGGCCAACCTGATGGAG
134 6 SUPPLEMENTARY DATA
CAGCTGTTCGGCAGAGAGTTCAAGCAGTTCGTGGAGGCCCACGCCGACAACTACACCACCGATCTGCTGATCCTGCCC
ACCAGCCTGAAGAAGGAGCTGCTGCTGTACCCCGCCCTGCCCACCGACGGCAGCACCGGCGTGGAGCTGGTGCCCAGA
AGCGCCGAGCCCGGCTACCTGGTGACCAAGGTGGTGAGCAAGCTGCACGTGACCCTGTACAACTGCAGCTTCGGCAGA
AGCAACTGCAGCCTGTGCAGAGCCGCCAACCCCGACTACAGATGCGCCCAGGTGACCGACTTCGGCTTCGCCAAGAGA
GTGAAGGGCAGAACCAGCACCCTGTGCGGCACCCCCGAGTACCTGGCCCCCGAGATCATCGAGCAGGACGCCTTCCAC
AGAAGCCTGCTGGCCTGCTGCCTGGAGGCCGTGACCTTCAGCTACAAGCCCCCCGGCAACTTCCCCTTCATC
>TIPC236_TC3 Insert
CACTACGGCGTGATCACATGCGAGGGCTGCAAGGGCTTCTTCAGACAGAGCCAGAGATGCAACGCCGCCTACAGCTGC
ACCAGACAGCAGCAGCAGGACGAGATGCTGAACCTGGGCTTCACCATCGGCAGCTTCATGCTGAGCGCCACCACCCTG
CCCCTGGGCATCCTGATGGACAGATACAACAACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGAGAAAGACC
ATCCAGACCATCGCCCTGATCACCTACCTGATGGAGTTCAAGAACCAGATCACCACCCTGCAGGGCCAGGCCAAGAAC
AGAACCAACCCCAACAGAAGCGAGGTGCAGGCCAACCTGAGCCTGTTCGACACCATGGCCGACGGCCTGAGCCTGGAG
GAGCAAGTGACCGGCAAGGGCGCCGACAGAGAGCTGCTGGTGGGCGACAGCATCGCCAACCTGACCGAGGCCACCAAC
CACAGACAGAACATCGAGAAGATGGCCGTGGAGCAGAAGGAGAAGTACCTGGGCCTGTACACCATCCTGCCC
>TIPC236_TC4 Insert
AACCTGGAGCCCGTGCCCAGCGGCGCCAGAATCAAGGGCGCCGCCATGTTCGCCCTGAACGAGAACCCCGTGAGCGGC
GACCCCTTCTGCGTGAGCGGCCTGGACCCCGCCAGAAAGTACAAGTTCCTGCTGTTCAGACTGCAGAACGGCAAGAGA
CACGGCCCCGTGCCCGTGGAGGCCAAGCAGAGCCAGCACATGACCGAGGTGGTGAGAAGATGCCCCCACAGAGAGAGA
TGCAGCGACAGCGACGGCCTGGCCCCCCCCCAGCACGGCGGCAAGAAGCCCAAGTACCCCCCCAACAAGGTGATGATC
TGGGGCGACCTGAAGAAGAAGACCGTGATCGAGATCGAGTTCAGCACCTATCTGCCCAGCAGCCCCGAGAGAGAGGTG
CAGATCGTGAGCACCACCGACAGCAGCTTCCCCTACGCCATCTACACCCAGAGAGTGAGA
> MITD Construct
(including Mart1 and HY epitope; () = indication of multi epitope insertion site)
ATGAGAGTGACCGCCCCCAGAACCCTGATCCTGCTGCTGAGCGGCGCCCTGGCCCTGACCGAGACCTGGGCCGGCAGC
TACACCACCGCCGAGGAGCTGGCCGGCATCGGCATCCTGACCGTGATCCTGGGCGTGCTGCTG(GAGAGCAGGTACGC
TTCACCTGCGAGAGAC)GAGTGCCCCCCCCACATCGAGAACTTCAGCGACATCGACATGGGCGAGATCATCATGGGCA
ACATCGTGGGCATCGTGGCCGGCCTGGCCGTGCTGGCCGTGGTGGTGATCGGCGCCGTGGTGGCCACCGTGATGTGCA
GAAGAAAGAGCAGCGGCGGCAAGGGCGGCAGCTACAGCCAGGCCGCCAGCAGCGACAGCGCCCAGGGCAGCGACGTGA
GCCTGACCGCCTGATAA
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